

1 you're --

2 Q Oh, at the other one.

3 A -- at the other room. But if you're confined to  
4 a single room, I think two or three an hour is about the best  
5 you can do.

6 Q Okay. Over the -- the course of your practicing  
7 in gastroenterology I -- I would assume you've used bite  
8 blocks for the upper endoscopies?

9 A Yes.

10 Q Was there ever a time when those pieces of  
11 equipment were reusable to your knowledge?

12 A Yes.

13 Q And when -- what time period was that?

14 A Oh, up until about maybe 10 or 15 years ago.

15 Q Okay. And now it's all disposable?

16 A To my knowledge, yes. I think the industry  
17 standard is to use disposable bite blocks.

18 Q Okay. And would you ever in your practice in  
19 the disposable era reuse a bite block?

20 A No.

21 Q During -- at your practice do you utilize CRNAs  
22 to sedate during the procedures you perform?

23 A Yes.

24 Q And how -- how many CRNAs are employed in your  
25 practice?

1           A     At the present time one.

2           Q     In your -- over the time in your practice, how  
3 would you describe your interaction with the CRNA during a  
4 procedure?

5           A     The CRNA is responsible for the sedation of the  
6 patient and the monitoring of vital signs during the  
7 examination. And that's the purview of the CRNA. The surgeon  
8 or gastroenterologist who has performed the procedure is  
9 responsible for the supervision of the nurse anesthetist, but  
10 we do rely on their training and expertise to properly monitor  
11 the patient and perform the procedure safely.

12          Q     Have you ever administered the anesthesia  
13 yourself during a procedure, or is that always done by the  
14 CRNA?

15          A     I have back with the use of Valium and Demerol  
16 and later Versed and propo -- excuse me, Fentanyl, but I  
17 haven't administered propofol.

18          Q     Okay. In -- when you -- in your practice over  
19 the years, have you had patients move around or -- how -- what  
20 are -- I guess, describe the range of movement you've seen  
21 with patients who are sedated with propofol?

22          A     For the most part, they're comfortable and they  
23 don't really move.

24          Q     Okay. If there's an issue with whether or not  
25 to give another -- or give another dose of propofol to a

1 patient during the course of a procedure, can you describe  
2 what communication you might have with the CRNA?

3 A As I'm withdrawing the instrument, a lot of  
4 times the patients do start to awaken. If the anesthetist is  
5 unaware that I'm in the process of withdrawing the instrument  
6 I will tell them, you know, I'm just about done and, you know,  
7 you really don't want the patient to get excess sedation, so  
8 we'll hold off on giving any further -- further sedation.

9 The withdraw of the instrument, for the most part is  
10 not painful or uncomfortable for the patient, and in fact,  
11 sometimes they like to watch on the monitor as we're removing  
12 the instrument. If they do -- if they are uncomfortable, we  
13 will give them additional sedation even if we're just  
14 withdrawing the instrument.

15 Q If there's a difference of opinion as to whether  
16 or not the patient requires more sedation, how is that  
17 arbitrated between you and the CRNA?

18 A I think for the most part the gastroenterologist  
19 sets the tone.

20 Q Okay. In your -- in your work you would treat  
21 patients who have contracted hepatitis C?

22 A Yes, ma'am.

23 Q And can you give the members of the jury just a  
24 little bit of a description of hepatitis C and -- in the sense  
25 of once you contract you develop symptoms and how soon, that

1 type of thing?

2           A     Hepatitis C is generally a blood-borne pathogen;  
3 that is, it's given by -- it's transmitted by needle stick  
4 exposure, blood transfusions, IV drug abuse, occasionally  
5 intranasal cocaine use, and more unusually close intimate  
6 contact with sexual intercourse.

7           The initial phase is called acute hepatitis. That's  
8 people who have had hepatitis C for less than six months.  
9 About 25 percent of those patients will be symptomatic with  
10 yellowing of the eyes which we call jaundice; they'll be  
11 fatigued, they might lose weight, and then they generally  
12 recover.

13           A majority of those patients will go on to chronic  
14 hepatitis C, which is a phenomena where they don't have any  
15 symptoms but they continue to have viral replication and  
16 inflammation of the liver.

17           Q     And you treat people with hepatitis C with  
18 Interferon treatment?

19           A     With Interferon, Ribavirin, Telaprevir, and  
20 Boceprevir, yes.

21           Q     And can you describe the nature of that  
22 treatment, what the patient has to go through to complete that  
23 treatment?

24           A     Well, it depends on the stage and genotype for  
25 -- there are six different genotypes of hepatitis C. The most



1 common we deal with are genotypes 1, 2, and 3. About 70  
2 percent of Americans have genotype 1 and, you know, there's a  
3 1a and 1b, but they're basically treated the same, which is a  
4 48-week course of Interferon and Ribavirin.

5 Q And is the -- is the treatment difficult, or  
6 what are the side-effects of the treatment of Interferon and  
7 Ribavirin?

8 A The side-effects are fatigability, low-grade  
9 fevers, feeling bad and punky, loss of hair which we call  
10 alopecia, anemia, thyroid disorders, sometimes dermatologic  
11 problems and rashes.

12 Q And of the people that go through the Interferon  
13 treatment, what is the rate of success of them eradicating the  
14 virus or getting better?

15 A This is an evolution, you know, with the  
16 Interferon and Ribavirin therapy alone -- excuse me, just  
17 with -- excuse me -- Interferon alone, the success rate for  
18 genotype 1 was only about 8 percent. With the addition of  
19 Ribavirin and a 48-week protocol, the success rate went up to  
20 45 percent. With the addition of the first-generation  
21 protease inhibitors like Boceprevir and Telaprevir, the  
22 success rate has gone up to 60 or 65 percent.

23 Q And when -- when we say "success rate," does  
24 that mean the virus is cleared from the person?

25 A We call it a sustained virologic response. And

1 this is defined by the absence of any detectable virus six  
2 months after completion of antiviral therapy.

3 Q And are there any studies that you know of of  
4 whether, like, once the virus is cleared from someone could  
5 they become symptomatic or have problems, like, a decade later  
6 or -- or once it's cleared, are you good?

7 A We don't have a lot of long-term data about  
8 that. But our best belief is that those patients have been  
9 permanently cleared of the virus and will have no recurrence.

10 Q The -- the weeks of the treatment itself, is  
11 that, in your experience, traumatic for the patients that you  
12 have go through it?

13 A I think it's very difficult, yes.

14 Q And are some people unable to complete the  
15 treatment or --

16 A That's correct. I mean, the side-effects are so  
17 severe that they just cannot complete the full 48-weeks of  
18 therapy and they have to leave -- leave the antiviral program.

19 Q And if they leave the antiviral program, what  
20 types of problems might they experience if they're unable to  
21 complete the therapy?

22 A Well, unfortunately the hepatitis C virus is  
23 prone to fairly frequent mutations. And what you've done when  
24 you have a partial therapy is select for the most resistant  
25 subpopulation of viruses. So you end up with a patient who is

1 actually more difficult to have successful antiviral therapy  
2 in the future.

3 Q And will -- I mean, will that, like, ultimately  
4 impair their liver function, or what types of health problems  
5 would they experience from stopping it?

6 A With the ongoing inflammation of the liver, it  
7 leads to some scarring which we call fibrosis; and once that  
8 fibrosis has reached a certain stage, we call that cirrhosis.

9 Q Okay. And if you are one of the people that  
10 gets through the treatment and the virus, the sustained --  
11 what did you call it a sustained --

12 A Sustained virologic response.

13 Q Okay. And once you get to that point, are there  
14 any precautions that are recommended medically that people  
15 take so they don't transmit the disease to other people?

16 A Those patients are considered cured and will not  
17 transmit the virus.

18 Q And the ones that are unable to complete the  
19 therapy, do they have to take precautions?

20 A Right. We recommend for people in nonmonogamous  
21 relationships to use barrier protection. Don't use, you know,  
22 don't share razor blades and toothbrushes, don't donate blood.

23 MS. WECKERLY: May I approach, Your Honor?

24 THE COURT: Mm-hmm.

25 BY MS. WECKERLY:

1           Q     Sir, I'm showing you what's been admitted as  
2 State's 108. Do you recognize what that is?

3           A     No.

4           Q     Is the -- let's see if I -- have you seen this  
5 report on colonoscopy procedure times at all?

6           A     No.

7           Q     Okay. And that one was published in 2006, but  
8 you're not familiar with it?

9           A     No, I'm not.

10          Q     Okay. And did I -- did the State ask you to  
11 bring this second demonstrative exhibit to court?

12          A     Yes.

13          Q     What is that?

14          A     This is a bottle of propofol.

15          Q     And what size vial is that?

16          A     20ccs.

17          Q     Okay. And is that -- not -- maybe not that  
18 bottle or that vial anymore. Is that the size vial that you  
19 would use in your practice?

20          A     Yes.

21          Q     Or the CRNAs use in your practice?

22          A     Yes.

23          MS. WECKERLY: Court's indulgence.

24          THE COURT: Mm-hmm.

25          MS. WECKERLY: Thank you, sir. I'll pass the

1 witness.

2 THE COURT: All right. Cross?

3 CROSS-EXAMINATION

4 BY MR. WRIGHT:

5 Q Dr. Nemec, my name is Richard Wright. I  
6 represent Dr. Desai. The -- that propofol vial, the exhibit  
7 there, is that single use?

8 A Yes.

9 Q Does it say it on there?

10 A Yes.

11 Q What's it say?

12 A It says, Single patient infusion vial. It's  
13 really little.

14 MR. WRIGHT: I'll pass it to the jury.

15 THE COURT: That's fine.

16 MR. WRIGHT: Pass it around.

17 BY MR. WRIGHT:

18 Q They also come in 50cc size, correct?

19 A That's correct.

20 Q Prior to the hepatitis outbreak here in Las  
21 Vegas in early January -- in 2007, early 2008, were propofol  
22 vials like 50s being multiused? Meaning used for multiple  
23 patients to your knowledge?

24 A There was split dosing. That is a  
25 anesthesiologist would draw up vials of propofol prior to

1 starting procedures for use throughout that day.

2 Q Okay. So if -- just if I could take a 50cc and  
3 draw up 10 separate -- pardon me, five separate 10cc syringes  
4 and then use them throughout the day was the practice?

5 A It was a common practice among --

6 Q Okay.

7 A -- anesthesiologists, yes.

8 Q That -- to your knowledge has that now changed  
9 here?

10 A That's correct, yes.

11 Q Okay. And that changed after the outbreak that  
12 occurred?

13 A That's correct.

14 Q Okay. After six weeks of trial I'm still  
15 confused on acute hepatitis, chronic hepatitis C, symptomatic  
16 and nonsymptomatic, okay? Does -- does the acute hepatitis,  
17 chronic hepatitis, that deals solely with time, duration?

18 A That's correct.

19 Q Oh -- okay.

20 A Zero to six months after the infection we call  
21 that acute; more than six months, we call it chronic.

22 Q Okay. So that -- the -- the acute designation,  
23 I mean, we're not medical here and sometimes you think of  
24 acute as severity.

25 A That's correct.

1 Q Okay.

2 A But that's -- you're right, people do have that  
3 belief, but acute has nothing to do with severity, it has to  
4 do with when it occurred. Acute is --

5 Q Okay.

6 A -- recent and chronic is long term.

7 Q Okay. So every -- every hepatitis virus  
8 transmission, if -- every -- whenever I got it then, like,  
9 using six months as an arbitrary cutoff, I'm acute for six  
10 months; thereafter chronic, if I still have it?

11 A That's correct.

12 Q Okay. And so that -- every person who had --  
13 contracts hepatitis C has acute hepatitis C, but --

14 A That's correct; however, frequently it's never  
15 recognized because they have no symptoms or they don't seek --

16 Q Okay.

17 A -- medical attention. They thought they had the  
18 flu or something.

19 Q Okay. And so then we get into the, what we've  
20 called symptomatic and nonsymptomatic, right?

21 A That's correct.

22 Q Okay. So I -- I could contract hepatitis C and  
23 whether I have -- well, just suppose I got it today, and then  
24 whether I demonstrate symptoms or not has nothing to do with  
25 acute or chronic.

1           A     Generally symptoms occur in the acute phase. As  
2 the virus becomes chronic, many of those symptoms resolve and  
3 the patient is symptom free, until with the chronicity and the  
4 development of scarring of the liver and the person goes on to  
5 cirrhosis, then they have the symptoms of cirrhosis; not so  
6 much hepatitis C; but cirrhosis.

7           Now, there are some exceptions. There are, you  
8 know, vasculitis problems that you can see with hepatitis C  
9 like with the cryoglobulinemia where we have so much antigen,  
10 so much virus, hooked up to so many antibodies that it starts  
11 to sort of cause a sludge phenomena in the lower extremities,  
12 you know, where it's colder and they'll develop, like a  
13 dermatitis or a skin -- skin problem --

14          Q     Okay.

15          A     -- as a consequence of the cryoglobulins. And  
16 that would be a direct hepatitis C complication. But most of  
17 the chronic problems are related to the failure of the liver.

18          Q     The -- in -- every time I think I get it I read  
19 a new sentence that floors me on this acute/chronic. I got to  
20 read a sentence to you. These -- these patients have tested  
21 positive for the virus, but have not developed an acute case  
22 of the disease. Does that make sense?

23          A     What do you mean by "these patients"? What  
24 patients are you talking about?

25          Q     Just -- well, just patients who have tested



1 positive for hepatitis C virus.

2 A Patients that --

3 Q I -- I --

4 A -- test positive for hepatitis C have hepatitis  
5 C.

6 Q Right. Okay. But when --

7 A We know whether it's acute or chronic based on  
8 -- well there's a couple of ways. One is that if we had  
9 serial serologic tests -- that is, the person was negative in  
10 January and became positive in March -- you know that it's  
11 acute.

12 Q Okay.

13 A But -- or if they had a -- a risk factor. That  
14 is, they had had a blood transfusion that we later found out  
15 was contaminated with hepatitis C, then we would set up a  
16 timeline; but most patients with hepatitis C that we see out  
17 in the community we have no idea when they got it without some  
18 sort of historical marker they tell us about. Sometimes  
19 they'll say, you know, when I was a teen I used drugs, then we  
20 know they probably got it in their teens.

21 Q I got it. So when -- like in -- in this  
22 sentence that I've written out here, these patients have  
23 tested positive for the virus, and it's talking about  
24 hepatitis C, but have not developed an acute case of the  
25 disease. I mean, I'm guessing the person is just misusing the

1 word "acute" and is meaning symptomatic? I mean, this -- this  
2 is where I get mixed up when I read these things.

3 A I still don't understand, who is "these  
4 patients"?

5 Q Patients who tested positive for hepatitis C.

6 A That's not what it says.

7 Q I mean, but acute has nothing to do -- well, the  
8 next sentence. Fewer than 10 percent of persons infected with  
9 the virus develop acute hepatitis C. Do you know what that  
10 would mean?

11 A Nope.

12 Q Okay. Me neither and that's why I'm confused on  
13 some of these things. The -- because it -- the word to me,  
14 the way I'm understanding it as acute and the chronic  
15 distinction, we could just say the first six months of  
16 hepatitis C is acute.

17 A I don't know what the author of that sentence  
18 meant. Perhaps they just confused acute with symptomatic. I  
19 don't know.

20 Q Okay. And so the -- everyone that contracts  
21 hepatitis C at the beginning has acute, whether they know  
22 it --

23 A Correct.

24 Q -- or not?

25 A That's correct.

1 Q And then if they don't get rid of it either  
2 themselves, naturally, or through treatment, they then will  
3 have chronic thereafter?

4 A Correct.

5 Q Okay. And then the -- the  
6 symptomatic/nonsymptomatic [sic], that -- and symptomatic, as  
7 you said, is normal -- it occurs in acute hep C, first six  
8 months --

9 A Yes.

10 Q -- if it occurs?

11 A Now, we do have patients with chronic hepatitis  
12 C that are fatigued, and it probably is because of the  
13 viremia, the ongoing viral replication.

14 Q Okay.

15 A But usually the most pronounced symptoms are in  
16 the acute hepatitis.

17 Q Now -- colonoscopies without anesthesia, okay?  
18 And we've heard a lot in this courtroom about CRNAs and the  
19 vast majority of the people get propofol and go to sleep and  
20 then wake up and don't remember. Are -- do some patients get  
21 colonoscopies without anesthesia?

22 A Yes.

23 Q And how frequent is that?

24 A Maybe once a month I'll do one without sedation.

25 Q Okay. And does -- what -- why? Are they

1 allergic to it, or what -- I mean --

2 A Some patients want to watch the procedure. Some  
3 patients don't like the idea of being sedated. Some patients  
4 don't want to take a whole day off from work. There's --

5 Q Well, is it -- I mean, it's not a painful  
6 procedure? Or do they just tolerate pain well?

7 A The ones who request no sedation tend to do very  
8 well without the sedation. We occasionally have patients who  
9 we do a colonoscopy with little sedation because they are not  
10 hemodynamically stable. This might be in a, you know, an  
11 emergent situation in the ICU or the ER and because you're  
12 worried about their blood pressure, you don't give them very  
13 much. And some of those patients do have quite a bit of  
14 discomfort during the procedure.

15 So I think a lot of it is the frame of mind the  
16 person is in if they -- you're right, I think some people just  
17 tolerate pain better.

18 Q Okay. Some of them who don't want -- who you  
19 perform colonoscopies on who don't want anesthesia, are some  
20 of those physicians?

21 A Yes.

22 Q Okay. When you -- when you're performing a  
23 colonoscopy and working -- you're working with a CRNA as a  
24 team; is that correct?

25 A Correct, yes.

1 Q And is it -- when you have completed your entry  
2 with the scope and you are withdrawing the scope that is --  
3 that is the least painful part of it; is that fair?

4 A That's correct. Yeah, the -- getting the scope  
5 up to the cecum, which is the upper part of the colon, is much  
6 more uncomfortable than withdrawing the instrument.

7 Q Okay. And if you are, say three or four minutes  
8 towards the completion, the withdrawal, and you see the CRNA  
9 either asks you or he is going to redose more sedation, would  
10 it be unusual for you to say, I'm almost done, don't even --

11 A That's not unusual at all. I frequently would  
12 say let's hold off, I'm just about done --

13 Q Okay.

14 A -- and complete the exam.

15 Q I want to talk to you about Gwendolyn Martin, a  
16 patient of yours. She is one of the victims in this case, and  
17 you treated her for her hepatitis C; is that correct?

18 A Am I allowed to -- you know, is this breaching a  
19 patient confidentiality issue?

20 Q I don't think so because --

21 THE COURT: I'll see counsel up here, no, I mean, her  
22 medical records have --

23 MR. WRIGHT: -- she -- she was here --

24 THE COURT: -- already come in. She's named in the  
25 --

1 THE WITNESS: Okay.

2 THE COURT: -- indictment. I'll see counsel up here  
3 though.

4 (Off-record bench conference.)

5 BY MR. WRIGHT:

6 Q The answer is you can testify about your  
7 treatment of her and it's fully protected and allowed under --  
8 what?

9 THE COURT: Well, you -- it's allowed because I'm  
10 directing you to answer the questions.

11 THE WITNESS: Okay.

12 BY MR. WRIGHT:

13 Q She appeared here and testified --

14 THE COURT: -- that she was being treated by you and  
15 --

16 THE WITNESS: Okay. Fine.

17 BY MR. WRIGHT:

18 Q And the -- and I'm aware of it because I have a  
19 deposition that you gave and --

20 A Okay. Fine.

21 Q -- her -- in the civil case and included with it  
22 as exhibits were your -- your medical records for Gwendolyn  
23 Martin, okay?

24 A Fine.

25 Q Okay. You -- I wanted to go through -- and you

1 recall her as a patient?

2 A Yes.

3 Q Okay. And I wanted to go through that because  
4 that is a successful treatment of a hepatitis C patient; is  
5 that correct?

6 A Correct.

7 Q Okay. And do you -- do you recall that it was  
8 in November of 2007 when you first got Gwendolyn?

9 A I can't remember the exact time, but it was  
10 either late 2007/early 2008.

11 Q Okay. And can you -- without -- if -- I don't  
12 want to -- I don't intend to drag this out and go through all  
13 of your records, and the dates really are not significant, but  
14 if you do want to look at your records, I'll give you a copy  
15 of the deposition that I'm talking about and your records are  
16 there.

17 A Okay. Thank you.

18 Q Would you like -- did you float through there?  
19 You recognize those as your records?

20 A Yes.

21 Q Okay. And when she -- you're -- you are a  
22 gastroenterologist who treats people who have hepatitis C?

23 A Yes.

24 Q And so Gwendolyn Martin came to you, and at the  
25 time had acute hepatitis C?

1 A Yes.

2 Q Okay. And what -- just generally walk us  
3 through your treatment and what you did for her.

4 A We confirmed the diagnosis by doing hepatitis C  
5 RNA, quantified or found out exactly how much virus that she  
6 had, determined her genotype and started her on antiviral  
7 therapy.

8 Q Okay. And you could -- you did the blood  
9 testing and things to confirm she had hepatitis C, right?

10 A Correct.

11 Q You recall it was acute hepatitis C and she was  
12 symptomatic, had been in the hospital?

13 A That's correct.

14 Q Okay. And had jaundice, the classic symptoms,  
15 and nausea, fatigue; do you recall that?

16 A Yes.

17 Q Okay. And so then you confirmed it through  
18 testing and then started her on what treatment?

19 A I believe it was Interferon and Ribavirin.  
20 That's correct.

21 Q Okay. And so -- and she was a genotype 1a?

22 A Yes.

23 Q Okay. And so that, if I understand -- and I --  
24 because I read your deposition, sir, and the -- everyone with  
25 hepatitis C, if they're going to get the Interferon and what



1 do you call -- what's that other Ribo?

2 A Ribavirin.

3 Q Ribavirin treatment, regardless of your genotype  
4 you get the same treatment, it's just the duration is  
5 different?

6 A No, I -- I think it is a little bit different.

7 Q Okay.

8 A If someone has minimal inflammation on a biopsy  
9 for chronic hepatitis C, genotype 1 you might hold off on  
10 therapy. Plus we have evolving therapies and, you know,  
11 sometimes we hold off if they're early on waiting for the  
12 second-generation protease inhibitors and direct-acting  
13 antiviral agents that will -- are going to be approved by the  
14 FDA probably second quarter 2014.

15 Q Okay.

16 A So they're not exactly the same, but at the time  
17 we were treating, yes.

18 Q Okay. And so the -- she started -- and her as a  
19 48-month -- week treatment?

20 A Correct.

21 Q Okay. And within a couple of months of the  
22 commencement of the treatment you are seeing her on monthly or  
23 six month -- pardon me, six-week intervals --

24 A Correct.

25 Q -- is that correct? Because you are monitoring

1 her progress --

2 A Correct.

3 Q -- and testing as we go along. And do you  
4 recall that you did a liver biopsy?

5 A I don't recall that, but --

6 Q Okay.

7 A -- do you have a page?

8 Q Yep. I'll use your deposition transcript. I'll  
9 just refer you to a page.

10 A Okay.

11 Q 32.

12 A Okay. Yes.

13 Q Okay. And the liver biopsy is done for what?

14 A To determine how much inflammation and fibrosis  
15 there is.

16 Q Okay. And do you see there the results?

17 A Yes.

18 Q Okay. And what was that?

19 A The grade two inflammation and stage one  
20 fibrosis.

21 Q Okay. And what -- characterize that as to  
22 severity or something?

23 A There's four different stages of inflammation --  
24 I guess, five, zero, one, two, three, and four and five;  
25 stages of fibrosis, zero, one, two, three, and four.

1 Q Okay. And so was hers on the low end?

2 A Yes.

3 Q Okay. And do you recall that -- first let me  
4 back up a minute. She has acute hepatitis C?

5 A Yes.

6 Q And of course, before you put her on the  
7 treatment, she elected to take the treatment, correct?

8 A Yes.

9 Q Tell the jury about the discussion you have with  
10 the patient about what it -- just like, I'm a new patient, I'm  
11 in, I got acute hepatitis C and I'm scared to death.

12 A Well, I told Mrs. Martin that I had not seen  
13 acute hepatitis C before. This is a fairly rare thing to be  
14 able to treat because there are so few new cases of hepatitis  
15 C, we're generally not seeing them. Most of what we see, in  
16 fact, all prior to Mrs. Martin coming in to see me, was  
17 chronic hepatitis C.

18 Our experience with treating hepatitis C -- when I  
19 say, "our experience," the worldwide experience with treating  
20 hepatitis C is -- that's acute is fairly limited. But it was  
21 felt that theoretically an early intervention with the  
22 hepatitis C gave the best possibility of having a favorable  
23 long-term response.

24 Q Okay. But I'm scared to death. What are the  
25 side-effects going to be for me?

1           A     You're going to feel fatigued, might have some  
2 hair loss, anemia, low-grade fevers.

3           Q     What are my chances? What if I -- I don't know  
4 whether I should do it or not?

5           A     Well, I would tell you that for most patients  
6 with this particular genotype, your success would be about 45  
7 or 50 percent; but given that we're treating earlier, we  
8 should have a better outcome than that.

9           Q     Okay. I'm lean.

10          A     You're lean?

11          Q     Well, hypothetically.

12          A     Your chances of having a successful eradication  
13 are better than if you were overweight.

14          Q     Okay. And Mrs. Martin was motivated?

15          A     Yes.

16          Q     And wanted to fight it?

17          A     Yes.

18          Q     Okay. And then what if it doesn't work, Doctor?  
19 I mean, I'm going to go through this for 48 weeks and I'm  
20 hearing it's 50/50 --

21          A     Well, we do have --

22          Q     -- do I then do it again?

23          A     We do have early indicators of success. People  
24 have an early virologic response; that is, they lose their  
25 viral load or -- we can't detect any virus. Early on in the

1 treatment gives a much likelier positive outcome.

2 Q Okay. But what -- at the end of 48 weeks am I  
3 -- what's -- how are we going to know if it worked or not?

4 A By checking the virus in the blood.

5 Q Okay. And if -- if there is -- if it's not in  
6 my blood anymore at the end of the 48 weeks, will I then know  
7 I'm most probably cured?

8 A We'd have to wait another six months, and if the  
9 virus was absent six months after completion of therapy then,  
10 we call that sustained virologic response. At least that's  
11 what the researchers do. I call it a cure.

12 Q Okay. And what if at the end of 48 weeks I  
13 still have -- it's still detected in my blood? Can I do it  
14 again?

15 A It would be unlikely you would have a successful  
16 outcome by re-treating; however, there are some hepatologists  
17 that would put the person on, not a curative protocol, but a  
18 suppressive protocol just to keep the amount of virus lower by  
19 giving the Interferon/Ribavirin on a chronic basis.

20 Q Okay. If I -- maybe I ought to wait a few  
21 months because -- my -- you just tested me and my viral  
22 load -- is that the right word?

23 A Yes.

24 Q Okay. My viral load has gone down. Is there  
25 any chance I'm going to kick this on my own?

1           A     Yes, it is possible you kick it on your own.

2           Q     Okay. And if I -- and if I do, I just don't get

3 any treatment and then all of a sudden I have no sustained,

4 what's that word, sustained --

5           A     Well, we wouldn't call it a sustained --

6           Q     Okay.

7           A     -- virologic response, we would call it self --

8 self -resolution of the virus. You just fought it off with

9 your own antibodies and immunity.

10          Q     Okay. And that happens to some people?

11          A     Yes.

12          Q     Okay. And so if that happens with me, I simply

13 fought it off and it's gone?

14          A     That's correct.

15          Q     Okay. If I don't -- if I elect not to take

16 treatment, how long do you think I'm going to stay

17 symptomatic, if I'm, you know, having symptoms before I move

18 in the nonsymptomatic chronic?

19          A     Probably about six months.

20          Q     Okay. So I either put up with this for about

21 six months then -- and if I don't fight it off myself I'm

22 going to have chronic hepatitis C probably for the rest of my

23 life?

24          A     That's correct.

25          Q     Okay. And then am I going to die of hepatitis

1 C?

2 A There's a 20 percent chance that you go on to  
3 cirrhosis and death of the liver if the hepatitis C is chronic  
4 and not treated.

5 Q Okay. So if I just do nothing, get past the  
6 symptoms, most probably I'm going to die of old age and not  
7 hepatitis C?

8 A Yes.

9 Q Okay. And there is a 20 percent chance I'll get  
10 cirrhosis of the liver -- I mean, this is from the statistics  
11 and studies -- within, is it 20 years of --

12 A Well, we've seen it as little as five or even  
13 two or three years, but generally this takes decades of  
14 ongoing inflammation of the liver. But, you know, everybody's  
15 got a different immune system and, you know, as you're older  
16 your ability to fight off infections might not be as vigorous  
17 as a younger person and who, you know, may have a more  
18 accelerated progression of disease.

19 Q Okay. Cognitive deficits. I'm worried I have  
20 hepatitis C now. I just caught it and I have symptoms. What  
21 cognitive impact is this going to have on me?

22 A Well, in the acute phase a person would have the  
23 same type of cognitive deficits that you'd have, like, with a  
24 virus or a cold. Your ability to concentrate is impaired.  
25 Attention to detail might fall off. But as you became more

1 chronic, that would tend to normalize. Later in the disease  
2 if you developed cirrhosis and the buildup of the toxins in  
3 the blood which we call encephalopathy, then you'd have a  
4 fairly profound century -- excuse me, deficit of mentation.

5 Q Okay. Now, going back to Mrs. Gwendolyn Martin,  
6 the -- she successfully went through 48 weeks of treatment?

7 A Correct.

8 Q And she tested clear -- whatever you call it?

9 A Correct.

10 Q Okay. And then again at six months?

11 A Yes.

12 Q Okay. And so she is -- she is cured?

13 A We call it a sustained virologic response. The  
14 likelihood of this virus coming back is very, very, very  
15 small.

16 Q Okay. And the -- it's obviously not pleasant  
17 treatment?

18 A No.

19 Q And there's side-effects forgetting the -- I'm  
20 symptomatic to begin with because I've got hep C; now I'm  
21 going to go through this 48 weeks and that's going to cause  
22 what generally?

23 A Mostly fatigue as a consequence of the  
24 Interferon and maybe exacerbated by the underlying anemia as a  
25 consequence of Ribavirin therapy. Sometimes they just get



1 muscle aches at the sight of the injection of the Interferon.  
2 They just don't feel it very well.

3 Q Okay. And the -- Gwendolyn, if you recall, and  
4 I just know from reading your deposition, had a good support  
5 structure; her husband was there every single time?

6 A Yes.

7 Q And she cleared it and was a success story?

8 A For clearing the virus, yes.

9 Q Okay. Now, we had a -- were you aware of any  
10 dementia for Gwendolyn Martin?

11 A She -- you know, I'm not a neurologist. She  
12 told me she had some cognitive problems during the treatment.  
13 She continued to have some anxiety issues. I think, you know,  
14 when someone gets hepatitis C as a consequence of, you know,  
15 IV drug abuse or, you know, bad behavior, that's one thing.  
16 But when it's, you know, in a healthcare setting, that's  
17 fairly traumatic for that person.

18 Q Okay. The -- I mean, anything about brain  
19 damage caused to her because of the treatment or the  
20 hepatitis --

21 A I don't know of any anatomic or physiologic  
22 brain damage.

23 Q Okay. We had a --

24 THE COURT: You again.

25 THE MARSHAL: Everybody, check your cell phones; make

1 sure they're on silent.

2 BY MR. WRIGHT:

3 Q We had a doctor in here this morning. Dr.  
4 Richard Perrillo testified. He calls himself a  
5 neuropsychologist. Did he ever consult with you regarding  
6 Gwendolyn Martin?

7 A Not that I recall.

8 Q Okay. He testified that -- understand, he  
9 testified he was hired by plaintiff's personal injury lawyers  
10 for her case to give an assessment of her.

11 THE COURT: Mr. Wright, keep your voice up.

12 BY MR. WRIGHT:

13 Q He testified he was brought in by -- or  
14 plaintiff's personal injury lawyers to assist Gwendolyn Martin  
15 and four other people suing for their civil cases, okay?  
16 Regarding Gwendolyn Martin, he said he was -- he was certain  
17 she had brain damage, I can tell you that. It's not brain  
18 fog. She has front occipital -- front occipital dementia and  
19 is permanently disabled, although it may not be permanent  
20 because the brain has plasticity.

21 You ever hear anything like that?

22 A I'm not a neurophysiologist and no, I never --  
23 I'm not familiar with that.

24 Q Okay. Does that sound like Gwendolyn Martin to  
25 you?

1           A     Well, you know, I've only known Gwendolyn Martin  
2 since she had her bout of hepatitis C and I didn't know her  
3 beforehand, so I can't say, you know, whether there was a  
4 change in her skillsets or cognitive abilities. I don't know.

5           Q     Okay. He said that the disease -- and he -- we  
6 were talking about hepatitis C. He said the disease and the  
7 treatment of the disease cause dementia, and that hepatitis C  
8 is neuro viral and affects your brain before the liver. You  
9 ever hear of that?

10          A     No.

11          Q     He said the neuro not -- cognitive impairment is  
12 independent from the Interferon treatment, and that the  
13 Interferon treatment is a double-whammy. It sort of  
14 accelerates one's brain dysfunction caused by the hepatitis C.  
15 Have you ever seen or heard anything like this in the studies  
16 you've read about --

17          A     No.

18          Q     It -- with hepatitis C, even the treatment -- I  
19 opt to take the treatment, I've got hepatitis C, I'm going to  
20 go through 48 weeks of Interferon, whatever side-effects I  
21 have, even if cognitive from the treatment, those are going to  
22 cease when I'm done with the treatment; is that fair?

23          A     Well, you know, I would hope so, but, you know,  
24 I think you need to understand that there are all sorts of  
25 unintended consequences of the therapies we give patients, and

1 some of these consequences aren't known for years or even  
2 decades later. So there may be long-term sequelae of the  
3 treatment that, you know, most gastroenterologists are not  
4 aware of.

5           However, in my own practice most patients after  
6 completing therapy seem to be alert, oriented, and not having  
7 any appreciable cognitive deficit that I can detect.

8           Q     Okay.

9           A     But I don't specifically challenge that. I  
10 don't give them neurocognitive testing.

11          Q     Almost done. Just check my list. Thank you  
12 very much, sir.

13          THE COURT: Mr. Santacroce?

14          MR. SANTACROCE: Thank you.

15                               CROSS-EXAMINATION

16 BY MR. SANTACROCE:

17          Q     Good afternoon, Doctor. I just wanted to follow  
18 up a little bit about what Mr. Wright was touching on  
19 regarding the relationship of cognitive damage to the  
20 hepatitis C virus. I believe in your grand jury transcript  
21 you seemed to associate that deficit with the degree of liver  
22 damage; is that correct?

23          A     In patients with cirrhosis, you know, end-state  
24 cirrhosis, rate 4 fibrosis, yes.

25          Q     So am I -- as I understand it, there would have

1 to be significant liver damage, i.e. cirrhosis, in order for  
2 there to be permanent cognitive damage? There's a  
3 relationship there, isn't there?

4 A Well, the cognitive deficit associated with  
5 cirrhosis is not irreversible. I mean, those patients can  
6 clear their sensorium with, you know, treatment with, you  
7 know, antibiotics like -- like facts and medications like  
8 Lactulose. Dietary changes can help them improve their  
9 sensorium quite a bit. So it's not permanent; it's not  
10 irreversible.

11 Q So even with that degree of damage to the liver,  
12 cirrhosis of the liver, the cognitive abilities can come  
13 back --

14 A Yes.

15 Q -- in return? Yes?

16 A Yes.

17 Q And I believe you described, sort of, this  
18 cognitive damage early on as being like related to, like,  
19 flu-like symptoms like a child would get if they have a high  
20 fever, correct?

21 A Correct.

22 Q And after that fever passes, all of that  
23 cognitive ability, or the majority, comes back, correct?

24 A Correct.

25 Q Can you give me some kind of idea as to how long

1 it takes to develop cirrhosis of the liver?

2 A It's variable. It can be as short as three or  
3 four years, and sometimes it never does occur; the person  
4 succumbs to old age.

5 Q But I mean on an average, three is the -- three  
6 to four years is the low end, isn't it?

7 A It's usually a couple of decades.

8 Q Okay. So 10 to 20 years?

9 A Yes.

10 Q And even if someone has cirrhosis of the liver  
11 when you first detect it, what's the lifespan of someone that  
12 has cirrhosis of the liver?

13 A It depends on how bad the cirrhosis is. You  
14 know, we have a classification for that, you know, the child's  
15 classification for liver disease and people with advanced  
16 liver disease, their prognosis could be very poor with a life  
17 expectancy of less than six months.

18 Q I want to just talk a little bit about the CRNAs  
19 -- your familiarity with CRNAs in your practice. In the  
20 procedure room you have a CRNA?

21 A Correct.

22 Q Yourself?

23 A Correct.

24 Q Do you have a nurse also?

25 A No, we have a tech.

1 Q GI tech?

2 A Yes.

3 Q Okay. In that procedure room, who is in charge

4 of that procedure room?

5 A The gastroenterologist.

6 Q So that would be you?

7 A Yes.

8 Q If you were performing the procedure. Is that

9 standard and customary?

10 A Yes.

11 Q And in fact, the CRNA doesn't need an

12 anesthesiologist to supervise them in Nevada, correct?

13 A No, they do not.

14 Q An M.D. can supervise a CRNA --

15 A That's correct.

16 Q -- such as yourself? You're the supervisor of

17 that CRNA in that procedure room?

18 A Yes.

19 Q You talked about -- maybe you didn't talk about

20 it here, but I was reading in your grand jury transcript about

21 the procedures that you use in logging in information about a

22 patient after the procedure?

23 A Yes.

24 Q Do you use electronic devices to do that?

25 A Yes.

1 Q Can you tell me how that goes?

2 A Well, it's a computer program that has various  
3 boxes that are clicked, you know, normal examination or polyp  
4 or ulcer or inflammation and it -- it generates a report.

5 Q Okay. And you talked about that normally you  
6 would do that right after the procedure, correct?

7 A Correct.

8 Q But there would be times when you wouldn't get  
9 to it right after the procedure and it would be some minutes  
10 later, correct?

11 A Some minutes, but it wouldn't start a new  
12 procedure until it had been completed.

13 Q Correct. And you also said you would -- there  
14 wouldn't be six patients that would come in before you would  
15 do it --

16 A No.

17 Q -- because you would remember it?

18 A Right.

19 Q But there could be a matter of several minutes  
20 before you actually logged into that computer, or whatever you  
21 call it, and -- and put in the results of what you found,  
22 correct?

23 A That's correct.

24 Q Now, in that machine does it have a time stamp,  
25 a time strip; do you know?



1           A     Probably. I don't know.

2           Q     So the time that you ended the procedure or the  
3 time that the CRNA logged in the end of the procedure could  
4 actually be a couple of minutes different from what your notes  
5 indicate on the machine, correct?

6           A     There is -- we run into this problem a lot of  
7 times in the procedure room. We've got a clock and in our  
8 office it's an atomic clock that has the exact time. There's  
9 also a clock on the scope that takes the pictures and has a  
10 time stamp for the pictures that we take that is not  
11 synchronized with the atomic clock. And then we have another  
12 machine that generates the procedure report with a different  
13 clock.

14                 So you can have three different times a couple of  
15 minutes apart for the exact same procedure. So a lot of times  
16 you won't see synchrony. In our facility we are -- our stop  
17 time and stop time for the procedure is all coordinated with  
18 the clock on the scope.

19           Q     Okay. But you can't change the clock on the  
20 computer that you're typing in your notes, right?

21           A     I'm sure someone could. I can't. I don't know  
22 how.

23           Q     I couldn't either. But I'm just saying, I mean,  
24 you don't calibrate every time you do a procedure?

25           A     No, we do not.

1 Q Okay. So there -- there could be -- and  
2 typically it's some variation in the time?

3 A Yes.

4 Q Fairly common?

5 A Fairly common.

6 Q You talked about in your grand jury testimony, I  
7 think, someone asked you about the procedures can get very  
8 messy at times, correct?

9 A Yes.

10 Q It's a messy business?

11 A Yes.

12 Q And when you're extracting a scope -- I don't  
13 know if you -- I'm using the right words, but when you pull a  
14 scope out, things can happen, right?

15 A Well, specifically what kind of things?

16 Q I don't want to tell you what we've discussed  
17 here. You tell me, you're the doctor.

18 A Well, you know, I think what we're talking about  
19 is splatter of fecal material --

20 Q Correct.

21 A -- on removal of the scope. And, you know, we  
22 try to keep that to a minimum and, you know, make sure that,  
23 you know -- because the staff doesn't want to get splattered,  
24 you know, we try to be careful when we remove the scope.

25 Q But it happens?

1           A     It occasionally will happen, yes.

2           Q     And it can be very messy?

3           A     When there's a bad prep, yes.

4           Q     When you say a "bad prep," that means the  
5 patient hasn't prepped properly?

6           A     Sometimes they prep properly but the prep did  
7 not have its desired effect. There's residual fecal material  
8 within the colon.

9           Q     Okay. And related to that you talked about  
10 scope cleaning in your -- in your grand jury testimony --

11          A     Yes.

12          Q     -- right? And, I believe you testified that  
13 there was -- in your practice the scope cleaning takes 55  
14 minutes?

15          A     Correct.

16          Q     That's relatively new since the hep outbreak?

17          A     No, I think that's been fairly standard.

18          Q     Okay.

19          A     I mean, there is a timer on the scope washer  
20 and, you know, by the time you get the prewashing and  
21 brushings done and get it into the cleaner and then do all the  
22 due diligence to make sure the scope is clean, that's how long  
23 it takes.

24          Q     And I believe you testified that you cleaned two  
25 scopes at a time in the enzymatic fluid?

1           A     Well, I don't know about -- I don't know about  
2     that.

3           Q     Okay.

4           A     I don't know.

5           Q     Let me see if I can find that.

6           A     I think you're talking about a double scope  
7     washer?

8           Q     Yeah, tell me about that.

9           A     Well, there's some scope washers that you can  
10    clean two -- two scopes at the same time.

11          Q     Okay. And what does that look like?

12          A     It's like a plastic box and there's a lid that  
13    opens up and --

14          Q     And you put enzymatic fluid in there?

15          A     You know, the details of how you clean the scope  
16    is not what I do. I don't know.

17          Q     All right. I'll yield on that point. But you  
18    would acknowledge that the cleaning of the scopes is  
19    important?

20          A     Yes.

21          Q     And why is that?

22          A     Because viruses, parasites, bacteria can be in  
23    the channels of the scope and can potentially be transmitted  
24    to another patient.

25          Q     So if a scope wasn't properly cleaned, it has

1 the potential to transmit disease?

2 A Yes.

3 Q Well, I think that's all I have, Doctor. Thank  
4 you very much.

5 THE COURT: All right. Redirect?

6 MS. WECKERLY: No redirect. Thank you.

7 MR. WRIGHT: I want one more. What's one of those  
8 scopes cost?

9 THE WITNESS: They're -- well, you know, there's more  
10 to the scope than just the scope. You've got the processor  
11 and the light source and all the telemetry, but the scope  
12 itself costs about 30 or 35,000.

13 MR. WRIGHT: That's it.

14 THE COURT: Anything else, Ms. Weckerly, based on  
15 that last question?

16 MS. WECKERLY: No.

17 THE COURT: Do we have any juror questions for this  
18 witness?

19 All right. Doctor, apparently there are no further  
20 questions for you. Thank you for your testimony. You are  
21 excused at this time.

22 THE WITNESS: Thank you.

23 THE COURT: And, State, I believe that's all you have  
24 for today?

25 MR. STAUDAHNER: That's correct, Your Honor.

1 THE COURT: All right. Ladies and gentlemen, we're  
2 going to go ahead and take our weekend recess.

3 During the weekend recess you're reminded that  
4 you're not to discuss the case or anything relating to the  
5 case with each other or with anyone else. You're not to read,  
6 watch, listen to any reports of or commentaries on this case,  
7 any person or subject matter relating to the case. Don't do  
8 any independent research by way of the Internet or any other  
9 medium, and please do not form or express an opinion on the  
10 trial.

11 We will reconvene Monday morning at 9 a.m. Please  
12 place your notepads in your chairs and follow the bailiff  
13 through the rear door.

14 (Jury recessed for the weekend at 4:44 p.m.)

15 THE COURT: Ms. Weckerly, what do we have to look  
16 forward to on Monday?

17 MS. STANISH: That's what we were talking about.

18 MS. WECKERLY: Well, I know it will be --

19 MR. WRIGHT: I didn't know whose it was.

20 MS. WECKERLY: That's whose it is. Well, I know  
21 -- I know we'll have Brian Labus Monday and Tuesday. I'll  
22 have to kind of schedule everybody else after that, but --

23 THE COURT: Okay.

24 MS. WECKERLY: -- that will give us a --

25 THE COURT: All righty.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

(Court recessed for the weekend at 4:45 p.m.)

**CERTIFICATION**

I CERTIFY THAT THE FOREGOING IS A CORRECT TRANSCRIPT FROM THE AUDIO-VISUAL RECORDING OF THE PROCEEDINGS IN THE ABOVE-ENTITLED MATTER.

**AFFIRMATION**

I AFFIRM THAT THIS TRANSCRIPT DOES NOT CONTAIN THE SOCIAL SECURITY OR TAX IDENTIFICATION NUMBER OF ANY PERSON OR ENTITY.

**KARR REPORTING, INC.  
Aurora, Colorado**

  
KIMBERLY LAWSON



1 MR. WRIGHT: I'll hold the door.

2 THE WITNESS: I think the point is you cannot give me  
3 anesthesia from that far, No. 1. And No. 2, you cannot do the  
4 preanesthesia evaluation from that distance either. So, you  
5 know, it's present with the patient.

6 BY MS. STANISH:

7 Q Right.

8 A It has to be face-to-face. You can't give  
9 anesthesia unless you're face-to-face with the patient, or  
10 you're at the head of the table or how -- side of the table,  
11 whatever you want to call it, but you're still present with  
12 the patient.

13 Q Okay.

14 A Present.

15 Q Right. Okay. I get it.

16 THE COURT: May I see counsel at the bench, please?

17 MS. STANISH: Wait, I just have one more question.

18 THE COURT: Okay. Ask the question.

19 BY MS. STANISH:

20 Q So as I understand your testimony, you know, if  
21 they're -- what you expect, what you're adamant about, is that  
22 there is a set of rules and everyone follows them.

23 A Supposed to, yes.

24 Q And fair statement that you want a set of rules  
25 that everyone can understand?

1           A     Yes, I would like for everyone to understand  
2 them.

3           Q     But not everyone does.

4           A     Not everyone does.

5           Q     And not everyone, even though there's a contract  
6 provision that requires them to do so, not everyone keeps up  
7 with it?

8           A     Not everyone does.  You're --

9           Q     And not everyone does it personally, providers.  
10 They may have a billing coder, a third-party coder help with  
11 these intricacies of the billing scheme?

12          A     Yes, that's why many physicians in any kind of  
13 practice or hospitals will have people that have the  
14 knowledge, the skills, the credentials to accurately reflect  
15 what's -- where the provider comes in, in this case  
16 anesthesia, is they have to make sure their documentation is  
17 accurate because these people over here that are going to be  
18 taking this information and this procedure and this  
19 documentation to support what they want to bill because if  
20 they don't you're asking these people over here to build  
21 something that is not really supported by documentation.

22                So even if the providers don't know these people  
23 over here, the coders, people like me should be educating  
24 them.  But they normally don't like that.  They don't like it  
25 at all.

1 Q I wonder why.

2 A Because, you know, what they really want to do,  
3 most providers, is they just want to practice medicine. They  
4 just want to give anesthesia. They just want to practice  
5 medicine. But there's more to it than that. We're -- you  
6 know, we're back to the quality of care and the health record,  
7 you know, how important that is. We're back to being accurate  
8 and have sufficient documentation to support what you want  
9 these people to bill for you.

10 It -- it's just being responsible, it's being  
11 accurate, it's being appropriate; and if you don't know it,  
12 don't understand it, then I think you should seek out that  
13 information from those who have it and keep asking until you  
14 do understand it because that is what insurers expect and  
15 certainly Medicare does, and their language can be difficult  
16 at times.

17 Q At times?

18 A Frequently.

19 Q All right.

20 A It can be difficult, but that doesn't release us  
21 from the responsibility of trying to find out and there's many  
22 ways to find out so that you will be accurate in what you're  
23 doing.

24 Q Great. Thank you.

25 A You're welcome.

1 THE COURT: All right. Is that it for you, Ms.  
2 Stanish?

3 MS. STANISH: Yes.

4 THE COURT: Mr. Santacroce -- you don't need to  
5 approach the bench. Mr. Santacroce, do you have any  
6 questions?

7 MR. SANTACROCE: No.

8 THE COURT: Any redirect based only on what Ms.  
9 Stanish asked?

10 MS. WECKERLY: No, Your Honor.

11 THE COURT: Any juror questions for the witness  
12 before I excuse her? No juror questions?

13 All right. Ma'am, thank you for your testimony.  
14 You are excused at this time.

15 THE WITNESS: Thank you.

16 THE COURT: What's that? Oh. Ladies and gentlemen,  
17 we're going to go ahead and take our lunch break. We'll be in  
18 recess for the lunch break until 1:50.

19 During the lunch break you're reminded you're not to  
20 discuss the case or anything relating to the case with each  
21 other or with anyone else. You're not to read, watch, listen  
22 to any reports of or commentaries on this case, any person or  
23 subject matter relating to the case. Do not do any  
24 independent research by way of the Internet or any other  
25 medium. Please don't form or express an opinion on the trial.

1 Notepads in your chairs. Follow the officer to the  
2 door.

3 (Jury recessed at 12:44 p.m.)

4 THE COURT: While I remember, before we take our  
5 lunch break I just wanted to note on the record that at the  
6 conclusion of yesterday, after I had left the bench I had my  
7 JEA Sheri run in and tell the lawyers that they didn't need to  
8 be here until 9:30 this morning and that's when they got here.  
9 So I just wanted the record to be clear on -- on that, that it  
10 was a 9:30 start time.

11 MS. STANISH: Thank you, Your Honor.

12 THE COURT: All right. Go to lunch.

13 (Court recessed from 12:46 p.m. to 1:52 p.m.)

14 THE COURT: Bring them in.

15 (Pause in the proceedings.)

16 THE COURT: Bring them in.

17 THE MARSHAL: Ladies and gentlemen, please rise for  
18 the presence of the jury.

19 (Jury entering at 1:56 p.m.)

20 THE COURT: All right. Oh. All right. Court is now  
21 back in session. And the State may call its next witness.

22 MR. STAUDAHER: Mark Silberman, Your Honor.

23 THE COURT: Sir, just right up here, please, next to  
24 me. And then just remain standing, facing this lady right  
25 there and she'll administer the oath to you.

1 MARK SILBERMAN, STATE'S WITNESS, SWORN  
2 THE CLERK: Thank you. Please be seated. And please  
3 state and spell your name.  
4 THE WITNESS: My name is Mark Silberman, that is  
5 S-I-L-B as in boy, E-R-M-A-N.  
6 THE COURT: All right. Thank you.  
7 Mr. Staudaher?  
8 MR. STAUDAHER: Thank you, Your Honor.  
9 DIRECT EXAMINATION  
10 BY MR. STAUDAHER:  
11 Q Mr. Silberman, are you the designated custodian  
12 of records person most knowledgeable from the American  
13 Association of Nurse Anesthetists?  
14 A I am.  
15 Q Were you sent out here to -- to act in that  
16 capacity to talk about records of your organization?  
17 A Yes.  
18 Q Are you familiar with those records?  
19 A I am.  
20 Q And did you provide those records to us  
21 initially in this case?  
22 A I did.  
23 MR. STAUDAHER: May I approach, Your Honor?  
24 THE COURT: You may.  
25 BY MR. STAUDAHER:

1           Q     I'm showing you what has been marked as Proposed  
2 State's 219 to 227. And just flip through those generally,  
3 and we'll go through them in a little more detail. Yeah, flip  
4 through them, and you can go ahead and just tell me -- tell us  
5 if you're familiar with them, if, you know, the records of  
6 your organization and if those are the ones you provided to  
7 us?

8           A     (Witness complied.) Yeah.

9           Q     And exactly what are these records?

10          A     These are documents that we provided in response  
11 to a subpoena. The subpoena requested information related to  
12 a series of documents and a letter that was issued by the  
13 AANA, the president of the AANA in, I believe it was 2002 in  
14 response to a hepatitis outbreak that had taken place, and it  
15 also included some membership regarding -- information  
16 regarding two members and a press release related to that same  
17 outbreak.

18          Q     The records that you just looked at, are they  
19 records of your organization?

20          A     Yes, they're records from the AANA.

21          Q     Are they kept in the ordinary course of  
22 business?

23          A     They are.

24          Q     Do you rely upon those records in the duties and  
25 things that you need to do as -- in conducting your business?

1 A We do.

2 Q Do these accurately and truly represent the  
3 records that are contained at your location, your business?

4 A Yes, they do.

5 MR. STAUDAHER: Your Honor, at this time I'd move for  
6 admission of State's Proposed 219 to 227.

7 THE COURT: Any objection?

8 MR. SANTACROCE: No objection.

9 MS. STANISH: No objection.

10 THE COURT: All right. Those are admitted.

11 (State's Exhibit 219 through 227 admitted.)

12 BY MR. STAUDAHER:

13 Q Now, I'm going to ask you -- as we go through  
14 them I'm going to ask you some questions about them, but the  
15 exhibits themselves are unhighlighted. I'm going to show you  
16 some that -- to facilitate your examination that are  
17 highlighted. Those are my highlights. I'm just putting that  
18 on the record as we go forward, okay?

19 And I'll --

20 MS. STANISH: It's --

21 BY MR. STAUDAHER:

22 Q -- refer to the pages by Bates --

23 MS. STANISH: -- it's --

24 MR. STAUDAHER: -- I'm sorry?

25 MS. STANISH: -- do you mind if I borrow that other



1 one --

2 MR. STAUDAHER: Sure.

3 MS. STANISH: -- while you have your --

4 MR. STAUDAHER: You bet.

5 MS. STANISH: -- colored one?

6 BY MR. STAUDAHER:

7 Q And I will refer to them by Bates Number, which  
8 is -- appears in the lower-right-hand corner, and I won't tell  
9 the whole thing every time, but it's DA Endoscopy AANA  
10 Documents, and then the number is the Bates Number.

11 Now, the first thing I want to do is to go and look  
12 at what is termed Bates No. 1 and ask you some questions about  
13 it.

14 A Okay.

15 Q I'll display this on the screen. And as we go  
16 through this, I just want you to know that if you need to at  
17 any time, this screen -- you can take your fingernail and draw  
18 on it like that, and then you just tap it down here on this  
19 corner and that will go away, okay?

20 A All right. Thank you.

21 Q So if you need to highlight something, I would  
22 ask you since we're using documents to actually kind of point  
23 out the areas that we're talking about if we need to, okay?

24 A No problem.

25 Q Now, specifically -- and I'll go in a little bit

1 more -- before I do that what -- are you familiar with this  
2 particular document?

3 A Yes.

4 Q And what is this?

5 A This is a printout of the web page. This was a  
6 copy of the letter that was sent out by the then president of  
7 the AANA, Dr. Lester, in 2002.

8 Q And do you know why this letter was sent out?

9 A This letter was sent out as an advisory to all  
10 nurse anesthetists in response to a series of events regarding  
11 the -- an outbreak of hepatitis and to make sure that all  
12 nurse anesthetists had access to all of the information and  
13 policies and guidelines regarding the reuse of needles.

14 Q Regarding what again?

15 A The reuse of needles.

16 Q Now, as far as this particular outbreak is  
17 concerned, you said that it went out to the membership as you  
18 had it at the time?

19 A Correct.

20 Q If you know -- I assume that there are more --  
21 there's nurse anesthetists that practice in the country than  
22 are members of your organization; is that fair?

23 A That is true.

24 Q Do you know about how many percentagewise nurse  
25 anesthetists are part of your organization?

1           A     Historically and consistently the AANA, the  
2 membership represents over 90 percent of nurse anesthetists.

3           Q     As far as the -- your organization what kinds of  
4 things do you do as an organization for your membership?

5           A     It's an advocacy organization. It's a  
6 professional -- a professional organization, so it advocates  
7 on behalf of the profession. It provides continuing  
8 education. It provides guidance policies. It sets standards  
9 for the practice of nurse anesthesia.

10          Q     The membership as it is constituted, I mean,  
11 what kinds of things do you do for the members as -- as sort  
12 of members of your organization?

13          A     There are multiple annual meetings that are open  
14 to the public; the board establishes policies, guidelines;  
15 there are -- there's an AANA journal which publishes  
16 information for members; there are newsletters, and then  
17 there's obviously political advocacy with regards to  
18 legislation, both on a national level, but also to assist  
19 state by state.

20          Q     Now, you mentioned journal. Is there -- is  
21 there other -- another professional organization for nurse  
22 anesthetists besides yours?

23          A     The -- well, there are other professional  
24 nursing associations. The only nursing association dedicated  
25 to nurse anesthetists is the AANA.

1 Q So you're the exclusive one?

2 THE COURT: And, sir, some of the jurors are having  
3 trouble hearing you.

4 THE WITNESS: Sorry.

5 THE COURT: Right in front of you there is that black  
6 box; that's the microphone. So if you can just speak up into  
7 that so we can make sure everybody hears you.

8 THE WITNESS: Will do. And my apologies.

9 BY MR. STAUDAHER:

10 Q So I want to go back to this. You said that  
11 there was an outbreak of hepatitis C and you wanted -- your  
12 organization wanted to disseminate information to the  
13 membership?

14 A That was what the purpose of this letter was.

15 Q Now --

16 THE COURT: And, Mr. Staudaher, you need to keep your  
17 voice up too.

18 MR. STAUDAHER: I'm sorry. I'll try to talk louder  
19 myself.

20 BY MR. STAUDAHER:

21 Q As far as that is concerned, this particular  
22 notification, was this an unusual event, or is this something  
23 that happens every six months or so with your organization?

24 A The outbreak of hepatitis or the --

25 Q A notification --

1 A -- issuance?

2 Q -- like this.

3 A This was an extraordinary situation. An  
4 extraordinary notice that was sent out.

5 Q So tell us about that, if you would. I mean,  
6 what about the notice, what was accompanying the notice, that  
7 kind of thing.

8 A So the notice itself -- I guess if I can --

9 Q Well, I'll move it to whatever you want me to.

10 A There's a reference to what is accompanying --  
11 here we go, in this paragraph here. The notice is a letter  
12 from the president of the AANA, and what was sent out was the  
13 standards of the AANA related to office practice and I believe  
14 it was also a hospital-based practice, and then the guidelines  
15 related to infection control, and then the code of ethics that  
16 the AANA has in place.

17 Q So the documents that accompanied this that you  
18 provided are those what we -- we have in the exhibits that are  
19 now in evidence in this case?

20 A Correct. The exhibits you showed me, with the  
21 exception of the membership information and then the press  
22 release, those other documents is what accompanied this  
23 letter.

24 Q Okay. Now, specifically I want to go try and  
25 zoom in on this a little bit more. Can you clear that for us,

1 please? Will you read that section for us, please? It's --

2 A Beginning with --

3 Q -- highlighted.

4 A -- after discussion?

5 Q Yes.

6 A After discussion with infection control experts,  
7 we have concerns that there may be a widespread  
8 misunderstanding by healthcare practitioners of the dangers  
9 associated with the reuse of needles and syringes. Needles  
10 and syringes are single-use items and should not be reused on  
11 the same patient or from patient to patient.

12 The possible exception is when a syringe and needle  
13 are used on the same patient for incremental dosing; however,  
14 once the syringe is partially or completely emptied, it should  
15 not be refilled for use even on the same patient.

16 Reuse of needles and syringes is a clear violation  
17 of AANA's infection control standards and guidelines, ASA's  
18 recommendations for infection control, as well as guidelines  
19 adopted by individual healthcare organizations.

20 Q Now, I want to go slide this up a little bit and  
21 have you tell us what the date of this letter is.

22 A The letter was issued on September 30, 2002. I  
23 believe that is the date that the letter went out. There's  
24 a -- I don't want to call it another version, but the letter  
25 also has a date, I think, of the week prior, which I believe

1 was when it was finalized for mailing.

2 Q So this one says September 30th of 2002,  
3 correct?

4 A Correct.

5 Q Now, I'll show you what is listed as Bates No.  
6 3. And this one has a date that is September 23rd of 2002; is  
7 that correct?

8 A Correct.

9 Q Is this the second letter that you were talking  
10 about?

11 A It was. Yes, it is.

12 Q Okay. And if you need to -- me to bring  
13 anything back to you so you can -- I know I'm giving you kind  
14 of a window to look at on the screen. If you need it in  
15 better context, I can return it to you to look at, okay?

16 The same language, though, appears in this secondary  
17 letter?

18 A Yes.

19 Q Now, what was the purpose of having two separate  
20 letters; if you know?

21 A My understanding is the only difference in the  
22 dating of the letters is when they were prepared to be sent  
23 out versus when it was posted on the website.

24 Q Okay. So --

25 MR. SANTACROCE: I didn't hear the last part of that.

1 THE WITNESS: When the letter was prepared to be sent  
2 out versus when it was posted onto the AANA website.

3 BY MR. STAUDAHER:

4 Q Now, with regard to the accompanying documents  
5 that you talked about, Bates No. 84, is this one of those  
6 series of documents that was presided -- provided to the nurse  
7 anesthetist?

8 A Correct.

9 Q And what is this particular item?

10 A That is the cover page for the standards for  
11 office-based anesthesia practice, the policy of the AANA.

12 Q What you go by?

13 A Correct.

14 Q And this was disseminated along with that letter  
15 to all the membership?

16 A Correct.

17 MS. STANISH: What was the Bates stamp on that,  
18 please?

19 MR. STAUDAHER: Oh, that was 84, I believe.

20 BY MR. STAUDAHER:

21 Q Now, specifically I want to ask you a couple of  
22 questions related to, I think it was another one of these  
23 documents. Just let me get to it here. There's another  
24 document that I wanted to ask you about that is Bates No. 25,  
25 which is -- it's titled, Infection Control Guide. Was this



1 also sent out to the membership along with that letter?

2 A Correct.

3 Q With regard to that particular item, I want to  
4 move forward to Bates No. 36. Do you see the title of that  
5 section?

6 A Yes.

7 Q What is it?

8 A That subsection is, Administration of Drugs and  
9 Solutions.

10 Q Slide down to the highlighted portion. Could  
11 you read that for us, please?

12 MS. STANISH: I'm sorry, could I have the Bates stamp  
13 --

14 MR. STAUDAHER: Oh, I'm sorry --

15 MS. STANISH: -- again?

16 MR. STAUDAHER: -- 36.

17 THE WITNESS: Strict adherence to infection-control  
18 procedures and standard precautions as required.  
19 Multiple-dose vials should be limited to a single patient use  
20 unless strict aseptic technique is used and a new sterile  
21 syringe and access device are used each time the vial is  
22 penetrated. The danger of cross-contamination from  
23 multiple-dose vials used for more than one patient must be  
24 weighed against any cost savings.

25 BY MR. STAUDAHER:

1 Q So part of your infection control guide?

2 A Correct.

3 Q Moving to the next one. There is a diagram --

4 and this is Bates No. 38. And the highlighted portions are

5 what I'd like you to read, and then if you can tell us what

6 the purpose of this diagram is.

7 A The --

8 Q Go ahead and read it first --

9 A -- it is --

10 Q -- for us.

11 A -- Classification of risks for transmitting

12 infection in anesthesia applications. And the next

13 highlighted section reads, Critical Risk. Items that enter a

14 sterile area of the body or the vascular system, condition at

15 the time of use equals sterile.

16 Q So we have that as being a critical risk, then

17 we have three other areas -- or, I guess, a total of four.

18 This one here?

19 A Reads, Semicritical Risk.

20 Q Noncritical and Environmental Surfaces?

21 A Correct.

22 Q So of the classification here, which is the

23 highest level of risk?

24 A It is critical risk.

25 Q With regard to -- make sure we're on the right

1 document here -- Bates No. 50. A conclusionary section of  
2 that document. Go ahead and read for us these sections if you  
3 would.

4 A When --

5 Q And the highlighted portion is all you need  
6 read.

7 A The assumption is made that all patients are  
8 potentially infectious. Acceptance of this concept requires  
9 anesthesia providers to approach the risk of infection,  
10 transmission of organisms, and cross-contamination in a  
11 careful, consistent, and logical -- I'm assuming it finishes  
12 "manner." It is clearly unacceptable to adopt the practice of  
13 standard precautions at one time and disregard it or apply its  
14 practices in part at other times.

15 Q You can go -- go ahead and read it since it's  
16 just two paragraphs. Read the entirety of that.

17 A The unique requirements of decontamination,  
18 disinfection, and sterilization for anesthesia equipment,  
19 ancillary devices, and accessories requires nurse anesthetists  
20 to fully understand and minimize the actual risks present for  
21 all parties. Anesthesia equipment mandates specialized  
22 attention as to how each product is processed to effectively  
23 destroy potentially infectious organism without destroying the  
24 integrity, performance, and safety of the product.

25 Decisions regarding the level of decontamination for

1 routine disease-specific, or case-specific management are no  
2 longer the sole responsibility of one individual. The CRNA in  
3 conjunction with all healthcare providers share the  
4 responsibility and accountability to ensure the safety of  
5 employees, staff, and patients.

6 Q Is that also part of your policy of the AANA?

7 A That is correct.

8 Q Now, I want to move to a section which you --  
9 you said was, I believe, some -- some sort of computer -- it  
10 was a thing related to the membership itself or two members  
11 specifically?

12 A Yes, there was --

13 Q Who --

14 A -- membership information.

15 Q -- who were those members that you gave  
16 information about?

17 A Mr. Lakeman and Mr. -- I don't want to pronounce  
18 it wrong -- I believe, Mathahs or Mathias.

19 Q Okay. I'm going to show you a first page --  
20 this is Bates No. 57. Tell us what we're looking at here.

21 A This is --

22 Q I need to -- let me move it out so we can try  
23 and get the entire document there.

24 A This is a printout from the prior computer  
25 system used by the AANA. I believe it was the WANG [phonetic]

1 system and the -- it contains various information on Mr.  
2 Lakeman's membership with the AANA.

3 Q So he was an active member?

4 A Correct.

5 MR. SANTACROCE: At what time period?

6 MR. STAUDAHER: We'll get to that.

7 BY MR. STAUDAHER:

8 Q I mean, he had been an active member at some  
9 point; is that correct?

10 A That is correct.

11 Q The next page, Bates No. 58. Do you see this?

12 A I do.

13 Q Okay. Can you tell us what this document is?

14 A This is a printout from the newer, the Aptify  
15 system that -- I think it was in 1999 the AANA converted over  
16 to to track membership information.

17 Q So you had two different systems over the course  
18 of your organization's life?

19 A I believe there are substantially more than two,  
20 but those are the most two recent, yes.

21 Q Okay. And do these two capture the time period  
22 in question that we were interested in?

23 A Yes.

24 Q So this one came from which system again?

25 A This came from the Aptify system.

1           Q     Now, can you tell us what we're looking at here  
2 on this particular --

3           A     This -- it's listed under the orders tab, but  
4 what it is is the listing of bills sent out and then payments  
5 made with regards to membership. And it identifies the time  
6 period of each, and then identifies the individual, in this  
7 case Mr. Lakeman, whether or not he was an active member?  
8 There's a few classifications. There's active, inactive,  
9 retired.

10          Q     So in order to be active what do you have to do?

11          A     To be an active member of the AANA, assuming  
12 that you're not a student anesthetist at the time, nurse  
13 anesthetist at the time, you need to have completed the  
14 national certification exam or successfully have been  
15 recertified by the now national board of certification and  
16 recertification of nurse anesthetists, and you have to have  
17 completed an accredited educational program by the -- at a  
18 nursing school accredited by the council on accreditation.

19                The other requirements of being a nurse anesthetist  
20 also include having completed a critical care and then also  
21 having your RN.

22          Q     Do you as part -- I mean, in part of your  
23 organization you mentioned a journal; is that right?

24          A     Right.

25          Q     Is that something that gets sent out to the

1 members?

2 A It does.

3 Q Do you have other mailings and the like during  
4 the course of, you know, a year that gets sent to members and  
5 so forth?

6 A There's newsletters, there's emails, there's  
7 various, you know, just advocacy issues or things that might  
8 be of interest or note for the membership, so yes.

9 Q So the information that was contained in the  
10 document -- the letter that I had showed you earlier, as well  
11 as the accompanying pamphlets, the infection control guy, the  
12 code of ethics, all of that kind of thing -- did -- did those  
13 items actually make it into -- I mean, some form to get to  
14 the -- every one of the members? I mean, as far as either  
15 emailed, mailed, both, what? How did you get them out?

16 A The -- in this instance these were all hard-copy  
17 mailed to all members, along with the letter from President  
18 Lester.

19 Q So to be an active member, do you have to  
20 continue to give your address information and so forth? I  
21 mean, do you have to know where these people are?

22 A I mean, it certainly helps, yes.

23 Q Okay. I mean, can you --

24 A The AANA --

25 Q -- communicate with them --

1 A -- does track its members' information.

2 Q Okay.

3 A Contact information.

4 Q And do you -- did you track -- and as a part of  
5 your coming here, the locations where Mr. Lakeman had worked  
6 in the past, or where he had resided, rather?

7 A Yes.

8 Q Did there appear to be any time period in which  
9 you weren't able to track him? I mean --

10 A No, there was an --

11 Q -- if you lost him or something?

12 A No, there was an address that was identified in  
13 1999, then there was an address change in 2004, and then one  
14 more in 2007 when he moved to, I believe, Georgia.

15 Q Okay. So the prior address in 2007 before he  
16 moved to Georgia was where?

17 A In Las Vegas. I don't recall the exact address.

18 Q But it was in Las Vegas?

19 A Yes.

20 Q Now, looking at the -- at this section here, the  
21 lower-right -- left-hand corner, rather, of Bates No. 58. Can  
22 you tell us what we're looking at there as far as those  
23 entries? And let me zoom in on those a little bit, just so  
24 that they're a little bit bigger for --

25 A So this just represents basically bills issued



1 and payments made starting in 1998 and continuing through  
2 2007, showing an active membership. And then in 2008 and 2009  
3 showing an inactive membership.

4 Q Okay. So at least during this period of 2000 --  
5 and it looks like there was a renewal; is that what this date  
6 is?

7 A That would be the date that the -- I believe  
8 it's the payment was received.

9 Q So you get the money for membership?

10 A For dues.

11 Q Okay. So we're talking about July 11, that's  
12 when that was received and it shows that he is active?

13 A Correct.

14 Q Now, the following year the same -- same month  
15 it's now showing he's inactive?

16 A That -- yes.

17 Q But if we go back in time to 2002, what is it  
18 showing?

19 A It shows an active membership.

20 Q So you had his address; he was an active member  
21 at that time?

22 A Correct.

23 Q When this -- all this mailing went out?

24 A Correct.

25 Q Can you say with 100 percent certainty that he

1 actually got this stuff?

2 A No.

3 Q But no -- is there any indication that it was  
4 ever returned or bounced back, anything like that?

5 A No.

6 Q Now, as far as the code of ethics that I asked  
7 you about a moment ago -- and this is Bates No. 22. Let me  
8 zoom back out. Can you read those highlighted portions? And  
9 this is entitled what? What is the -- what is the section?

10 A Section 1 is, Responsibility to Patients.  
11 Subsection 1.2, The CRNA protects the patient from harm and is  
12 an advocate for the patient's welfare. Section 1.4, The CRNA  
13 avoids conflicts between his or her personal integrity and the  
14 patient's rights. In situations where the CRNA's personal  
15 convictions prohibit participation in a particular procedure  
16 and the CRNA refuses to participate or withdraws from the  
17 case, provided that such refusal or withdrawal does not --  
18 does not harm the patient or constitute a breach of duty.

19 Section 1.5, The CRNA takes appropriate action to  
20 protect patients from healthcare providers who are  
21 incompetent, impaired, or engaged in illegal or unethical  
22 practice. And Section 1.7, The CRNA does not knowingly engage  
23 in deception in any form.

24 Q Now, the very first page of that document, just  
25 so we know which one we're looking at, is entitled, Code of

1 Ethics, correct?

2 A That is correct.

3 Q Now, the last one that I want to go through with  
4 you is a document that is entitled Scope and Standards for a  
5 Nurse Anesthesia Practice; do you see that?

6 A Yes.

7 Q And this is Bates No. 78 for counsel. Now,  
8 specifically, Bates No. 80. And these are the standards,  
9 correct?

10 A Correct.

11 Q If we go to standard 6, can you read that for  
12 us?

13 A Standard 6, There shall be complete, accurate,  
14 and timely documentation of pertinent information on the  
15 patient's medical record. And then it includes an  
16 interpretation, Document all anesthetic interventions and  
17 patient responses. Accurate documentation facilitates  
18 comprehensive patient care.

19 Q Okay. And then the last page of that, which is  
20 Bates No. 81. And I think there is the section here -- let's  
21 just go ahead and start over with section -- Standard 8.

22 A Standard 8. The highlighted portion reads,  
23 Adhere to appropriate safety precautions.

24 Q And then -- and you can read the whole  
25 paragraph. That's fine.

1           A     As established within the institution to  
2 minimize the risks of fire, explosion, electrical shock, and  
3 equipment malfunction. Document the patient's medical  
4 record -- excuse me. Document on the patient's medical record  
5 that the anesthesia machine and equipment were checked.

6           Q     Now, the last one here Standard 9, it looks  
7 like.

8           A     Standard 9 reads, Precautions shall be taken to  
9 minimize the risk of infection to the patient, the CRNA, and  
10 other healthcare providers.

11          Q     And again, are those the policies and practices  
12 that are disseminated to all members that they're supposed to  
13 adhere to, those standards?

14          A     Correct.

15          Q     And at least that was what the standard was back  
16 in 2002?

17          A     These are all of the standards that were sent  
18 out with the letter from the president.

19          Q     Have those standards appreciably changed since  
20 2002 as far as the things that we went over?

21          A     Regarding those core issues, no.

22          MR. STAUDAHER: I have nothing further, Your Honor.

23          THE COURT: All right.

24          MR. STAUDAHER: Pass the witness.

25          THE COURT: Cross?

1 MR. SANTACROCE: Thank you.

2 CROSS-EXAMINATION

3 BY MR. SANTACROCE:

4 Q Good afternoon, Mr. Silberman.

5 A Good afternoon, sir.

6 Q Can you tell me what your position with the AANA  
7 is?

8 A Yes, sir. I am their outside general counsel.

9 Q Oh, so you're a lawyer?

10 A Yes, sir.

11 Q And what does it mean, "outside general  
12 counsel"?

13 A It means I'm not a full-time employee of the  
14 AANA, but I am their general counsel. So I am --

15 Q Are you in a different location than they are  
16 located?

17 A I mean, I work for a law firm, yes.

18 Q Okay. So you're not physically in the building  
19 where the AANA is?

20 A No.

21 Q And what -- were you employed as general counsel  
22 for the AANA in 2002?

23 A No.

24 Q Did you work in any capacity with the AANA in  
25 2002?

1 A No, sir.

2 Q This -- do you belong to any professional  
3 organizations like the ABA?

4 A I believe I belong to the Illinois State Bar  
5 Association.

6 Q Do you get a magazine every month from them?

7 A I do.

8 Q Do you read everything in it?

9 A Not everything, no, sir.

10 Q I want to talk to you a little bit about these  
11 exhibits that you were just shown. Starting off with this  
12 letter of 2000 -- September 30, 2002. Your organization, as I  
13 understand it, is noncompulsory. In other words, a CRNA  
14 doesn't have to belong to your organization to be a CRNA?

15 A That is correct.

16 Q And your organization is an advisory group,  
17 correct -- or an advocacy group?

18 A That's certainly a component of it, yes. It  
19 represents the professional organization.

20 Q Well, I guess what I'm getting at is, you guys  
21 don't establish rules and regulations --

22 A Correct.

23 Q -- correct?

24 A Correct.

25 Q Okay. This letter went out as a result of a

1 hepatitis C outbreak where?

2 A I believe it was in Oklahoma.

3 Q Okay. And in 2002, correct?

4 A Yes.

5 Q And it was set out -- I believe the predicate in  
6 there was that there was a widespread misunderstanding; is  
7 that correct?

8 A That is what the document says, yes, sir.

9 Q And what was that widespread misunderstanding?

10 A There -- so, I can speak to what the records  
11 that I have provided and reviewed show --

12 Q Sure.

13 A -- which is in the press release it shows there  
14 was differing opinions with regards to the reuse of needles  
15 and whether -- amongst all anesthesia providers, and other  
16 physicians.

17 Q Okay. Do you know more specifically what that  
18 misunderstanding was? Was it -- I guess, was it contrary to  
19 what you set forth in this letter?

20 A Well, but what was set forth in the letter was  
21 the policy of the AANA, which has always been consistent that  
22 needles shouldn't be reused.

23 Q So it was a misunderstanding that CRNAs were  
24 reusing needles and syringes?

25 A I guess I'm not understanding the --

1           Q     Okay. You were trying to set the record  
2 straight here, I guess, saying that the AANA policy is what  
3 you set forth in the letter?

4           A     Correct.

5           Q     Because CRNAs were doing different types of  
6 procedures and had different kinds of policies, correct?

7           A     I don't believe it was just CRNAs. I think  
8 there was concerns regarding all anesthesia providers and they  
9 wanted -- the AANA wanted there to be clarity.

10          Q     So an anesthesiologist as well as CRNAs were  
11 reusing needles and syringes?

12          A     I can't speak to that factually, but I believe  
13 that was part of the concern of the outbreak.

14          Q     And reusing propofol on more than one patient?

15          A     I would be speculating.

16          Q     Okay. Well, I mean, there's a basis for this,  
17 is there not? The infection in Oklahoma was from some sort of  
18 reuse of needles and syringes, wasn't it?

19          A     Again, that's my understanding, but I don't know  
20 the full circumstances of that or what drugs were being  
21 utilized.

22          Q     Okay. In any event the ANA -- AANA decided to  
23 publish this letter and send it out to their members, correct?

24          A     Yes, sir.

25          Q     Of which Mr. Lakeman was a member at the time,



1 correct?

2 A That is correct.

3 Q And I believe we looked at one of these exhibits  
4 which showed him to be an active member; is that correct?

5 A Correct.

6 Q And this letter would have been sent to where?  
7 Where would this letter have been sent?

8 A I would have to look to see what address was  
9 reflected in --

10 Q Is it not showing --

11 A 2000 and --

12 Q -- on your screen there?

13 A Well, the address that it shows shows 8117  
14 Highlands Drive.

15 Q And what's the city and state?

16 A Midland, Georgia. I don't know the -- as I had  
17 mentioned, there was two changes in address, and I believe in  
18 2007 it showed a change to Georgia, but prior to 2007 the two  
19 addresses that were listed on the system were in Nevada.

20 Q So in 2002 you sent this advisory letter to Mr.  
21 Lakeman in Georgia?

22 A No, sir. What I'm telling you is the document  
23 you just presented --

24 Q Mm-hmm.

25 A -- shows the address from 2007. That was what

1 came up because it was most recent in the system when the  
2 document was printed out.

3 Q Where did --

4 A But --

5 Q -- where did you send the letter to Mr. Lakeman?

6 A Based on the records, I have every reason to  
7 believe it would have been sent to the address that was on  
8 file in 2002, which was in Nevada.

9 Q Okay. 2002 in Nevada? So if I represented to  
10 you that he didn't start his employment in Nevada until later  
11 than that, would you have any reason to dispute that?

12 A Again, I'd be speculating.

13 Q But at least your testimony is that you sent  
14 this letter to a Nevada address in 2002?

15 A My testimony is that there is an address that's  
16 in the system that was his address in 2002, and it would have  
17 been sent to that address, yes, sir.

18 Q Okay.

19 A I believe it to be in Nevada, but I don't have  
20 that information in front of me.

21 Q So you can't testify where it was sent?

22 A Not from memory and certainly not from that  
23 screen because that screen shows the address in 2007, which  
24 was in Georgia.

25 Q Now, you were shown some exhibits -- and I want

1 to get a clarification as to what this means. Standards for  
2 office-based anesthesia practices, what does that mean?

3 What's an office-based anesthesia practice?

4 A As compared to a hospital-based.

5 Q Okay. So you have hospital-based and  
6 office-based?

7 A Yes, sir.

8 Q Is that correct?

9 A Yes.

10 Q Oh, okay. And what -- what is the distinction?  
11 Are there different rules for hospitals and different rules  
12 for offices -- office-based practice?

13 A Again, not wanting to get into clinical  
14 differences, as I'm not a nurse anesthetist, but there are  
15 distinct things that are reflected in the practices to reflect  
16 the environment in which the anesthesia is being administered.

17 Q Can you give me some specifics?

18 A Again, I think it's going to depend on the  
19 equipment available and it's going to depend on who is  
20 involved in the administration of anesthesia. But again, I  
21 would also submit that the practice -- or the -- excuse me,  
22 the policy would speak for itself.

23 Q What does this mean -- this sentence mean here,  
24 Most office-based practice settings are not regulated. What  
25 does that mean?

1           A     To me as an attorney?

2           Q     No, as a spokesman for the AANA -- a  
3 spokesperson. A person that's here to testify about it.

4           MR. STAUDAHER: Actually, Your Honor, I believe he's  
5 the custodian of records. Not a spokesperson --

6           MR. SANTACROCE: Well, the --

7           THE COURT: Well, as the -- not as an attorney, but  
8 as a -- as the custodian of records -- and well, you said PMK  
9 also for the association.

10          THE WITNESS: I guess I just want to be clear that I  
11 do not purport and don't want to be offering clinical,  
12 medical, you know, professional --

13          THE COURT: All right. So you --

14          THE WITNESS: -- guidance.

15          THE COURT: -- feel that you can't --

16          THE WITNESS: I wouldn't feel --

17          THE COURT: -- answer that question?

18          THE WITNESS: -- comfortable answering that question.

19          THE COURT: All right. That's fine.

20 BY MR. SANTACROCE:

21          Q     Were you not designated the person most  
22 knowledgeable for the AANA?

23          A     Again --

24          MR. STAUDAHER: Your Honor, I'm going to object.  
25 That doesn't have to do with office medical-based practice.

1 It's the organization itself that --

2 THE COURT: I'll see counsel up here.

3 (Off-record bench conference.)

4 BY MR. SANTACROCE:

5 Q Sir, would you read that sentence for me  
6 beginning with most?

7 A Certainly, sir. Most office-based practice  
8 settings are not regulated; therefore, the CRNA should  
9 consider the benefit of uniform professional standards  
10 regarding practitioner qualifications, training, equipment,  
11 facilities, and policies that ensure the safety of the patient  
12 during operative and anesthesia procedures in the office  
13 setting.

14 Q And is it your testimony today that you don't  
15 know what that, Most office-based practices are not regulated,  
16 means?

17 A I don't -- I can offer you my opinion as an  
18 attorney and as a healthcare regulator, but not as --

19 Q Not --

20 THE COURT: No, we have enough --

21 THE WITNESS: -- a nurse anesthetist.

22 THE COURT: -- attorneys already.

23 BY MR. SANTACROCE:

24 Q We have -- yeah.

25 A I didn't -- sorry.

1           Q     Don't need more attorney opinions. The answer  
2 is no, you don't know?

3           A     Correct.

4           Q     Now, after this September 30th letter went out  
5 to the membership, was there a survey conducted in November of  
6 2002 trying to ascertain whether there was compliance with  
7 this directive?

8           A     Again, I -- there was a survey conducted in --  
9 later in 2002 that I believe accompanied the press release  
10 that I provided.

11          Q     And that would be Exhibit 224; is that correct?

12          A     Correct.

13          Q     Showing you Exhibit 224. Is that it?

14          A     That is the press release, and then I believe  
15 the documents behind it relate to the survey.

16          Q     All right. Well, let's talk about this survey  
17 that was conducted after your letter of September 30, 2002.  
18 Can you tell me what the purpose of the survey was?

19          A     And again, I believe the document speaks for  
20 itself, but the survey was to reach out to different  
21 healthcare providers to ascertain whether or not there were  
22 issues with regards to the reuse of needles or syringes.

23          Q     And do you know what that study found?

24          A     I would have to look at the survey to be able to  
25 -- I could generally speak to it, but --

1           Q     Well, let's take a look at it and see what it  
2 says. Starting with this paragraph and this sentence, would  
3 you read this?

4           A     Can I just ask you to pull it out a little so I  
5 can see the whole --

6           Q     Let me --

7           A     Perfect. Thank you, sir. The survey also  
8 suggests that the reuse of a needle and/or syringe on the same  
9 patient is somewhat of a gray area for healthcare providers.  
10 31 percent of the survey respondents who use -- who only use  
11 needles and syringes indicated that they reuse on the same  
12 patient. The percentage jumps to 35 percent when taking into  
13 account providers using needleless systems in which the -- in  
14 which case the syringe would be reused on the same patient.

15               Discussions among healthcare professionals about the  
16 appropriateness of reuse with needleless systems is ongoing.

17           Q     So even after your 2002 letter, the survey found  
18 that it was still a gray area among providers, correct?

19           A     I believe the survey was taking place at the  
20 same time the letter was sent out, and the results were  
21 published in November.

22           Q     Okay. And what can you point to to help me  
23 appreciate that point?

24           A     That was my understanding as I looked into the  
25 circumstance to identify the documents and the background

1     thereof.

2                 Q     And what specifically did you look into to  
3     identify that?

4                 A     I spoke to the senior staff, I spoke to the CEO  
5     and executive director of the AANA and to the head of our  
6     program staff, who assisted me in originally identifying the  
7     documents responsive to the subpoena we received.

8                 Q     So other than that hearsay testimony, did you  
9     look at anything? Did you look at anything that actually said  
10    that?

11                A     Well, I looked at the documents that you're  
12    holding and that I believe -- they accompanied the survey --  
13    or excuse me, the press release which was issued in November,  
14    and presumably the survey itself had to precede the issuance  
15    of the results. So, I guess I'm making an assumption.

16                Q     Okay. Well, we don't want you to make any  
17    assumptions unless you can support it, okay?

18                Pointing out this paragraph here. Could you start  
19    from the quoted paragraph?

20                A     Beginning with, In the?

21                Q     Yeah.

22                A     In the anesthesia field alone, Lester said 3  
23    percent of physician anesthesiologists and 1 percent of CRNAs  
24    amounts to roughly 750 anesthesiologists and 250 nurse  
25    anesthetists, or a total of 1,000 providers. That is 1,000



1 too many.

2 Q Okay. And do you know what those 750  
3 anesthesiologists were doing?

4 A I believe that was the percentage applied to the  
5 number of practitioners to yield how many people were  
6 utilizing or reusing needles.

7 Q And this was after the 2002 letter, correct?

8 MR. STAUDAHER: Objection, Your Honor.

9 BY MR. SANTACROCE:

10 Q At least the publication --

11 MR. STAUDAHER: That's not his testimony.

12 BY MR. SANTACROCE:

13 Q -- of it?

14 A It's reflected in the November press release.

15 Q 750 -- and how many people were surveyed?

16 A Again, I would have to look back to the document  
17 itself. I want to say I believe it was at 1,000, but I don't  
18 want to be incorrect. I believe it was contained in the cover  
19 letter.

20 Q Well, do you want to take a look --

21 A If I could.

22 Q -- at the cover letter? Sure.

23 A It does not say in the cover letter, but I  
24 believe it might have been part of -- here's the methodology:  
25 There were 500 telephone phone interviews.

1           Q     Okay. Let's look at some of that methodology.  
2 Well, let's go to the key findings, first of all, and then  
3 we'll look at the methodology. Key findings, okay? The first  
4 bullet point, what was some of the key findings there?

5           A     Needle or syringe use is more prevalent practice  
6 among --

7           Q     Reuse, isn't it?

8           A     -- excuse me. My apologies. Needle or syringe  
9 reuse is a more prevalent practice among healthcare providers  
10 overall than may have been expected. Self-reported data --  
11 excuse me, did you want me to keep reading? Self-reported  
12 data illustrates that needle/syringe reuse is most prevalent  
13 among anesthesiologists, 40 --

14          Q     How many percent?

15          A     -- 42 percent.

16          Q     So nearly half of all anesthesiologists -- that  
17 is, M.D.s -- are reusing needles and syringes, correct?

18          A     Yeah, I believe that was the result of the study  
19 -- or of the telephone, I -- or of the survey.

20          Q     Okay. Go on.

21          A     Somewhat less prevalent among nurse  
22 anesthetists.

23          Q     And we would know them as CRNAs?

24          A     Yes, sir.

25                     (Off-record colloquy.)

1 BY MR. SANTACROCE:

2 Q What was the percentage of CRNAs that were  
3 reusing needles and syringes?

4 A Again related to this survey, 18 percent.

5 Q So you have nearly half of the M.D.  
6 anesthesiologists reusing, but only 18 percent of CRNAs; is  
7 that what the survey said?

8 MR. STAUDAHER: And, Your Honor, of the sample that  
9 he said, I would object to it if he says, "all"  
10 anesthesiologists. He said --

11 BY MR. SANTACROCE:

12 Q And when I say "all," I'm talking about the  
13 sample survey.

14 A That --

15 Q My comments are related to the survey, okay?  
16 Just so we understand.

17 A And, yes, then we're on the same page. That is  
18 what the survey showed.

19 Q Okay. And then it goes on to talk about oral  
20 surgeons, 15 percent, and then less common among nurses,  
21 correct?

22 A Yes, sir.

23 Q Now, go on to the third bullet point and  
24 remembering that this was a key finding in the survey. The  
25 third bullet point?

1           A     Many respondents believe that reusing  
2 needles/syringes is an acceptable practice under certain  
3 circumstances, and they wanted a chance to explain the nature  
4 of those circumstances. The most common instances involve  
5 same-patient dosing, intravenous or IV tubing and emergency  
6 situations.

7           Q     Okay. Was there a problem with IV tubing? Was  
8 there a outbreak of hep C that you're aware of due to IV  
9 tubing?

10          A     I couldn't speak to that, sir, no.

11          Q     Okay. And then the last bullet point again, key  
12 findings of the survey. You can read the last bullet point.

13          A     Although same patient needle/syringe reuse is  
14 estimated to be fairly high, ranging from 9 percent to 56  
15 percent by provider type, the estimation of reusing the same  
16 needle/syringe on multiple patients ranges from 0 percent to 3  
17 percent by provider type.

18          Q     Okay. So it was a common practice to reuse  
19 needle and syringes on the same patient, correct? According  
20 to the key points?

21          A     I don't know if I would describe it as a common  
22 practice, but --

23          Q     Of course not --

24          A     -- I mean, the numbers --

25          Q     -- you're a lawyer --

1 A -- are what they are.

2 Q -- you wouldn't do that. But go ahead.

3 A Well, I mean, I believe the survey showed 18  
4 percent reporting amongst CRNAs that were interviewed and 42  
5 percent amongst M.D. anesthesiologists that were interviewed.

6 Q Okay. Is that not a fairly significant number  
7 to you?

8 A Again, I think it was sufficiently significant  
9 that that's why the press release and the letter was sent out.

10 Q Now, let's take a look at some of the  
11 methodology. Well, I guess this next portion are just charts  
12 to substantiate the figures that we just read, or is there  
13 something different in there?

14 A To my knowledge, they simply are slides that  
15 break down the results.

16 Q Okay. And regarding this slide, if you would  
17 just read this part -- this first sentence here?

18 A Overall, respondents were asked if they  
19 themselves ever reused needles or syringes to administer  
20 medications.

21 Q Next sentence.

22 A One might find it surprising that 42 percent of  
23 anesthesiologists admit to the practice of reusing needles or  
24 syringes.

25 Q Do you find it surprising?

1 A You're asking my personal opinion?

2 Q No.

3 MR. STAUDAHER: Objection, Your Honor.

4 THE COURT: Yeah, that's sustained.

5 BY MR. SANTACROCE:

6 Q Again, some more data from the survey. Could  
7 you read that paragraph?

8 A The question of whether there are any  
9 circumstances when it is acceptable to reuse needles or  
10 syringes is a rather polarizing one.

11 Q What does "polarizing" mean?

12 A There's a split.

13 Q Okay.

14 A Only 15 percent of nurses stated that there are  
15 circumstances when it is acceptable, but significantly more  
16 physicians, CRNAs, oral surgeons, and anesthesiologists  
17 believe there are circumstances of acceptability with the  
18 highest being anesthesiologists. 65 percent of  
19 anesthesiologists responded that there are instances when it  
20 is acceptable to reuse needles or syringes.

21 Q Some more data. Could you read this paragraph?

22 A Significantly more than any other healthcare  
23 providers, anesthesiologists believe the reuse of needles or  
24 syringes is an acceptable practice. 51 percent of the  
25 anesthesiologists who responded to the survey believe reuse is

1 an acceptable practice. Oral surgeons, CRNAs, and other  
2 physicians are all in the range of approximately one-fourth  
3 who believe reuse is acceptable. Among nurses only 11 percent  
4 think reuse is acceptable.

5 Q Apparently nurses got your memo but  
6 anesthesiologists didn't.

7 THE COURT: I don't think you need to respond to  
8 that.

9 BY MR. SANTACROCE:

10 Q And then, finally, the last bit of data that we  
11 have on these charts, could you read that paragraph? Let  
12 me --

13 A The chart above displays responses to the  
14 question of whether the healthcare provider surveyed would  
15 allow another healthcare provider to reuse a needle or syringe  
16 on themselves or a family member. The responses correlate  
17 closely to responses previously discussed about one -- excuse  
18 me -- about whether one apparent -- one -- excuse me. About  
19 whether one believes that reuse of needles or syringes is an  
20 acceptable practice.

21 Apparently, if a healthcare provider truly believes  
22 that reusing needles or syringes is acceptable, he/she would  
23 not be concerned about treating -- about being treated this  
24 way or having a family member treated this way.

25 Q I got all these exhibits out of order, so I'm

1 scrambling to find them. Sorry.

2 A Not a problem.

3 Q Sorry for the delay. You'll still be able to  
4 make your plane.

5 We're going to look at the Infection Control Guide,  
6 Exhibit 223 for a minute, okay? Talked a little bit about  
7 some of those things in there. I don't know if you're going  
8 to be able to answer this for me. It says that the potential  
9 for infection and transmission of microorganisms exist during  
10 the administration of drug therapy. Instructions for  
11 preparation, storage, administration of all pharmaceutical  
12 agents provided by each manufacturer should be read and  
13 followed. Drug administration by injection offers many  
14 opportunities for contamination.

15 Then it goes on to say, These include previously  
16 used needles/syringe, drug administration sets, intravenous  
17 tubings, and fluid containers.

18 My question is what is a drug administration set?

19 A I --

20 Q I know, you're a lawyer. Okay. I'll take that  
21 as you don't know.

22 A I would not feel comfortable answering that.

23 Q Okay. And the same with intravenous tubing?

24 A I would feel comfortable that intravenous tubing  
25 is just that, intravenous tubing.



1 Q Okay. Are you familiar with heplocks?

2 A I am not, sir.

3 Q Again, we're referring to the infection control  
4 guide; do you see that?

5 A Yes, sir.

6 Q I'm referring to Bates Stamp 000036, bullet --  
7 or paragraph No. 2. Is that on your screen?

8 A It is not, sir. Yes, sir.

9 Q Is it now?

10 A Yes, sir.

11 Q Can you read that for me?

12 A I believe I read this before but, Multiple-dose  
13 vials should be limited to a single-patient use unless strict  
14 aseptic techniques is used and a new sterile syringe and  
15 access device are used each time the vial is penetrated. The  
16 danger of cross-contamination from multiple-dose vials used  
17 for more than one patient must be weighed against any cost  
18 savings.

19 Q Maybe I'm misunderstanding, but didn't your 2002  
20 directive say, can't use multi-dose vials?

21 A Not that you can't use multi-dose vials for the  
22 same patient, utilizing and reusing the same syringe and  
23 needle.

24 Q Okay. It says, Should be limited to  
25 single-patient use unless strict aseptic technique is used,

1 correct?

2 A Correct.

3 Q So you can use multi-dose vials?

4 A Utilizing a new needle each time and a new  
5 syringe.

6 Q So as long as you have aseptic practices?

7 A That's what the -- that's what the, excuse me,  
8 Standard 2 says.

9 Q And that's not contrary to the 2002 letter?

10 A I don't believe it is, no.

11 Q Okay. So is it the AANA guidelines that  
12 multi-use vials or multi-dose vials are okay to be used as  
13 long as aseptic practices are employed?

14 MR. STAUDAHNER: Objection.

15 THE WITNESS: Well, I mean, the --

16 MR. STAUDAHNER: Mischaracterizes his testimony, Your  
17 Honor.

18 THE COURT: Well, I think --

19 THE WITNESS: The procedure --

20 THE COURT: -- he --

21 THE WITNESS: -- speaks for itself. It -- what it  
22 says, It should be limited to single pace [sic] use unless a  
23 strict aseptic technique is used and a new sterile syringe and  
24 access device are used each time the vial is penetrated. So  
25 it's not just the aseptic technique, but it's also using a new

1 syringe and using a new needle.

2 BY MR. SANTACROCE:

3 Q Okay. But the vial can be reentered?

4 A Again, in accordance with that policy, yes.

5 Q Okay. In your practice do you find that the --  
6 the practice of reusing needles and syringes still goes on  
7 today? Do you receive reports on that?

8 A I just want to clarify, you're asking for  
9 information I have through the AANA or in my practice?

10 Q AANA.

11 A Okay.

12 Q Not your practice. I'm sorry.

13 THE COURT: It's unusual we get to pick on a lawyer.

14 THE WITNESS: And I will stipulate to its being  
15 appropriate, so...

16 BY MR. SANTACROCE:

17 Q But you are slippery, guy, I give you that.

18 A The -- I am not aware of any regular complaints  
19 that have been brought to the AANA recently regarding the  
20 reuse of needles.

21 Q Okay. Do you get reports from the CDC on a  
22 periodic basis?

23 A I believe the AANA does, yes.

24 Q Okay. Would you be surprised to know the CDC,  
25 even after this Las Vegas outbreak, conducted studies where

1 they found that the -- that the reuse of needles and syringes  
2 was still going on in at least three different states?

3 MR. STAUDAHER: Objection, Your Honor. Outside the  
4 scope of this witness's --

5 THE COURT: Yeah, it's sustained.

6 BY MR. SANTACROCE:

7 Q Would the AANA as a person most knowledgeable be  
8 surprised to know that?

9 THE COURT: Well --

10 MR. STAUDAHER: Objection, Your Honor. Same  
11 objection.

12 THE COURT: -- the same thing.

13 BY MR. SANTACROCE:

14 Q Do you receive any information or updates from  
15 the CDC as to whether the policies that you have initiated are  
16 being followed? When I say "you" --

17 A I don't believe -- I don't believe the -- I  
18 don't believe the -- I don't believe the CDC tracks compliance  
19 with the AANA policy, but the AANA policy is consistent with  
20 CDC guidelines; if that answers your question.

21 Q Okay. And you're sure about that?

22 A I believe that to be the case. I believe it's  
23 incorporated, but --

24 Q Well --

25 A -- I don't have the current policy in front of

1 me.

2 Q -- you know the passage we just used about the  
3 needles and syringes in vials -- you -- well, first of all, do  
4 you know what the CDC current policy is?

5 A I do not offhand.

6 Q Okay. Well, forget it, then.

7 I think that's all I have. Thank you, sir.

8 A Thank you, sir.

9 THE COURT: All right. Ms. Stanish?

10 CROSS-EXAMINATION

11 BY MS. STANISH:

12 Q Good afternoon.

13 A Good afternoon.

14 Q I won't be long. Without rehashing what Mr.  
15 Santacroce just reviewed with you am I correct in  
16 understanding that in 2002, according to the AANA they  
17 identified a misunder -- a widespread misunderstanding amongst  
18 healthcare practitioners regarding the misuse of needles and  
19 syringes, correct?

20 A That was the concern, yes.

21 Q And then it appears that with -- through these  
22 surveys that were discussed a moment ago it's a either a  
23 difference of opinion or a continued misunderstanding,  
24 correct?

25 A I don't know that the survey wasn't part of

1 the --

2 Q Okay.

3 A -- what led to the concern, but --

4 Q Let me -- Mr. Santacroce had asked you if you  
5 were aware of the most recent CDC guidelines -- I'll call them  
6 refinements of guidelines -- that deal with the single use of  
7 a syringe, the single use of a vial and no multidosing, one  
8 time only, one patient, throw everything away. Are you  
9 familiar with that?

10 A I'm familiar with the general policy, but not  
11 the specifics.

12 Q Are you involved in -- in drafting any of the  
13 position or policy statements of the AANA?

14 A I am, but to be clear, looking at it from a  
15 legal and regulatory perspective, not from a healthcare  
16 administration or delivery perspective.

17 Q I'm going to show you this document from the  
18 AANA. Is it double A, N-A; is that what you say?

19 A American Association -- AANA.

20 Q You don't say, like, AANA?

21 A Nope.

22 Q All right. If you would just read this to  
23 yourself so that we can discuss that.

24 A Do you want me to read the entire document or  
25 just the highlighted portions?

1 Q Just whatever you feel comfortable so that you  
2 get a handle on what this is about.

3 A (Witness complied.)

4 Q Are you familiar with this 2009 policy of the  
5 AANA?

6 A Not to be a lawyer, but I'd -- it was a position  
7 statement, not a policy. So it was just a statement  
8 reflecting what the current position state was -- position was  
9 regarding the safe practices of needles and syringes.

10 Q What?

11 A That's a -- there -- simply put, it's just there  
12 are things that are labeled policies as, you know, it said the  
13 infection control policy. This is identified a position -- as  
14 a position statement. So...

15 Q How you guys take a stand on something? Is that  
16 what "position" means?

17 A Making it clear what the position of the AANA  
18 is.

19 Q This document was prepared in -- what's the date  
20 on that?

21 A The first page of the document shows it in 2009.

22 Q And am I -- the -- describe for the jury what  
23 this position of AANA is.

24 A It reflects the position of the AANA on the safe  
25 practices for needles and syringes, and it reflects the fact

1 that the -- I mean, if I can --  
2 Q Let me do this.  
3 MS. STANISH: Your Honor, may I just mark this and  
4 throw it into evidence so that we can display it and chat  
5 about it?  
6 THE COURT: Any objection?  
7 MR. STAUDAHER: No, Your Honor.  
8 THE COURT: All right. Go ahead.  
9 MS. STANISH: Okay. I'll -- it has my highlights on  
10 it, but I'll replace it.  
11 THE COURT: Okay. Well, we'll send a clean copy back  
12 to the jury, but for --  
13 MS. STANISH: Okie-doke.  
14 THE COURT: -- purposes of right now --  
15 MS. STANISH: Thank you.  
16 THE COURT: -- go ahead and mark that. You can use  
17 your highlighted version.  
18 MS. STANISH: Pardon me?  
19 THE CLERK: [Inaudible.]  
20 MS. STANISH: Yes.  
21 THE COURT: It will be next in order.  
22 MS. STANISH: Yes.  
23 THE COURT: Which would be what?  
24 THE CLERK: P1.  
25 THE COURT: P1.



1 (Defendant's Exhibit P1 admitted.)

2 BY MS. STANISH:

3 Q Can you read that?

4 A I can.

5 Q Okay. Fair statement that this 2009 document  
6 was prepared because of continued -- the -- well, because of  
7 this case; can you tell?

8 A I would not make that representation. It does  
9 make reference to the fact that it was to the events that had  
10 occurred over the last 10 years, so from 1999 to 2009.

11 Q So not only this case but 32 other cases in the  
12 last 10 years, correct?

13 A The document does reference 33 outbreaks, yes.

14 Q And what the 2000 -- what this document does is  
15 this position statement further emphasizes or clarifies this,  
16 Never administer medication from the same syringe to multiple  
17 patients even if the needle is changed. Now, we've already --  
18 did this show to you, to the AANA, that there is continued  
19 misunderstanding about reusing a syringe once you put a new  
20 needle on it?

21 MR. STAUDAHER: Objection. Speculation unless he  
22 knows.

23 BY MS. STANISH:

24 Q Unless you know.

25 THE COURT: Right. I have a feeling he's not going

1 to engage in rampant speculation.

2 THE WITNESS: Yeah, I mean, I'm not inclined to.

3 THE COURT: I knew that. I knew that about you.

4 THE WITNESS: Thank you.

5 BY MS. STANISH:

6 Q And that's why they sent the lawyer instead of a  
7 CRNA or maybe this Mr. Lester who sent this letter in 2002,  
8 correct?

9 THE COURT: So if you can answer the question whether  
10 or not this was in response to widespread -- I don't remember  
11 Ms. Stanish's word.

12 MS. STANISH: Well, it sounded like he said he didn't  
13 have knowledge, so I moved on to the next question.

14 THE WITNESS: Well --

15 THE COURT: Right.

16 THE WITNESS: -- I mean, my response to the  
17 widespread issue was that it referenced 33 outbreaks over the  
18 course of the 10 years preceding.

19 BY MS. STANISH:

20 Q All right. All right. When Mr. Lester sent his  
21 letter out in 2002 reminding those CNRs [sic] who got the  
22 letter that this is how we're refining the reuse of needles  
23 and syringes. The standard of care didn't change on September  
24 30, 2002, did it?

25 MR. STAUDAHER: Objection. Outside the scope of his

1 knowledge about standard care changes.

2 MS. STANISH: Let me rephrase it.

3 THE COURT: Yeah, rephrase it.

4 BY MS. STANISH:

5 Q You wouldn't have had -- AANA wouldn't keep  
6 having to send out these kind of position papers in -- if the  
7 standard of care had changed in September 2002.

8 A To be clear, I think you're misrepresenting.  
9 This -- this -- the document reflected what the policies were  
10 of the AANA, and therefore they put out the fact that the  
11 position of the AANA was, not to reuse needles. I mean,  
12 that's what the documents --

13 Q And he -- you can -- the AANA has to -- has  
14 continued to try to emphasize and refine its policies because  
15 in the past we have seen that there's at least a disagreement  
16 or a misunderstanding about what is appropriate and what is  
17 not.

18 MR. STAUDAHER: Is there an --

19 THE COURT: Is that a --

20 MR. STAUDAHER: -- an outright question?

21 THE COURT: -- question?

22 THE WITNESS: Yeah, I --

23 BY MS. STANISH:

24 Q Correct?

25 A -- I think the issue is that there seems to be

1 behavior that isn't consistent with what the AANA position was  
2 and therefore they continue to reiterate and clarify their  
3 position.

4 Q They reiterate it and they refine it, correct?

5 A Based on new information, correct.

6 Q And this was new information, the new  
7 information being that people are still misunderstanding the  
8 reuse of syringes with new needles on it.

9 MR. STAUDAHER: Objection. Speculation.

10 THE WITNESS: I can't speak to what other people are  
11 or are not misunderstanding.

12 BY MS. STANISH:

13 Q If I told you that we had testimony in this  
14 courtroom for I don't know how long now that there -- CRNAs to  
15 this day are still using multi -- or single-use vials, 50  
16 milliliter-use vials to prefill syringes and use them on  
17 multiple patients. Would that be a violation of the AANA  
18 policy?

19 A Would the multiple use of a single-use item --  
20 that would be inconsistent with the AANA policy.

21 Q And do -- the AANA, has it done any further  
22 surveys since that one in 2002 that you're aware of?

23 A Not to my knowledge.

24 Q Okay. You weren't at the AANA in 2002?

25 A I was not.

1           Q     You really wouldn't have an indication one way  
2 or the other whether Mr. Lakeman's letter was returned to the  
3 mail room at the AANA in 2002?

4           A     No, my only comment was based on the fact that  
5 anytime there's an identified issue with regards to an  
6 address, it's then updated in the system, and there was  
7 nothing in the system that indicated an update in the address  
8 during that time.

9           Q     So you're the custodian of records, not the mail  
10 boy in 2002?

11          A     I'm not claiming to be either in 2002.

12          MS. STANISH: All right. I have nothing further.

13          THE COURT: Any redirect?

14          MR. STAUDAHER: Just -- just two. Oh, could I have  
15 that? Thanks.

16                         REDIRECT EXAMINATION

17          BY MR. STAUDAHER:

18           Q     This position statement -- now, the other  
19 document we had, Bates No. 1, this was a letter sent out to  
20 the entire membership, correct?

21          A     Correct.

22           Q     And it was because of -- I think you said  
23 because of that outbreak, this specific letter with all the  
24 policies was sent to everyone?

25          A     Correct.

1           Q     Mr. Lester here, I mean, is he still with the  
2 organization?

3           A     I'm embarrassed to say I don't know. He's a  
4 former president. I have not formally met him. I --

5           Q     So he's not sitting there --

6           A     -- I did not look at his membership information.

7           Q     -- so he's not sitting there when you go to  
8 visit the AANA?

9           A     No, he's certainly not a current board member or  
10 has not been in the last few years.

11          Q     This -- this one here, the one that Ms. Stanish  
12 showed you and it's entitled Position Statement, does it  
13 indicate here that this is like some sort of an emergency  
14 letter or anything sent out?

15          A     No.

16          Q     Or it's just the position -- position of the  
17 AANA?

18          A     Correct, it's a position statement.

19          Q     Now, you were asked some questions again on  
20 cross regarding Mr. Lakeman getting sort of the notification  
21 of those documents that we have been talking about up to this  
22 point, correct?

23          A     Yes, sir.

24          Q     I don't know if you have -- do you have anything  
25 with you or anything you can reference or did reference to

1 find out whether or not he was -- I mean, there was any  
2 problem at all with his address when these things were sent  
3 out?

4 A I looked at a screen shot that had changes of  
5 address, and that was what I was testifying regards -- that  
6 with regards to Mr. Lakeman there was in 2004 a change of  
7 address, and then again in 2007 the address -- the move to  
8 Georgia.

9 Q So in 2004 there was a change of address, and  
10 then 2007 there was a change of address?

11 A Correct. That was what the -- again, when I say  
12 a screen shot, when you go on the computer you can print out  
13 what you're seeing on there, so I printed that out.

14 Q But you didn't have anything about a change of  
15 address around 2002 that was an issue?

16 A No. The only changes of address -- there was  
17 two on the same day, which appeared to be -- speculating, on a  
18 correction of a typo because it started with two numbers and  
19 then corrected the address in 2004, and then a change in 2007  
20 to Georgia.

21 Q But again, nothing --

22 A Nothing.

23 Q -- in 2002?

24 A No changes in that time, no.

25 MR. STAUDAHER: Nothing further, Your Honor.

1 THE COURT: Mr. Santacroce?

2 RECROSS-EXAMINATION

3 BY MR. SANTACROCE:

4 Q Perhaps I misunderstood you when I asked you the  
5 question about the address changes. I thought you said 2002;  
6 was I mistaken?

7 A There was a change in 2004 and then a change in  
8 2007.

9 Q And again, what were you referring to?

10 A There's -- when you go onto the Aptify system,  
11 there's actually a -- a tab that I think is called addresses,  
12 or address history, and I clicked on that.

13 Q So address changes in 2004 and 2007?

14 A I believe that's correct.

15 Q And a letter was sent out in 2002?

16 A Correct.

17 Q And do you know what address it was sent to?

18 A I can go back to the printout I got to -- again,  
19 the address that it would have been sent to in 2002 would have  
20 been the address that preceded the change in 2004.

21 Q Okay. And I'm asking you what address that was.  
22 Do you have any knowledge of that?

23 THE COURT: Do you have that address of whatever  
24 address was on file in 2002?

25 THE WITNESS: I think I have a copy of the screen



1 shot, I can --

2 BY MR. SANTACROCE:

3 Q Sure.

4 A -- if everyone's okay?

5 MR. STAUDAHER: Yeah.

6 THE WITNESS: Okay. How do you want me to -- or do  
7 you want me to just testify from it?

8 THE COURT: No. No. Mr. Santacroce will walk up and  
9 take a look at whatever it is you have.

10 BY MR. SANTACROCE:

11 Q Let me show it to my colleagues too.

12 A And if you -- if -- okay, I'll show you what --

13 Q Yeah.

14 A -- is -- you have here the address. This is the  
15 date, so this October 1999 would have been when the system was  
16 converted over, and then it shows -- this was what I was  
17 pointing out. In 2004 there's a reference to 63 Goody, but  
18 then it's corrected to 6381 on the same day. So that's what  
19 led me to believe it was a typo. And then there was a change  
20 in 2007. That was the Georgia change.

21 MR. WRIGHT: What did they say?

22 MR. SANTACROCE: Let me show my colleagues.

23 MS. STANISH: Yeah. What happened up there?

24 MR. SANTACROCE: He was explaining what this was  
25 here. We'll let him explain to the jury.

1 THE COURT: Well, if you're --  
2 MR. SANTACROCE: We're not hiding --  
3 THE COURT: -- going to use it --  
4 MR. SANTACROCE: -- anything.  
5 THE COURT: -- yes, Mr. Santacroce.  
6 MR. SANTACROCE: What's that?  
7 THE COURT: I said if you're going to use it, yes, he  
8 will --  
9 MR. SANTACROCE: Well, no, I just want to --  
10 THE COURT: -- he will --  
11 MR. SANTACROCE: -- clear it up.  
12 THE COURT: -- that's fine. I mean --  
13 MR. SANTACROCE: And I don't want the jury to think  
14 that we're hiding the ball or anything here.  
15 BY MR. SANTACROCE:  
16 Q So let's just -- why don't you explain to the  
17 jury what this is, if the -- if the State doesn't mind?  
18 MR. STAUDAHER: No, he can admit it as far as I'm  
19 concerned.  
20 THE WITNESS: The only thing I could ask you to do is  
21 if you could scoot it over a little so I can, I guess, use  
22 this touch feature.  
23 So starting off in -- in this column here there's a  
24 date in October of 1999, and I believe that was when the  
25 conversion over from the prior system took place, and the

1 address that it shows there is No. 3 Mallard Court. There was  
2 a change here at -- and -- oh, goodness, in -- on May 3rd of  
3 2004 that switched to 6361 Goody Court.

4 When I referenced that I thought there was a type.  
5 It was because 63 Goody Court was entered in, and then that  
6 same day it was changed to 6361.

7 BY MR. SANTACROCE:

8 Q What was the "Oh, goodness" that you just said?

9 A Just the arrow popped up. Sorry.

10 Q Oh, I didn't know if there was something --

11 A No. No.

12 Q -- there was a revelation here I should know  
13 about.

14 A And then, finally, if you'll look in 2007, that  
15 was when the address that you and I spoke about earlier,  
16 Highlands Drive, which I believe to be in Georgia. And so  
17 with regards to your prior questioning, nothing would have  
18 been sent to that Highlands Drive address in 2007 -- or excuse  
19 me, 2002, because that address didn't go on file until 2007.

20 Q Okay. So --

21 MR. SANTACROCE: -- go ahead, Your Honor.

22 THE COURT: Oh, I was just going to say, so the 2002  
23 address would have been the Mallard Court address?

24 THE WITNESS: Correct.

25 THE COURT: Okay.

1 BY MR. SANTACROCE:

2 Q Okay. Now -- so I'm asking you where -- do you  
3 know where the letter was sent? Do you have personal  
4 knowledge --

5 A No, I do not have personal knowledge --

6 Q -- okay.

7 A -- of to where it was sent.

8 THE COURT: Do you want that marked as an exhibit?

9 MR. STAUDAHER: Yeah, I'll stipulate to its  
10 admission. That's fine.

11 MR. SANTACROCE: Great.

12 MR. STAUDAHER: If we can have it.

13 MR. SANTACROCE: Should I just mark it?

14 THE COURT: Well, we've already shown it to them so  
15 --

16 THE CLERK: B3.

17 THE COURT: -- it will be B3 -- no, that's wrong.

18 BY MR. SANTACROCE:

19 Q Do you want it back?

20 A I am fine without it.

21 Q We can make you a copy.

22 THE COURT: I'm sure -- you can just access that  
23 again --

24 THE WITNESS: Correct.

25 THE COURT: -- if you wanted to off the computer.

1 MR. SANTACROCE: I have nothing further.

2 THE COURT: Oh, I know. There was some confusion. I  
3 need to make sure that the clerks are marking the exhibits  
4 consistently. It's supposed to be letter designation and then  
5 the No. 1 for Dr. Desai and letter designation and the No. 2  
6 for Lakeman exhibits.

7 MR. STAUDAHER: Your Honor, we could just make it a  
8 State's Exhibit, if that would be easier.

9 THE COURT: See, it should be C2.

10 (Defendant's Exhibit C2 admitted.)

11 THE COURT: Any other questions from the State?

12 MR. STAUDAHER: No, Your Honor.

13 THE COURT: Any juror -- any juror questions for this  
14 witness?

15 All right. Sir, there being no further questions,  
16 thank you for your testimony and you are excused.

17 THE WITNESS: Thank you, Your Honor.

18 THE COURT: All right. And, ladies and gentlemen,  
19 we're going to go ahead and take our afternoon recess until  
20 about 3:30.

21 During the afternoon recess you're reminded that  
22 you're not to discuss the case or anything relating to the  
23 case with each other or with anyone else. You're not to read,  
24 watch, listen to any reports of or commentaries on this case  
25 and any person or subject matter relating to the case. Don't

1 do any independent research, and please don't form or express  
2 an opinion on the trial.

3 Notepads in your chairs. Follow the Marshal.

4 (Jury recessed at 3:17 p.m.)

5 THE COURT: Nemec for the rest of the day?

6 MS. WECKERLY: Yes. Well, he's the only one else --  
7 he's all we have.

8 THE COURT: Now, he may have to come back. I mean, I  
9 don't know that we'll finish with him, but we're ending at 5,  
10 so -- you know, if it's 5:05 or 5:10 --

11 MS. WECKERLY: Right.

12 THE COURT: -- or something it's fine, but --

13 MS. WECKERLY: Well, I'll let the Defense tell him  
14 that.

15 (Court recessed at 3:18 p.m., until 3:35 p.m.)

16 (In the presence of the jury.)

17 MR. STAUDAHER: Would you like me to get the witness,  
18 Your Honor?

19 THE COURT: Oh, please.

20 THE MARSHAL: Thank you. Everybody may be seated.

21 THE COURT: All right. Court is now back in session.  
22 And Mr. Staudaher, I believe, is getting the next witness.

23 THE MARSHAL: I'm going to yell at him for doing my  
24 job.

25 THE COURT: And then just please remain standing,

1 facing that lady right there.

2 FRANK NEMEC, STATE'S WITNESS, SWORN

3 THE CLERK: Thank you. Please be seated. And please  
4 state and spell your name.

5 THE WITNESS: Frank Nemec, N-E-M-E-C.

6 THE CLERK: Thank you.

7 THE COURT: All right. Thank you.

8 Ms. Weckerly?

9 DIRECT EXAMINATION

10 BY MS. WECKERLY:

11 Q Sir, how are you employed?

12 A I'm a gastroenterologist.

13 Q And can you explain to the members of the jury  
14 your educational background that allows you to work as a  
15 gastroenterologist?

16 A I did my undergraduate work at the University of  
17 California Berkeley, studied bacteriology and immunology.  
18 Then I went to the UCLA School of Medicine. And after that an  
19 internship at USC and a residency and fellowship at University  
20 of California Davis.

21 Q And when did you start practicing in Las Vegas?

22 A 1984.

23 Q And in 1984 did you have your own practice, or  
24 were you with other partners?

25 A I was initially in solo practice.

1 Q And are you in solo practice now?

2 A No, I'm in a group with three other doctors.

3 Q Okay. And so you've been practicing as a  
4 gastroenterologist since 1984 until now?

5 A That is correct.

6 Q Can you describe for the members of the jury the  
7 process you go through when you perform an upper endoscopy on  
8 a patient?

9 A Well, first we have the patient give informed  
10 consent where we tell them the risks, the benefits, and the  
11 alternatives to upper endoscopy. They're then brought to  
12 the -- usually an ambulatory surgical center, which is an  
13 outpatient facility. They're kept NPO, meaning nothing by  
14 mouth, and then they're put on a gurney. An intravenous line  
15 is then placed by a nurse. The patient is then wheeled into  
16 the examining room. They're hooked up to monitors so we can  
17 look at their oxygen saturation and their respirations and  
18 their heart rate.

19 The patient is placed on their left side. The  
20 patient is given a light anesthetic, usually propofol. The  
21 upper endoscope is then introduced past the throat and down to  
22 the esophagus, into the stomach and up -- down into the  
23 duodenum. The scope is then removed and at that time we do  
24 the inspection, looking at the bulb and second portion of the  
25 duodenum, the antrum in the stomach; a retroflexion maneuver



1 is performed so it can look at the cardia fundus of the  
2 stomach and then look at the esophagus and vocal cords.

3 Q And typically what are -- what are you looking  
4 for in terms of, like, disease for an upper endoscopy?

5 A Ulcerations, esophagitis, inflammation, polyps.

6 Q All those. And biopsies are taken in some  
7 instances?

8 A If abnormalities are seen, yes.

9 Q And that -- the procedure from -- from  
10 introduction of the -- the instrument until it's removed, how  
11 long does a typical endoscopy -- upper endoscopy --

12 A About four or five minutes.

13 Q You also perform colonoscopies, I assume, in  
14 your practice?

15 A That's correct.

16 Q And can you briefly describe what the process is  
17 for that procedure?

18 A Well, the initial part is similar. The patient  
19 is given informed consent; intravenous line is put in. They  
20 previously had a bowel preparation the night before where  
21 they're given, you know, GoLytely or MiraLax to help clean out  
22 their gastrointestinal tract. They're brought into the  
23 examining room, again on the left side. A digital rectal  
24 examination is performed. An anesthetic is usually given  
25 before the rectal examination unless we're concerned about the

1 inadequacy of a preparation, in which case we would do the  
2 rectal examination before the sedation.

3           After the sedation is complete, we introduce the  
4 scope. It's advanced under fiber optic guidance up into the  
5 cecum, which is the upper part of the colon. We identify  
6 specific landmarks including the appendix -- excuse me, the  
7 appendiceal orifice, and the ileocecal valve.

8           And then with the removal of the instrument, look at  
9 the cecum, ascending colon, transverse colon, descending  
10 colon, sigmoid colon, and rectum. At the end of the procedure  
11 a retroflexion maneuver is performed so we can look at the  
12 back side of the rectum that ordinarily is not visible upon  
13 introduction of the instrument.

14           Q     Now, is there any -- are there any professional  
15 standards or recommendations about how long either of these  
16 procedures are supposed to take?

17           A     The only benchmark is the colon withdraw time.  
18 A paper was published by Doug Rex from University of Indiana,  
19 I think it was in 2002, where he specified that a colon  
20 withdraw time, an average of between 6 and 10 minutes  
21 optimizes the ability to detect adenomatous polyps of the  
22 colon.

23           Q     And is that generally accepted or is that, like,  
24 a debatable topic in the field?

25           A     I think there is some debate about -- about it.

1 I think probably a more important metric to determining  
2 whether or not you've got a quality colonoscopy program is the  
3 adenomatous polyp detection rate, looking for adenomatous  
4 polyps of at least 15 percent of men and 25 percent of women.

5 Q Would you say, though, there's any correlation  
6 between the amount of time taken during a procedure and the  
7 discovery of disease or -- or other issues?

8 A Well, that's what Dr. Rex found is that there  
9 was a correlation between the scope withdraw time and the  
10 ability to identify these polyps.

11 Q In your -- you have a gastroenterology practice,  
12 correct?

13 A Yes, ma'am.

14 Q How many colonoscopies could you perform in an  
15 hours' time?

16 A Probably two to three.

17 Q And are -- is there -- I assume there's a  
18 turnover time for the procedure rooms?

19 A Let me just clarify that. If I was confined to  
20 one examining room, it would be two to three. I think it's  
21 possible to do three or four an hour if you had two different  
22 examining rooms at -- at your disposal.

23 Q Okay. And that would include, like, the -- the  
24 turnover time for the room?

25 A Well, one room could be turned over while

1 minutes -- should you bill 15, you know, for -- the one unit  
2 for 15 or does it go to 2, but it's closer to 15. So I think  
3 of it that way.

4 Q You don't think like most people. This is  
5 complicated. Let me -- if I understand what you're saying,  
6 we're saying if we -- we start off with, let's just assume a  
7 colonoscopy is 5, and I think we have -- well, I don't know  
8 what we have yet. From 0 to 5 -- 15 you would add how many  
9 units?

10 A One.

11 Q And from 16 to -- oh, I didn't do that right.  
12 From 16 to 30, what would you add?

13 A If the procedure was 18 minutes --

14 Q Right.

15 A -- it would be 1.

16 Q I thought 0 to 15 was 1?

17 A It's 15-minute increments, but if -- if the  
18 procedure is 18 minutes, that extra 3 minutes is not enough to  
19 get you to the second unit.

20 Q Well, if I'm -- so you're saying if I'm between  
21 16 and 30 minutes --

22 A No, I didn't say that.

23 Q Okay. Go ahead, explain to me again. I didn't  
24 get it.

25 A That's why I was saying I don't think that way.

1           Q     Okay. Well, let me do it this way: Let me just  
2 give you a time and maybe you can walk us through it. Let's  
3 say I have a procedure that lasts 12 minutes, and I don't have  
4 a -- a modifier, okay? Let's keep it simple. There's no,  
5 like, somebody with a cardiac problem that I'm going to have  
6 to add some kind of patient modifier, okay? So just the  
7 colonoscopy and it lasts 12 minutes, what's my bottom line?

8           A     One.

9           Q     All right. It's only one unit?

10          A     Because it -- it falls the closest to 15  
11 minutes, you know, for one.

12          Q     Would you add -- would you add that to five  
13 units -- the base?

14          A     Yes.

15          Q     Okay. That's where I was disconnecting with  
16 you. So --

17          A     Oh, okay.

18          Q     -- what I -- what you're saying is we have a bit  
19 of a formula. You do a colonoscopy, you get five units  
20 automatically; is that correct?

21          A     I'm not familiar with what the base unit is for  
22 colonoscopy. I did not research that.

23          Q     Okay. Well, just for purposes of this  
24 discussion, let's assume it's five.

25          A     Okay.

1           Q     And assuming it's five. What I understand you  
2 to say is you take the base unit and you add the time units.  
3 And so if I have a procedure that's between 0 and 15, I get  
4 another point for a total of 6 units, correct?

5           A     Yes.

6           Q     And then, if I have a procedure that is between  
7 16 and 30 minutes how many more points do I get?

8           A     It depends on the total minutes.

9           Q     Okay.

10          A     Not a differentiation on the 16 to 30 or the 31  
11 to 45.

12          Q     Okay. Well, let's say, then -- let's say I have  
13 a procedure that's 18 minutes; how many points should I get?

14          A     One.

15          Q     One point?

16          A     CMS says for anesthesia services furnished after  
17 January 1, 1994 -- this is CMS transmittal 1324.

18          Q     Mm-hmm.

19          A     For anesthesia services furnished on or after  
20 January 1, 1994, carriers compute time units by dividing  
21 reported anesthesia time by 15 minutes. Round the time unit  
22 to one decimal place.

23          Q     What does that mean?

24          A     Well, that means if it were 18 units, you know,  
25 you divide that by 15, that gives you 1 unit, and you could

1 only go to one decimal place so it's still just 1 unit because  
2 it would be 1.0 whatever.

3 THE COURT: So if it's 1.5 or higher you round up,  
4 and if it's -- is it that rule we learned, you know, in  
5 school, 1.4 or lower you round down; is that how you do it?

6 THE WITNESS: You round the time unit to one decimal  
7 place. So if it was 1.49 then yes, you would round it to 1.5.

8 THE COURT: 1.5, and then you'd go to 2 units,  
9 correct? Or do you keep it at 1 point --

10 THE WITNESS: You keep the decimal -- one decimal  
11 place.

12 THE COURT: -- you keep the decimal. So it's not  
13 that you round up to the largest whole number --

14 THE WITNESS: Right.

15 THE COURT: -- you round to the --

16 THE WITNESS: To the decimal place.

17 THE COURT: -- the decimal point --

18 THE WITNESS: Mm-hmm.

19 THE COURT: -- so 1.47 would be 1.5, 1.42 would be  
20 1.4?

21 THE WITNESS: Right.

22 THE COURT: Is that what you're saying?

23 THE WITNESS: Correct.

24 THE COURT: Okay.

25 THE WITNESS: Correct.

1 MS. STANISH: Got it?

2 THE COURT: Do you have it, Ms. Stanish?

3 MS. STANISH: It doesn't matter; people -- they get  
4 it.

5 BY MS. STANISH:

6 Q So go -- if I have a procedure, then -- I'm just  
7 going to put 16 to 30, going back to my example. I have an  
8 18-minute procedure, okay? And I -- it's five units, remains  
9 the same assuming that's the base, and then what's my time  
10 unit? Are you telling me -- what do I put there for a --

11 A One.

12 Q One? So then there's no difference between a --  
13 what did I say, a 12-minute procedure and an 18-minute  
14 procedure?

15 A Not according to the CMS guideline.

16 Q All right.

17 A Which is a code where I'm bound to follow.

18 Q Understood. What if I have now a procedure that  
19 is -- I'm just -- pick a number in between there. How about  
20 32 minutes? Five base units plus -- how many points do I get  
21 if it's -- time units do I get if it is a 32-minute procedure?

22 A It would be -- in my head 2.1 off the top of my  
23 head. I'd have to write it down. 32 minutes?

24 Q How about 31 so we don't have to do a -- how  
25 about 31 minutes just so you don't have to mess with decimal



1 points?

2 A Okay. It would be two.

3 Q Okay. Good. Two. Now, the -- so in this case  
4 it's going to be seven units?

5 A But I still have a problem with it. 30 -- the  
6 16 to the 30 --

7 Q Okay.

8 A -- and the 31 --

9 Q The -- oh, because of the --

10 A -- to 45.

11 Q -- decimal. I'm sorry. So I'll change that for  
12 you based on our hypotheticals.

13 A Okay.

14 Q And so what I -- just to kind of summarize what  
15 you've told us, if it's a 12-minute procedure you're going to  
16 get a total of 6 units, correct?

17 A Correct.

18 Q If it's an 18-minute procedure you're going to  
19 get a -- it won't change, you're going to get 6 units?

20 A According to the CMS guideline, that's the way I  
21 would calculate it.

22 Q And do you know if it would change if you did a  
23 29-minute procedure?

24 A I would -- let's see. A calculation in my  
25 head --

1 Q I've got a calculator if you need it.

2 A -- I'm coming up with 1.0-something.

3 Q So it would -- okay. All right. When you get  
4 these total units, let's just say -- let's use this 18-minute  
5 procedure here. It -- or I guess you could even use the  
6 12-minute procedure since it's the same unit, what is the next  
7 step in calculating the value of the anesthesia service in  
8 this hypothetical?

9 A You have to look at modifying units. The  
10 modifying units -- anesthesia, when they do a pre-evaluation  
11 on a patient based on the patient's age and medical history,  
12 they give the patient an anesthesia classification, and the  
13 classification is, like, 1 to 5, 1 being the healthy patient,  
14 et cetera. If they're basically healthy and they're 79 years  
15 old, then you would probably -- the ASA classification would  
16 be a -- you would get 1 point for the age factor because the  
17 medical history is still good. And then as the -- it's called  
18 ASA, the classification system.

19 So as the classification goes up, the more points  
20 that would be added to the modifying units.

21 Q Okay. So it would be something you would add.  
22 If I had a -- is the -- it -- let's just, for the sake of  
23 argument say there's no -- well, no, I guess we should say --  
24 are there usually modifiers, do you know, in the world of  
25 anesthesia billing; if you know?

1 A Modifiers or modifying units?

2 Q Modifying units that you would --

3 A Okay.

4 Q -- actually add to this formula.

5 A Yes, for the ASA -- the anesthesia  
6 classification.

7 Q Okay. And the -- so we would have to have  
8 additional information on whether the patient requires -- has  
9 some condition that supports closer monitoring or something  
10 like that?

11 A Yes, the medical records should contain  
12 sufficient documentation to support the ASA classification  
13 that anesthesia is giving.

14 THE COURT: And is that something the  
15 anesthesiologist or the anesthetist would then calculate,  
16 like, you know, I have a 92 year old with a heart condition or  
17 whatever they're going to consider, they then calculate the  
18 modifying units?

19 THE WITNESS: I don't -- I doubt very seriously if a  
20 physician or a CRNA --

21 THE COURT: Would do that.

22 THE WITNESS: -- would be involved in the billing.  
23 It -- they could --

24 THE COURT: Okay.

25 THE WITNESS: -- be. Whoever does the billing --

1 THE COURT: Oh, okay, would figure that out.

2 THE WITNESS: -- they would know based on the ASA  
3 classification --

4 THE COURT: I see. Okay. All right.

5 THE WITNESS: -- what number units to put with it.

6 THE COURT: Okay. But you know what --

7 BY MS. STANISH:

8 Q But to kind of --

9 THE COURT: -- I'm sorry.

10 MS. STANISH: -- oh, I'm sorry. Go ahead.

11 THE COURT: No, I was going to say let's take a  
12 quick --

13 MS. STANISH: Okay.

14 THE COURT: -- break.

15 MS. STANISH: Okie-doke.

16 THE COURT: So we'll take about 10 minutes.

17 And, ladies and gentlemen, you're reminded that  
18 during this quick recess you're not to discuss the case or  
19 anything relating to the case with each other or with anyone  
20 else. Do not read, watch, listen to any reports of or  
21 commentaries on the case, person, or subject matter relating  
22 to the case. And please don't form or express an opinion on  
23 the trial.

24 Notepads in your chairs. Follow the officer through  
25 the door.

1 (Jury recessed at 11:16 a.m.)  
2 THE COURT: Ma'am, what time is your flight today?  
3 THE WITNESS: Oh, it's tomorrow morning.  
4 THE COURT: Oh, okay. So we don't have to worry  
5 about you.  
6 THE WITNESS: Don't tell them that.  
7 (Off-record colloquy.)  
8 (Court recessed at 11:16 a.m. to 11:35 a.m.)  
9 THE COURT: Kenny, bring them in.  
10 MS. WECKERLY: Judge, we have -- besides Ms. Syler we  
11 have another witness here this morning, and he's also out of  
12 state; and Dr. Nemec can't be here until 2:30. So we're  
13 hoping to put on the third witness this morning, and then just  
14 depending on where we are.  
15 THE COURT: What time is he leaving?  
16 MS. WECKERLY: He can fly tonight. I just --  
17 THE COURT: Okay.  
18 MS. WECKERLY: -- I just thought, like, if there's  
19 possibly time we'd like to do him this morning. I get that we  
20 can't --  
21 THE COURT: Yeah, I mean, I just don't like to --  
22 it's hard enough sitting here that when they're really  
23 starving, so that's why I like to --  
24 MS. WECKERLY: Okay.  
25 THE COURT: -- break by 1:00 --

1 MS. WECKERLY: Yeah.

2 THE COURT: -- 1:15. You know what I mean, I don't  
3 want to break for lunch at 2.

4 MS. STANISH: No, I don't either.

5 THE COURT: And I know Nemec's coming, what? You  
6 said at 2:30?

7 MS. WECKERLY: Yeah.

8 THE COURT: Okay.

9 MS. WECKERLY: Well, I -- I guess what I'm saying is  
10 it either needs to be a long lunch --

11 THE COURT: Oh, okay.

12 MS. WECKERLY: -- or something. Maybe we can do the  
13 direct to him or something?

14 THE COURT: Okay.

15 (Pause in the proceedings.)

16 THE MARSHAL: Ladies and gentlemen, please rise for  
17 the presence of the jury.

18 (Jury entering at 11:37 a.m.)

19 THE MARSHAL: Thanks, everybody. You may be seated.

20 THE COURT: All right. Court is now back in session.

21 Ms. Stanish, you may resume your cross-examination.

22 BY MS. STANISH:

23 Q All right. Back to the math. So we've -- we've  
24 talked about the base unit, the time units, the -- what was  
25 it, modifying units. What's the next step in the equation?

1 Is there more?

2 A Sometimes there may be modifiers on codes -- the  
3 CPT codes. For instance, if it's a CRNA, they would have a  
4 certain modifier on the -- the anesthesia code. If it's an  
5 anesthesiologist, an M.D., there would be a certain modifier  
6 for that.

7 Q You know, since we're talking about CRNAs in  
8 this case, you -- do you know whether the CMS has a particular  
9 modifier for a CRNA without supervision?

10 A Yes, they do.

11 Q What is that modifier -- do you know how many  
12 points it is? Or maybe I misspoke --

13 A Q -- I think it is Q -- QX for with supervision  
14 -- QZ.

15 Q Okay.

16 A QZ.

17 Q And is that QZ worth any points or -- according  
18 to CMS?

19 A Not to my --

20 Q What --

21 A -- knowledge. It just --

22 Q -- so it does nothing?

23 A -- differentiates who gave the anesthesia.

24 Q All right. So it doesn't affect our -- our math  
25 here on what is the value of anesthesia service?

1 A Not to my knowledge --

2 Q All right.

3 A -- it doesn't.

4 Q Now -- now that -- is there anything else that  
5 needs to be added besides base unit, time unit, modifying  
6 units?

7 A Not -- not to my knowledge. It --

8 Q Then what's the next step in determining the  
9 value of the anesthesia services?

10 A The -- this information has to go on the claim  
11 form and the -- the 1500 that you were talking about.

12 Q All right.

13 A And the -- this claim form has all the  
14 identification information about the patient, it has diagnosis  
15 coding, which is a separate kind of coding. That's called  
16 ICD-9. International classification of diseases.

17 Q They know that.

18 A It's the ninth edition.

19 Q They know that.

20 A They know that?

21 Q You don't have to explain it, they know that.

22 A So ICD-9 codes have to go on. Then there's a  
23 section for the CPT codes, which is actually the billing; and  
24 there are different columns to indicate the code, how many  
25 units, what is being billed. You know, for instance, if



1 something was \$50, you'd -- they would have a column for the  
2 \$50.

3 The bottom section of the form -- Block 31, the  
4 lower-left-hand corner of the claim form is the actual  
5 provider of service who actually performed. And, you know,  
6 then there's a block for their address, and, you know, where  
7 to mail the money to if it's via U.S. Mail; but like I said,  
8 most of it is electronic now, but it's still all that  
9 information, it's just electronic.

10 Q Mm-hmm.

11 A And there's one particular block and frequently  
12 what the block will say -- it's for the patient's signature --  
13 and frequently what the block will say is signature on file.  
14 And what that means is all those forms you sign when you go to  
15 the doctor's office or the hospital or the ambulatory surgery  
16 center, all those forms, you know, you're agreeing that if  
17 this insurer, whoever it might be, needs to see my medical  
18 records, I'm giving permission to release those records. So  
19 that's part of what you're signing. And that's why it will  
20 say signature on file. It's been many, many years where there  
21 was actual patient signatures even on the paper claims.

22 Q So going back to the value of anesthesia  
23 service, now that we -- once we have the bottom line on the  
24 number of units, so for instance, six units for a 12-minute  
25 procedure, do we have to multiply it by something to --

1 A Yes, you --

2 Q -- get a dollar figure?

3 A -- usually insurers have per unit -- so many  
4 dollars per unit, so then they would have to multiply it.

5 Q And it -- is that what's referred to as the  
6 conversion factor in the world of CMS?

7 A Yes.

8 Q And is there an additional multiplication  
9 regarding the modifying percent -- modifier percentage, or is  
10 that -- am I wrong on that?

11 A That I don't know or don't recall, either one.  
12 I don't -- I don't recall that.

13 Q Is it in -- in your notes up there or that  
14 document you have, does it refer to that?

15 A There -- there's -- on this CMS document there's  
16 information, you know, if someone was supervising -- an  
17 anesthesiologist was supervising more than one case, there's  
18 those kind of figures, if you will, but I don't think this  
19 particular one that I recall has any --

20 Q No more math?

21 A -- no more math that I can recall.

22 Q Good. So then what we basically do is come up  
23 with our total units, and then we -- come up with our total  
24 units and multiply it by whatever dollar figure -- is it --  
25 what do I call this, a rate or -- conversion rate, is that

1 what you -- we agreed on or what is it?

2 A Unit price is what I --

3 Q Okay.

4 A -- always --

5 Q Price.

6 A -- referred to it as.

7 Q And that -- so basically if I -- if I wanted --  
8 well, I don't know if I have to go that far. So total units  
9 multiplied by whatever the unit price is is going to give me  
10 the value of anesthesia service?

11 A To my recollection, yes.

12 Q And that's going to be the check that's sent to  
13 the provider?

14 A Yes, it's usually -- if it's Medicare -- well, a  
15 lot of large insurers do it as well -- it's a once-a-month  
16 check. And this is a very large check, say \$10,000. And then  
17 attached to the check is an explanation of payment. And on  
18 the explanation of payment it will have each individual  
19 patient listed where you file the claim, here's what you file  
20 for this date of service when the procedure was done, and  
21 here's what you billed, and here's what we're going to pay  
22 you, and here's what -- if there's secondary insurance, you  
23 know, you can bill it, and here's what you've got to write off  
24 it's noncovered.

25 Q Okay. So they kind of bundle all --

1 A They bundle it.

2 Q -- the claims together and one big payment with  
3 the details on what it includes?

4 A Yes.

5 Q And then if there's any claim that's denied for  
6 some reason, there would be a -- some -- I bet another code  
7 for that?

8 A Absolutely another code.

9 Q We're not going to go over those. Are there  
10 hundreds of codes for denial?

11 A I've never counted them; there's quite a few.

12 Q All right.

13 A And there's usually a -- the most frequent codes  
14 for denial, most providers -- the bill -- whoever does the  
15 billing, they're familiar with those. They don't have to look  
16 them up anymore to see what they mean. They already know what  
17 they mean.

18 Q Okay. A couple more areas I want to cover with  
19 you. On the Form 1500, the CRNA is deemed to be the provider,  
20 correct?

21 A Yes.

22 Q In the case of a QZ, is that the --

23 A Yes.

24 Q -- modifier, a QZ being a CRNA who is able to do  
25 the -- administer the anesthesia by themselves?

1           A     Correct, without medical supervision.

2           Q     Aside from the operating physician, of course?

3           A     Right. He doesn't -- unfortunately doesn't

4 count for that, for want of better terms.

5           Q     Well, they make their money by some other

6 code --

7           A     Exactly.

8           Q     -- right?

9           A     Absolutely.

10          Q     All right. And the -- on the 1500, then, to the

11 extent it is a CRNA who is performing the administration under

12 that Q2 code that you told us about, is -- their name will

13 actually appear as the provider on the Form 1500?

14          A     It should, Block 31, the lower-left-hand corner

15 of the claim form should be the actual provider of services --

16          Q     And --

17          A     -- that actually administer, in this case, the

18 anesthesia. Block 33, which is the far-right-hand corner of

19 the claim -- the 1500, that is the one if this CRNA worked at

20 the -- at the ASC; then in Block 33 you would have the ASC

21 name and their address. That's like who to send the payment

22 to.

23          Q     Okay. So the check goes to the facility, not

24 the individual --

25          A     Usually, yes.

1 Q -- CRNA?

2 A Yes.

3 Q And that would be common in a setting where the  
4 CRNA is an employee of the clinic?

5 A Yes, and then the CRNA would just get a salary  
6 or an hourly rate, however they're paid, and they would be  
7 paid by the ASC, but the ASC would get the insurance check, so  
8 to speak.

9 Q Just a couple other areas, ma'am. Is the -- do  
10 -- on the 15 -- Form 1500 it appears that the provider puts a  
11 charge, whether it's anesthesia \$560, but am I to understand  
12 that it is this formula that we've been discussing for a while  
13 that actually determines the amount of the check, not what the  
14 provider puts on that block? Do you know what block that's  
15 on, by the way?

16 A No, I would have to count backwards --

17 Q I've got it --

18 A -- to get --

19 Q -- just was testing you. I figured you would  
20 know what block on the 1500 Form is the charge of the  
21 provider.

22 A It's probably around Block 28, 29, somewhere  
23 around in there.

24 Q Let's check your credibility. Can't even read  
25 this. Pretty small but it's probably you're about right.

1 That -

2 A Okay.

3 Q -- but that charge that the provider puts in  
4 whatever block that is that I can't see, it is not that charge  
5 that they get. They don't get that amount that they put on  
6 the Form 1500, correct?

7 A It's very rare. It's very rare.

8 Q Okay. They get what is the bottom line on that  
9 equation that we just discussed?

10 A Based on that formula, so to speak, and based on  
11 the fee schedule.

12 Q Okay. And do some providers, if you know,  
13 simply say time doesn't matter, you get a flat fee?

14 A Well, many services rendered it is a flat fee  
15 based on the code. Some services are based on time and other  
16 services are -- it is what it is. Whatever that thing is,  
17 that's all it is. There's no -- it's not based on time.

18 Q Is that something that's just determined by the  
19 insurance company or agency that instead of using this formula  
20 from CMS because it's just too complicated or whatever, we're  
21 going to give you a flat fee for anesthesia service?

22 A I am not familiar with anyone that does that.  
23 It may occur, but I am not familiar with that at all.

24 Q In your experience, do most medical groups have  
25 third-party billing companies to deal with all these numbers

1 and codes and CMS and standards?

2           A     I don't know what the percentage would be. Many  
3 groups -- medical groups or medical companies will have a  
4 separate billing company. Many employ people within their own  
5 facility with the proper credentials that can do the billing  
6 right there from their own office or facility or hospital.

7           Q     You know, you reminded me of one more area I  
8 needed to cover. Thank you. Credentials. In order for a  
9 medical group to -- well, in order for a CRNA, for instance,  
10 to be on one of these Form 1500s, do they have to be  
11 credentialed?

12           A     Oh, absolutely --

13           Q     Now, what is --

14           A     -- they should be.

15           Q     -- and what does that mean exactly?

16           A     Basically, it means that whatever company that's  
17 going to employ any person that has credentials, then they --  
18 I hate to use the word "investigate," but they determine if  
19 the credentials are real, that the state did license them to  
20 practice under that name, to practice whatever their  
21 credentials say they should be doing. They just want to make  
22 sure that this person is who they say they are. They check  
23 their background for employment history, check with the state  
24 licensing boards, and every state has those.

25                 So I guess they vet that person to make sure that



1 they are who they say they are and that they can practice  
2 whatever that is. Like, I'm an RN so they would check me out  
3 to make sure that I had an RN license, I was licensed by the  
4 state for the practice of nursing.

5 Q Okay. And what about the medical group itself,  
6 the facility that, you know, employs the CRNA? Do -- do  
7 insurance companies require them to have some kind -- those  
8 facilities to have some kind of credentials? I mean, if I am  
9 a doctor with a group, how is it that I get the magnificent  
10 Blue Cross/Blue Shield to cover my patients?

11 A The -- the group would do all this before they  
12 would hire you, that yes, you are a physician, let's say, and  
13 to make sure that you're licensed as a physician in the state;  
14 and then the insurer anticipates that this group and -- has  
15 done this. Additionally, the insurer -- the large insurance,  
16 they make sure -- and this includes Medicare -- they make  
17 sure, once again, you are who you say you are, you are  
18 licensed, everything is correct. And then you can become a  
19 participating provider with Medicare or any other large  
20 insurance -- any insurance group versus -- and most  
21 practitioners want to be participating providers because the  
22 patients that have that insurance or don't want to go to  
23 people for healthcare services if they're nonparticipating  
24 because that's a different rate, and then you would have to  
25 pick up the difference, so to speak.

1 Q And are there -- I bet there's requirements for  
2 credentialing --

3 A Absolutely.

4 Q -- all right. And do you know in the world of  
5 GI -- ambulatory surgical centers, is there a particular  
6 agency that does the credentialing, if you know?

7 A There are so many agencies out there with many  
8 different acronyms that certify, inspect and then certify all  
9 different kinds of places, and it's supposed to indicate then  
10 to the insurer, to the public, that quality care would be  
11 given if they meet all the standards of care.

12 Q Well, thank you kindly.

13 MS. STANISH: I have no further questions.

14 THE COURT: All right. Mr. Santacroce?

15 MR. SANTACROCE: I have nothing further to add.

16 THE COURT: All right. Ms. Weckerly, any redirect?

17 MS. WECKERLY: Yes. Margaret?

18 MS. STANISH: Yeah.

19 MS. WECKERLY: Can I have your value [inaudible]?

20 MS. STANISH: My -- this thing?

21 MS. WECKERLY: I -- yeah.

22 MS. STANISH: No, sure you can.

23 MS. WECKERLY: Just for a minute.

24 MS. STANISH: If you can read it, there you go.

25 MS. WECKERLY: I can read it.

1 REDIRECT EXAMINATION

2 BY MS. WECKERLY:

3 Q Ma'am, you actually examined patient files  
4 related to this specific case, correct?

5 A Yes.

6 Q Okay. I'm going to bring some of those to you.

7 MS. WECKERLY: And for counsel's reference -- I'm  
8 just using the green files because this is what she reviewed,  
9 but it's all the same people.

10 MS. STANISH: All right.

11 MS. WECKERLY: May I approach the witness --

12 THE COURT: Sure.

13 MS. WECKERLY: -- Your Honor?

14 BY MS. WECKERLY:

15 Q I'm going to start with State's 47A, and this is  
16 a patient -- it will be 47C, and this is Kenneth Rubino. And  
17 can you look at that file and tell me if there are those  
18 modifiers noted in here noting the things that, I guess, say  
19 that he may be a risky patient for anesthesia or a patient  
20 where you could note that in a record and maybe add a unit or  
21 something because the -- the patient is a little bit  
22 compromised? Is there anything noted for Kenneth Rubino in  
23 terms of a modification?

24 A Yes. On the preanesthesia evaluation the ASA --

25 Q Mm-hmm.

1           A     -- classification is a 2. Meaning that there is  
2 probably some systemic disease process. It also says the  
3 patient is hypertensive -- high blood pressure. So that's  
4 probably what brought about the -- the ASA classification of  
5 2.

6           Q     And then would that mean that the units are  
7 worth more or that you can add a unit or how does that -- how  
8 does that work?

9           A     I think a 2 is a -- is one unit, I believe.

10          Q     Under the CMS guidelines?

11          A     Yes.

12          Q     Okay.

13          A     I'm sorry, a 2 is zero units.

14          Q     Okay. So even if you're a 2, you're  
15 hypertensive, and you have some sort of disease, you don't get  
16 to add anything?

17          A     Right.

18          Q     Okay.

19          A     One unit starts at ASA classification of 3.

20          Q     Okay. So he's a 2 but that doesn't -- but you  
21 don't get to add anything for that; is that fair?

22          A     Right.

23          Q     On --

24          A     But you still have to have the classification.

25          Q     Sure. Now, let's --

1           A     The documentation is slim.

2           Q     Brief documentation --

3           A     Brief.

4           Q     -- as to that classification, fair to say.

5     Okay. Let's move to -- this is Sonia Orellana and this is  
6     47D. Can you look at her -- her record and tell me if there's  
7     any modifiers on her that would make it possible to charge  
8     more for her anesthesia?

9           A     She is listed with an ASA classification of 2.  
10    I can't -- the only thing I can see where they came up with a  
11    2 based on their documentation is they just got the word  
12    thyroid written.

13          Q     Okay. So another instance of maybe slim  
14    documentation for how --

15          A     Yes.

16          Q     -- but she's still a 2 so you wouldn't be able  
17    to add anything because she's not yet a 3, right?

18          A     Right.

19          Q     Okay. Let's move on to the next one. This is  
20    Gwendolyn -- thank you -- Gwendolyn Martin, and this is for  
21    the record 47E. Can you look and see if there was anything  
22    that you could add because of her health status?

23          A     Let's see what the date on this is. This was an  
24    interesting one that I reviewed. I was -- the date of service  
25    in question was 9/21 --

1 Q Mm-hmm.

2 A -- so I reviewed 9/21. But as an auditor -- a  
3 medical record auditor and reviewer, whatever is there I'm  
4 going to review and frequently it's because you want to always  
5 give the benefit of the doubt to the provider. So I want to  
6 review everything they've got so that I can try to, again,  
7 give them every benefit of the doubt that you're  
8 documenting -- that your documentation is sufficient --

9 Q Okay.

10 A -- to support codes that would be billed. So I  
11 looked at 9/21 for --

12 Q Gwendolyn Martin?

13 A -- yes, it was an endoscopy with a biopsy. And  
14 the ASA classification, anesthesia classification was a 2.  
15 There was no documentation of any systemic disease at all,  
16 which should be, if it's a 2. So in reviewing the file -- and  
17 again, that was 9/21 -- there was 9/20, the day before, the  
18 patient had a colonoscopy and the ASA classification was a 1.  
19 So it would be very unusual that in 24 hours you would go from  
20 a 1 to a 2 as far as anesthesia is concerned, unless the  
21 evening of the 20th you had a heart attack or something, I  
22 don't -- you know, some catastrophic event would occur.

23 And I found that in several records, by the way, you  
24 know, where just within one week or one day the ASA  
25 classification would change. And that lends itself to very

1 poor, insufficient medical record documentation. And the  
2 reason that's so important, and I certainly feel very strongly  
3 about this, you don't know who is going to be taking care of  
4 you -- who may be doing the next procedure on you.

5           And this provider, whoever it is, doesn't know --  
6 what if something happened to this provider that did this  
7 procedure and then even the person -- let's say the person  
8 gave him anesthesia and the GI doctor were in a car going to  
9 dinner tonight and they were in a car accident and were  
10 killed, but yet, you know, this patient goes in next week for  
11 the next procedure, let's say. Then that next provider has  
12 got to rely on this.

13           It is -- it is your health record. Everyone should  
14 want it to be as accurate, as thorough as possible for quality  
15 healthcare. I feel very strongly about that. And then you've  
16 got the billing issue because what's in here should support  
17 what you're billing.

18           Q     So if I understand you as to Ms. Martin, her  
19 classification as to how risky she was to put under anesthesia  
20 changed from the 20th to the 21st, but there's still no  
21 documentation of why she was a 2 on the 21st?

22           A     Correct.

23           Q     But even as a 2, under the guidelines you're  
24 not allowed to enhance the cost of the anesthesia --

25           A     Correct.

1 Q -- they give? Okay.

2 A Because that's a zero --

3 Q Still a zero.

4 A -- additional units.

5 Q Okay. Now, let's move onto 47F, and this is  
6 Rodolfo Meana. Can you see how he was classified in terms of  
7 a risk for anesthesia?

8 A I'm looking for the anesthesia form.

9 Q Is it on the other side or no?

10 A It shouldn't be.

11 Q We may have to pull his court record. We can  
12 come back to him.

13 A Probably sort of got stuck somewhere else.

14 Q Oh, there it is.

15 A Oh, here it is. It's the very last page. For  
16 9/21 his ASA classification, anesthesia classification was 2.  
17 And hypertension is listed.

18 Q Okay.

19 A So he -- his classification is a 2. So it would  
20 be zero units according to the scoring system --

21 Q Okay.

22 A -- if you will.

23 Q Now, let's look at Patty Aspinwall, and can you  
24 see what her classification was?

25 A Her classification is a 1. And there's no



1 documentation on the anesthesia preevaluation of any disease.  
2 There -- there are certain parts that are just left blank that  
3 should have been filled in and they're blank.

4 Q But still a 1 is no --

5 A No.

6 Q -- not allowed to enhance.

7 A No, no units, correct.

8 Q All right. Now, let's look at Carole Grueskin,  
9 please. And, sorry -- can I just submit that, 47H for the  
10 record.

11 A Okay. This patient on 9/21 the classification  
12 was a 2. And this is an example of when you look more --  
13 delve more into the medical record because on the anesthesia  
14 preevaluation there's nothing listed indicating there's any  
15 type of systemic disease.

16 Q So the --

17 A Which a 2 says it is. So then, you know, you go  
18 looking and reading every single page trying to find out, you  
19 know, what brought about the 2 because this same patient two  
20 days before had a procedure and they were also listed as a 2  
21 and also no systemic disease or anything listed to determine  
22 how did you get to a 2.

23 Q So --

24 A How did you arrive at that as an anesthesia  
25 person -- practitioner, how did you arrive at a 2 on both days

1 two days apart? But at least it was the same classification  
2 that time.

3 Q Right. So she's a 2, no documentation, but also  
4 no enhancement because it's not yet a 3.

5 A Correct.

6 Q Okay. And just --

7 A So that really is a -- has to do with a  
8 quality-of-care issue rather than a billing issue since no  
9 units were added, but, you know, what about the quality of  
10 care? You know, on one hand you're saying this person is a  
11 little sicker, but yet there's no documentation of why they're  
12 sick.

13 Q And this is 47I, and this is Stacy Hutchinson.  
14 And what's her classification?

15 A She had a -- on 9/21 her classification is a 2.  
16 And it's marked hypertension. But no units would be added for  
17 that; it would be zero.

18 Q Okay. And this is Michael Washington. And  
19 that's 47J.

20 A This was July 25th and his classification is a  
21 3. Well, when I see an ASA classification going up, then you  
22 definitely need to see documentation of medical history. So  
23 one thing I do is I look at the age. That's not always an  
24 indicator because this patient was 67 years old, but that  
25 doesn't mean that you're sick just because you're 67. You

1 could be, you know, quite healthy.

2           They've got hypertension marked, diabetes, the  
3 patient had a heart attack, they've got coronary artery  
4 disease, and the patient had a stent placed. So, you know,  
5 this -- you can see this patient is sicker. At least there's  
6 some documentation.

7           Q     He's more compromised, correct?

8           A     Yes, he's a more compromised medical individual.  
9 And that kind of documentation -- it even talks about an  
10 irregular sinus rhythm, which just means coming out the top of  
11 the heart.

12          Q     So that would be one that you could enhance  
13 because he's a 3 --

14          A     Yes.

15          Q     -- right? Okay.

16          A     So that would be one unit.

17          Q     And if I could just have you look at one more,  
18 please. And this is State's Exhibit 1. And it's the record  
19 for Sharrieff Ziyad. Can you look at his classification?

20          A     Classification is a 2 by anesthesia. And they  
21 have documented cirrhosis of the liver and hepatitis C. So  
22 that patient is compromised. You know, I would -- as soon as  
23 I saw hepatitis and cirrhosis, I would start looking further,  
24 wondering if maybe this patient should be a 3. You know, that  
25 would be my thinking as an auditor and --

1 Q Sure.

2 A -- as an RN. This is not one I reviewed. So I  
3 don't know if you want me to look at that any further or not.

4 Q Well, I mean, you can if -- if you want, but in  
5 any -- the classification he was given by the CRNA was a 2 --

6 A Right.

7 Q -- is that fair?

8 A It was 2, so there would be no units --

9 Q Associated?

10 A -- right.

11 Q So out of all these files that I just went  
12 through, the only one that would be allowed to enhance the  
13 anesthesia billing would be the one for Michael Washington  
14 because he was the only 3, right? Because he had all those --

15 A Of those you showed me, yes.

16 Q -- he had all those health issues.

17 A Correct.

18 Q So those modifying units -- I mean, there's  
19 various classifications that we went through, but none of that  
20 would affect what they could have charged for anesthesia  
21 except for Michael Washington?

22 A Correct.

23 Q Now, Ms. Stanish showed you this value of  
24 anesthesia -- this is a really nice chart she made.

25 MS. STANISH: I thought so.

1 BY MS. WECKERLY:

2 Q And this -- and the -- the timing that she put  
3 on it, which is 0 to 15 and 16 to 30, you had discussions with  
4 her about how -- like an 18-minute procedure would still be  
5 one unit because it's closer to 15 minutes rather than 30 --  
6 that's how I think of it; is that right?

7 A Yes, the real thing is you would divide it by  
8 15, but because it's 18 you know it's very close to the 15  
9 so --

10 Q Okay. Yeah, that --

11 A -- but technically --

12 Q -- I mean, my way is a lazy --

13 A -- you would still have to divide it by the 15.

14 Q Right. Are there some insurers, though, that  
15 don't do what Medicare does and do they just say, Look, if you  
16 go over 15 we'll give you another unit? Are there some  
17 insurers that don't follow the Medicare standard of where  
18 you've got to get closer to one unit or the other?

19 A There may very well be. I'm not familiar in it  
20 -- familiar with anybody that does that, but there could be.

21 Q Okay. But according to the -- the CMS standard  
22 or the -- the federal standard, there is some calculation made  
23 on the units?

24 A Correct.

25 Q Thank you.

1 THE COURT: And that goes to this next -- a juror  
2 question -- were you done? I'm sorry.

3 MS. WECKERLY: No, if I -- I'm almost done. If you  
4 -- you can interrupt me if you want.

5 THE COURT: Well, okay. Since I already have. So  
6 the juror in this just goes into what Ms. Weckerly has said.  
7 Anesthesia time in the increments of 15 minutes, 15 minutes  
8 equals 1 unit. So say, for example, you had a 22-minute  
9 procedure -- impressed the juror did all the math -- that  
10 would be 1.4. So would that equal one unit?

11 THE WITNESS: Well, you bill it with one decimal  
12 place.

13 THE COURT: So it would be --

14 THE WITNESS: So it would be 1.4.

15 THE COURT: Okay. Let me make this easy then. Let's  
16 just say a unit is equal to \$100.

17 THE WITNESS: Okay.

18 THE COURT: So for 22 minutes would that be  
19 reimbursement at \$100 or reimbursement at \$140?

20 THE WITNESS: To tell you the truth, I never got into  
21 that end of it.

22 THE COURT: Okay.

23 THE WITNESS: You know, I would know that here's the  
24 fee schedule --

25 THE COURT: Okay.

1 THE WITNESS: -- but do they actually --

2 THE COURT: Well --

3 THE WITNESS: -- do these calculations because so  
4 many insurers are so different --

5 THE COURT: Okay.

6 THE WITNESS: -- I never, you know, there was only so  
7 much room in my brain for information and I thought --

8 THE COURT: Okay.

9 THE WITNESS: -- I could leave that off.

10 THE COURT: Okay. And then -- so for it to be 37  
11 minutes -- I'm sorry. So for it to be 3 units, you're not  
12 sure if that would be 37 units --

13 THE WITNESS: Three units?

14 THE COURT: -- I mean, 37 minutes. I'm sorry.

15 THE WITNESS: To get to three units, but, you know,  
16 you could just kind of multiply 3 times 15 and that brings you  
17 to 45. So I would have to literally do the math --

18 THE COURT: Okay.

19 THE WITNESS: -- divide 37 by 15 and it would wind up  
20 being some kind of a decimal because it -- you can only do one  
21 decimal place.

22 THE COURT: And that -- if I understand you --  
23 depends on the insurer whether it's rounded up or whether  
24 they're reimbursing with the decimal? Meaning, like, 1.5,  
25 whether that's 2 or whether that would be 1.5?

1 THE WITNESS: Right.

2 THE COURT: Okay.

3 THE WITNESS: Because I just am not familiar --

4 THE COURT: Okay.

5 THE WITNESS: -- enough with all the -- there's so  
6 many different insurance companies. I guess in a perfect  
7 world -- perfect healthcare world -- here's a set of rules and  
8 everybody follows them. How I wish that were the case.

9 THE COURT: That would make it easier?

10 THE WITNESS: Oh, yes, it would.

11 THE COURT: All right.

12 THE WITNESS: It would be a whole lot less gray.

13 THE COURT: Okay.

14 THE WITNESS: Be more black and white, which I would  
15 far prefer.

16 THE COURT: Okay. Ms. Weckerly, go ahead.

17 BY MS. WECKERLY:

18 Q And so in the Medicare or federal standard,  
19 there is that decimal calculation as to the units, at least,  
20 based on the time, correct?

21 A Yes.

22 Q Okay. But a --

23 A To arrive at the units. I can't really say how  
24 Medicare reimburses. You know, I don't have a fee schedule in  
25 front of me, so...



1 Q Right. And -- but other insurers might just  
2 round up to the next unit?

3 A They might if it's, you know, like, 1.5 or more  
4 they may go to 2, or if it's 1 --

5 Q They could have their own --

6 A -- a 1.4 or less they might just leave it at 1.  
7 They might very well do that.

8 Q Now, Ms. Stanish asked you a lot about the CPT  
9 coding, and my understanding of what you were talking about is  
10 how actual procedures, like medical procedures, are coded for  
11 billing, correct?

12 A Correct.

13 Q And you said that you didn't have the medical  
14 procedure codes from 2007?

15 A Correct.

16 Q So you don't know what, for instance, the  
17 medical procedure code is for a colonoscopy?

18 A No. It might very well not have changed since  
19 2007, but I don't know that for a fact. Sometimes if  
20 something changes they -- it will only change one digit even  
21 because of some other code they've added, so...

22 Q Now, you told us yesterday, I think, that under  
23 the CMS standard, anesthesia time is calculated as face time,  
24 essentially with the patient from the procedure room until  
25 they drop them off in recovery?

1 A Absolutely.

2 Q Was that the definition back in 2007?

3 A Yes, to my knowledge it has been the definition  
4 for the start and end of anesthesia since 1994. You know, I  
5 didn't find anything prior to that.

6 Q Okay.

7 A But after 1994 that was the definition of the  
8 start and end of anesthesia time.

9 Q And you, I think, testified yesterday that  
10 you're not allowed to be billing for two patients at the same  
11 time, or you can't overlap time in terms of anesthesia except  
12 for that one example of a doctor supervising CRNAs?

13 MR. SANTACROCE: I'm going to object. This has been  
14 asked and answered on direct. She's just going through direct  
15 all over --

16 THE COURT: Well --

17 MR. SANTACROCE: -- beyond the scope of cross.

18 THE COURT: -- overruled.

19 BY MS. WECKERLY:

20 Q It -- your -- my understanding is you can't  
21 overlap or bill for two patients at the same time?

22 A No, you cannot.

23 Q Was that the rule back in 2007?

24 A That's -- yes, that's always been the rule.

25 Q Okay. And you told us that you can't bill for

1 more hours than there are in the workday?

2 A Absolutely not.

3 THE COURT: Yeah, you are exceeding the scope of  
4 cross, Ms. Weckerly, so...

5 BY MS. WECKERLY:

6 Q Well, I just want to clarify, was that the CMS  
7 rule in 2007?

8 A Absolutely.

9 Q Thank you.

10 THE COURT: Still beyond the scope, but --

11 THE WITNESS: Can I add one clarifying remark?

12 THE COURT: Sure.

13 THE WITNESS: It's in regards to the HCFA -- pardon  
14 me, that was the old name for CMS. For the 1500 Form, the  
15 claim form, the absolute main thing that Medicare and all  
16 insurers expect is that that claim form, everything on it, is  
17 honest and true. You're even saying when you bill those codes  
18 on that claim form, you're even saying that this is the  
19 service that was rendered and I have documentation to back  
20 that up, to prove that it's correct coding.

21 So all insurers expect that these claim forms are  
22 clean, is what they call them, which means they're honest and  
23 everything on it is totally accurate.

24 RECROSS-EXAMINATION

25 MS. STANISH: Can I talk to you about what you

1 mentioned earlier about the benefit of the doubt? As I  
2 understood what you said, when you do an audit you try to give  
3 the provider a benefit of the doubt to -- when you're doing  
4 your review?

5 A Absolutely.

6 Q Would it -- you be giving the provider the  
7 benefit of -- well, let me phrase it this way. In your  
8 experience, are you aware that medical practices sometimes  
9 have different charts? Different types of charts?

10 A Different? They're all different. Every -- no  
11 matter where you go --

12 Q You know, let me interrupt you --

13 A -- there's very --

14 Q -- because I -- I'm not -- that -- I know I  
15 didn't make that clear. In a particular practice --

16 A Okay. Oh, okay.

17 Q -- that a provider has a procedure file, has a  
18 doctor file, you know, based on a consultation, has a computer  
19 system that has medical information in it. When you do your  
20 audits, would you want to have the collection of medical  
21 documents pertaining to a particular patient so that you could  
22 give them that benefit of the doubt?

23 A Yes, I would. I would want everything they had.  
24 But my first question would be why do you have -- say, a paper  
25 record or a partial paper record and part of it is in the

1 computer. In a -- an electronic system, unless only certain  
2 -- like, maybe the dictation report for the procedure may be  
3 electronic; but if you have paper records, that is usually  
4 printed out and placed in the paper record.

5 But that would be my first and main question, why do  
6 you have part records in paper form and part records in an  
7 electronic system? That makes no sense because some  
8 auditors -- I always called them the men in black -- the,  
9 like, Medicare auditors, DHHS, they won't necessarily from my  
10 experience give you the benefit of the doubt.

11 So if here's a paper record and then, you know, you  
12 review it and you said, okay, we're going to deny that claim,  
13 but then the provider jumps up and says wait a minute, wait a  
14 minute, we've got these four other things here in this  
15 computer, some medical record auditors say, sorry, you know,  
16 this is what you gave me, this is what I audited, payment  
17 denied. Claim denied.

18 So in other words, that would make no sense to me  
19 that you would do that, but yes, I would look at everything  
20 to -- when I say give the benefit of the doubt is I want to  
21 see all the documentation you have for that patient for this  
22 data service that would help me figure out what service was  
23 rendered, you know, what all was involved and was all the  
24 documentation to -- sufficient to support the billing.

25 Q And if there were other procedure files or

1 consultation files, what have you, be it in computer form or  
2 in paper form that the anesthesiologist or CRNA would have  
3 access to, you would want to know about that document?

4 A Yes, I would want to know, but why would it be  
5 separate from the -- like, those look like patient charts to  
6 me. Like those green folders, they look like patient chart.  
7 So why would everything not be in there? I mean, that's what  
8 I would be asking.

9 Q If you had -- if the CRNA had access to the  
10 other documents, because they were accessible would you want  
11 to see those documents before you judged whether the ASA codes  
12 were appropriate?

13 A Yes.

14 Q In your review you were given these -- did you  
15 actually get this -- this file to review, a green folder?

16 A There was approximately 130 electronic medical  
17 records that I reviewed, and there were 11 in green folders  
18 that I reviewed.

19 Q Did you -- do you know that you did not -- you  
20 did not receive the medical doctor's consultation form --  
21 document where the doctor visited -- the patient visited with  
22 the doctor prior to getting the procedure done? Did you --

23 A Are you talking about the preanesthesia  
24 evaluation or the gastroenterologist's documentation?

25 Q Gastro.

1           A     Okay. I would read all of that, but if I was  
2 looking at auditing for anesthesia coding and billing, then I  
3 would expect documentation to be appropriate on the anesthesia  
4 form, the preevaluation form, whether it's electronic or  
5 paper. In other words, they should document what they need to  
6 to support the ASA classification they're giving and not rely  
7 on somebody else. It's kind of like -- and we've all worked  
8 with people like this, you know, where they don't do part of  
9 their job because they know Susy Jane is going to do it  
10 because she always will pick up the slack.

11           So -- and to me it's the same thing, So why if I'm a  
12 CRNA or an anesthesiologist I should not be relying on the GI  
13 doctor? Do I need his document and read his document, yes,  
14 but I'm doing the preanesthesia evaluation, so I should be  
15 finding out from the patient and/or family or significant  
16 other their health status. And then I should document it  
17 because I'm the one that's going to be billing for anesthesia.

18           Q     You don't want your CRNA ignoring what the  
19 medical doctor found a few days before the procedure, though?

20           A     Absolutely not.

21           Q     You would want your CRNA to review that as well  
22 as make their own judgment.

23           A     Absolutely.

24           Q     And then what you want to see as an auditor is  
25 that the assessment is documented?

1 A Correct.

2 Q And you don't understand, as I understand your  
3 testimony, why a facility would have different files?

4 A I don't understand different files except in the  
5 example I gave, like the procedure report. Because in an  
6 auditing I always review, and I did in all the -- the records  
7 I reviewed, I also read the actual procedure report that the  
8 GI doctor dictated.

9 Q You didn't get that, though, in this --

10 A Yes.

11 Q -- per your evaluation? You got a -- you got  
12 something besides the green folder on each of those patients  
13 that you just reviewed?

14 A The electronic files that I had, the majority of  
15 them did not have the actual procedure report. But the green  
16 folders did have the procedure for the endoscopy --

17 Q You're saying --

18 A -- or colonoscopy, so I did review it.

19 Q -- you're saying separate and apart from the  
20 green folders, you got an additional documentation?

21 A Yes, I only reviewed 11 that were in green  
22 folders, hard copy, paper. The other 130 or so were  
23 electronic records. So I sat at a computer and scrolled  
24 through to read the entire record.

25 Q Thank you.



1 MS. STANISH: Court's indulgence.

2 Your Honor, the parties stipulate that the witness  
3 only receive the green procedure files and not the medical  
4 doctor's consultation report. There may have been another  
5 document in here, the procedure document that the witness was  
6 referring to, but ---

7 THE COURT: Right.

8 MS. WECKERLY: I -- the preprocedure.

9 THE COURT: Okay. You're stipulating that the  
10 consultation files that occurred before the procedure with the  
11 gastroenterologists were not transmitted to this witness; is  
12 that correct what we're stipulating to, Ms. Weckerly?

13 MS. WECKERLY: That's correct. These are the files  
14 from the medical offices; is that fair?

15 THE COURT: That she didn't get?

16 MS. WECKERLY: That she did not get.

17 THE COURT: Okay.

18 MS. WECKERLY: She got the procedure.

19 BY MS. STANISH:

20 Q With respect to the ASA classification, isn't it  
21 the case that -- and I think you -- it was your words, not  
22 mine, that in -- the inconsistencies that you noted in the ASA  
23 codes indicate either a lack of care in applying the ASA class  
24 or -- and possibly lack of complete understanding of the ASA  
25 classification system.

1           A     Those are my words, yes.

2           Q     With -- or in bold, in capital?

3           A     They could be either/or.

4           Q     And --

5           A     Or both --

6           Q     -- sure --

7           A     -- I guess.

8           Q     -- is it the -- is it the case that providers,

9     or the people doing the charting do not understand the set of

10    rules that are -- the set of rules by CMS?

11           A     There are many providers that do not understand

12    all the guidelines, rules, and regulations; however, it is

13    incumbent upon them to know them if you're going to be

14    billing.

15           Q     And going back to your comment that as far as

16    you knew the CMS standards for the end time of anesthesia had

17    not changed for many years, do you know whether there had

18    been -- what was the term you called it, like, clarification

19    definitional -- what did you call it before?

20           A     Guidelines?

21           Q     Yeah, guidelines. Let's call it guidelines

22    because am I right to understand from your -- when you had

23    chatted with me earlier on cross-exam that CMS oftentimes

24    revises the guidelines to try to clarify terminology?

25           A     Yes.

1           Q     And the term, personal attendance of a  
2 anesthetist or a CRNA has -- do you know -- since you were not  
3 able to access anything prior to 2009, do you know if the CMS  
4 has over the years had guidelines written to better explain  
5 what personal attendance means?

6           A     I can't say -- since I wasn't able to access  
7 2007 anesthesia coding, I can't say whether there has been a  
8 specific change in that terminology. They might have  
9 explained -- it's possible they could have explained it  
10 differently but --

11          Q     You don't know because you --

12          A     -- personal --

13          Q     -- can't access it.

14          A     -- attendance --

15          Q     Yes?

16          A     -- I mean, it is what it is. I mean, that's --  
17 you are attendant with that person. You are face-to-face with  
18 that person.

19                THE COURT: Is there a definition? Is that what  
20 you're asking, if there's a definition in the CMS or --

21                MS. STANISH: My -- I'll clarify it.

22                BY MS. STANISH:

23                Q     My understanding, ma'am, is that you have a  
24 code, but then you have -- almost every year the CMS will  
25 author guidelines in an effort to clarify terminology?

1           A     Sometimes they will.  Some guidelines, some  
2 terminology, some codes remain the same year after year after  
3 year without --

4           Q     Right.

5           A     -- change or edification.

6           Q     Right.  And I'm not just talking on the number  
7 assignment to various procedures, I'm talking the terminology  
8 that says something general, like, you can bill anesthesia in  
9 accordance with the -- the -- the standards in the community,  
10 whatever the broad language is.  Then we have a set of  
11 guidelines that CMS prepares to clarify these broader terms;  
12 is that correct?

13          A     If I understand the question, periodically there  
14 can be language clarification, but that doesn't mean they do  
15 it every year.

16          Q     Okay.  Fair enough.

17          A     Some stay the same.

18          Q     Right.  I understand.  And all I'm trying to get  
19 at is on redirect you had testified that as long as you knew,  
20 it's always been personal attendance.  All I'm trying to get  
21 at, I suppose, is that you didn't have the opportunity to  
22 review any CMS guidelines that relate to what is personal --  
23 what constitutes personal attendance?

24          A     Okay.  What I couldn't find for 2007 was in -- I  
25 could not really find anything about 2007 anesthesia codes.

1 On the time start and end time for anesthesia from --  
2 effective 2006, it -- once again, it's the CMS transmittal  
3 1324 --

4 Q Mm-hmm.

5 A -- effective date January 1, 2006 --

6 Q Mm-hmm.

7 A -- and this has not changed at all to my  
8 knowledge.

9 Q Could I --

10 A It says --

11 Q -- can I see that?

12 A -- anesthesia practitioner is present with the  
13 patient.

14 Q Okay.

15 A So that has to be face-to-face.

16 Q Where does it say face-to-face?

17 A Well, if you're -- if you're present with me  
18 we're face-to-face --

19 Q Well, watch this.

20 A -- aren't we?

21 Q Watch this.

22 THE COURT: Keep going. Keep going. I've got some  
23 chicken katsu in the back.

24 THE WITNESS: You're still present with me. You're  
25 still present.

**IN THE SUPREME COURT OF THE STATE OF NEVADA**

Electronically Filed  
SEP 02 2014 09:16 a.m.  
Tracie K. Lindeman  
Clerk of Supreme Court

DIPAK KANTILAL DESAI,	)	CASE NO. 64591
	)	
Appellant,	)	
	)	
vs.	)	
	)	
THE STATE OF NEVADA,	)	
	)	
Respondent.	)	
_____	)	

**APPELLANT'S APPENDIX VOLUME 32**

FRANNY A. FORSMAN, ESQ.  
Nevada Bar No. 000014  
P.O. Box 43401  
Las Vegas, Nevada 89116  
(702) 501-8728

RICHARD A. WRIGHT, ESQ.  
Nevada Bar No. 000886  
WRIGHT, STANISH & WINCKLER  
300 S. Fourth Street, Suite 701  
Las Vegas, Nevada 89101

Attorneys for Appellant

STEVEN S. OWENS  
Chief Deputy District Attorney  
Nevada Bar No. 004352  
200 Lewis Avenue  
Las Vegas, Nevada 89155  
(702) 671-2750  
Attorney for Respondent

## INDEX TO APPENDIX VOLUMES 1 through 41

<b><u>DOCUMENT</u></b>	<b><u>VOL.</u></b>	<b><u>PAGE(S)</u></b>
Indictment	1	000001-000042
Amended Indictment	1	000043-000084
Court Minutes 7/21/10	1	000085
Court Minutes 2/08/11	1	000086
Finding of Competency	1	000087-000090
Recorder's Transcript - Hearing: Video Deposition Tuesday, March 20, 2012	1	000091-000129
Indictment (C-12-283381 - Consolidated Case)	1	000130-000133
Second Amended Indictment	1	000134-000176
Third Amended Indictment	1	000177-000212
Defendant Desai's Motion and Notice of Motion for Competency Evaluation	1	000213-000229
Recorder's Transcript - Hearing Re: Defendant Desai's Motion for Competency Evaluation Status Check: Experts/Trial Readiness (All) Tuesday, January 8, 2013	1	000230-000248
Fourth Amended Indictment	2	000249-000284
Notice of Motion and Motion to Use Reported Testimony	2	000285-000413
Reporter's Transcript Re: Status Check: Experts (All) Thursday, March 7, 2013	2	000414-000440

<b><u>DOCUMENT</u></b>	<b><u>VOL.</u></b>	<b><u>PAGE(S)</u></b>
Defendant Desai's Opposition to State's Motion to Admit Foreign Documents Relating to Rodolfo Meana	2	000441-000445
Order	2	000446-000449
Court Minutes 3/21/13	2	000450
Defendant Desai's Opposition to State's Motion to Use Reported Testimony	2	000451-000454
Court Minutes 3/26/13	2	000455
Independent Medical Evaluation, 4/14/13 Filed Under Seal - Separately	2	000456
Reporter's Transcript - Calendar Call (All) State's Motion to Admit Evidence of Other Crimes Tuesday, April 16, 2013	2	000457-000497
Fifth Amended Indictment	3	000498-000533
Reporter's Transcript - Jury Trial Day 7 Friday, May 3, 2013	3	000534-000622
Reporter's Transcript - Jury Trial Day 8 Monday, May 6, 2013	3 & 4	000623-000773
Reporter's Transcript - Jury Trial Day 9 Tuesday, May 7, 2013	4 & 5	000774-001016
Reporter's Transcript - Jury Trial Day 10 Wednesday, May 8, 2013	5	001017-001237
Reporter's Transcript - Jury Trial Day 11 Thursday, May 9, 2013	6 & 7	001238-001517



<b><u>DOCUMENT</u></b>	<b><u>VOL.</u></b>	<b><u>PAGE(S)</u></b>
Reporter's Transcript - Jury Trial Day 12 Friday, May 10, 2013	7 & 8	001518-001784
Reporter's Transcript - Jury Trial Day 13 Monday, May 13, 2013	8 & 9	001785-002061
Reporter's Transcript - Jury Trial Day 14 Tuesday, May 14, 2013	9 & 10	002062-00
Reporter's Transcript - Jury Trial Day 15 Wednesday, May 15, 2013	10 & 11	002303-002494
Reporter's Transcript - Jury Trial Day 16 Thursday, May 16, 2013	11 & 12	002495-002713
Reporter's Transcript - Jury Trial Day 17 Friday, May 17, 2013	12 & 13	002714-002984
Reporter's Transcript - Jury Trial Day 18 Monday, May 20, 2013	13 & 14	002985-003247
Reporter's Transcript - Jury Trial Day 19 Tuesday, May 21, 2013	14 & 15	003248-3565
Reporter's Transcript - Jury Trial Day 20 Wednesday, May 22, 2013	15 & 16	003566-003823
Reporter's Transcript - Jury Trial Day 21 Thursday, May 23, 2013	16 & 17	003824-004014
Reporter's Transcript - Jury Trial Day 22 Friday, May 24, 2013	17	004015-004185
Reporter's Transcript - Jury Trial Day 23 Tuesday, May 28, 2013	18	004186-004384

<b><u>DOCUMENT</u></b>	<b><u>VOL.</u></b>	<b><u>PAGE(S)</u></b>
Reporter's Transcript - Jury Trial Day 24 Petrocelli Hearing Wednesday, May 29, 2013	19	004385-004510
Reporter's Transcript - Jury Trial Day 24 Afternoon Session Wednesday, May 29, 2013	20	004511-004735
Reporter's Transcript - Jury Trial Day 25 Thursday, May 30, 2013	21	004736-004958
Reporter's Transcript - Jury Trial Day 26 Friday, May 31, 2013	22	004959-005126
Reporter's Transcript - Jury Trial Day 27 Friday, June 3, 2013	22 & 23	005127-005336
State's Exhibit 18 - Meana Death Certificate Admitted 6/3/13	23	005337-005345
Reporter's Transcript - Jury Trial Day 28 Tuesday, June 4, 2013	23 & 24	005346-005611
Reporter's Transcript - Jury Trial Day 29 Wednesday, June 5, 2013	24 & 25	005612-005885
Reporter's Transcript - Jury Trial Day 30 Thursday, June 6, 2013	25 & 26	005886-006148
Reporter's Transcript - Jury Trial Day 31 Friday, June 7, 2013	27 & 28	006149-006430
Reporter's Transcript - Jury Trial Day 32 Monday, June 10, 2013	28	006431-006641
Reporter's Transcript - Jury Trial Day 33 Tuesday, June 11, 2013	29 & 30	006642-006910

<b><u>DOCUMENT</u></b>	<b><u>VOL.</u></b>	<b><u>PAGE(S)</u></b>
Reporter's Transcript - Jury Trial Day 34 Wednesday, June 12, 2013	30 & 31	006911-007143
Reporter's Transcript - Jury Trial Day 35 Thursday, June 13, 2013	31	007144-007382
Reporter's Transcript - Jury Trial Day 36 Friday, June 14, 2013	32	007383-007619
Reporter's Transcript - Jury Trial Day 37 Monday, June 17, 2013	33	007620-007827
State's Exhibit 228 - Table 20-1 - Modes of Transmission and Sources of Infection Considered Admitted 7/17/13	33	007828
Reporter's Transcript - Jury Trial Day 38 Tuesday, June 18, 2013	34	007829-008038
Reporter's Transcript - Jury Trial Day 39 Wednesday, June 19, 2013	35	008039-008113
Reporter's Transcript - Jury Trial Day 40 Thursday, June 20, 2013	35 & 36	008114-008361
Reporter's Transcript - Jury Trial Day 41 Friday, June 21, 2013	36 & 37	008362-008537
Reporter's Transcript - Jury Trial Day 42 Monday, June 24, 2013	37 & 38	008538-008797
Reporter's Transcript - Jury Trial Day 43 Tuesday, June 25, 2013	38	008798-009017
Reporter's Transcript - Jury Trial Day 44 Wednesday, June 26, 2013	39	009018-009220

<b><u>DOCUMENT</u></b>	<b><u>VOL.</u></b>	<b><u>PAGE(S)</u></b>
Reporter's Transcript - Jury Trial Day 45 Wednesday, June 27, 2013	39 & 40	009221-009473
Defendant's Proposed Instruction No. 2	41	009474-009475
Defendant's Proposed Instruction No. 3	41	009476
Defendant's Proposed Instruction No. 4	41	009477
Defendant's Proposed Instruction No. 5	41	009478
Instructions to the Jury	41	009479-009551
Verdict	41	009552-009559
Reporter's Transcript - Sentencing Hearing Thursday, October 24, 2013	41	009560-009583
Judgment of Conviction	41	009584-009589
Amended Judgment of Conviction	41	009590-009595
Notice of Appeal	41	009596-009600

  
CLERK OF THE COURT

TRAN

DISTRICT COURT  
CLARK COUNTY, NEVADA  
\* \* \* \* \*

THE STATE OF NEVADA,	)	
	)	
Plaintiff,	)	CASE NO. C265107-1,2
	)	CASE NO. C283381-1,2
vs.	)	DEPT NO. XXI
	)	
DIPAK KANTILAL DESAI, RONALD	)	
E. LAKEMAN,	)	
	)	
Defendants.	)	<b>TRANSCRIPT OF</b>
	)	<b>PROCEEDING</b>

BEFORE THE HONORABLE VALERIE ADAIR, DISTRICT COURT JUDGE

**JURY TRIAL - DAY 36**

FRIDAY, JUNE 14, 2013

APPEARANCES:

FOR THE STATE:	MICHAEL V. STAUDAHER, ESQ. PAMELA WECKERLY, ESQ. Chief Deputy District Attorneys
FOR DEFENDANT DESAI:	RICHARD A. WRIGHT, ESQ.
	MARGARET M. STANISH, ESQ.
FOR DEFENDANT LAKEMAN:	FREDERICK A. SANTACROCE, ESQ.

RECORDED BY JANIE OLSEN COURT RECORDER  
TRANSCRIBED BY: KARR Reporting, Inc.

KARR REPORTING, INC.

**007383**

## I N D E X

### WITNESSES FOR THE STATE:

#### RICHARD PERRILLO

Direct Examination By Ms. Weckerly	14
Cross-Examination By Ms. Stanish	25
Cross-Examination By Mr. Santacroce	35
Redirect Examination By Ms. Weckerly	48
Recross Examination By Ms. Stanish	49

#### JOAEN SYLER - (Resumed)

Cross-Examination By Ms. Stanish	59
Redirect Examination By Ms. Weckerly	92
Recross Examination Ms. Stanish	108

#### MARK SILBERMAN

Direct Examination By Mr. Staudaher	124
Cross-Examination By Mr. Santacroce	147
Cross-Examination By Ms. Stanish	171
Redirect Examination By Mr. Staudaher	179
Recross Examination By Mr. Santacroce	182

#### FRANK NEMEC

Direct Examination By Ms. Weckerly	189
Cross-Examination By Mr. Wright	202
Cross-Examination By Mr. Santacroce	225

E X H I B I T S

<u>STATE'S EXHIBITS ADMITTED:</u>	<u>PAGE</u>
219 through 227	126
<u>DEFENDANT'S EXHIBITS ADMITTED:</u>	<u>PAGE</u>
P1	175
C2	187

1 LAS VEGAS, NEVADA, FRIDAY, JUNE 14, 2013, 9:34 A.M.

2 \* \* \* \* \*

3 (Outside the presence of the jury.)

4 MS. WECKERLY: We're asking to please call a witness  
5 out of order.

6 THE COURT: Dr. Nemec?

7 MS. WECKERLY: Actually, no. He can't come until  
8 2:30. Dr. Perrillo where -- who is here now --

9 THE COURT: That's fine. I don't care.

10 MS. WECKERLY: Okay.

11 THE COURT: Just to let you know, we'll be ending at  
12 5 today.

13 MS. WECKERLY: Okay.

14 THE COURT: After Mr. Wright's impassioned plea.

15 MS. STANISH: Thank you, Your Honor.

16 MR. WRIGHT: Good. Thank you, Your Honor.

17 MS. STANISH: Just an issue I have on Dr. Perrillo,  
18 the next witness that the State wants to take out of order  
19 because of travel issues. He's a neuropsychologist.

20 THE COURT: Okay.

21 MS. STANISH: In my review of his report, he is  
22 talking about medical issues with hepatitis C causing dementia  
23 or being -- possibly causing dementia, as well as the drug  
24 treatment of -- as having that. I think that's beyond the  
25 scope of his expertise as a psychologist, and I'd like to



1 limit that testimony.

2 THE COURT: Well, anybody want to respond?

3 MS. WECKERLY: Well, I mean, you can have a hearing  
4 on his basis of knowledge, but he has studied that and he's an  
5 expert and he's looked at all her -- we're only talking about  
6 one victim with him.

7 THE COURT: Right. It's just the one -- the gal who  
8 can't testify because she has dementia and they want to link  
9 it to this. So, I mean, if he's treated other patients and  
10 he's --

11 MS. WECKERLY: He has even other --

12 THE COURT: -- and they have hepatitis and they have  
13 dementia and he's causally linked the dementia to the  
14 hepatitis or it exacerbates the dementia or whatever, then I  
15 think he's qualified to testify to that. They just need to  
16 lay a foundation. Or if that's part of his training that, you  
17 know, treating hepatitis dementia patients, then I think he  
18 can testify about that as long as they lay the foundation.

19 MS. STANISH: All right.

20 MR. SANTACROCE: And in that regard, Your Honor, he  
21 treated some patients that aren't genetically linked to the  
22 cluster in this case, and I'm going to ask for -- that he be  
23 admonished not to talk about those patients.

24 THE COURT: Ms. -- were you going to ask about those?

25 MS. WECKERLY: I wasn't planning on asking him about

1 it --

2 THE COURT: Okay.

3 MS. WECKERLY: -- but --

4 THE COURT: Well, they're not going to ask him, so --

5 MS. WECKERLY: -- but -- but I -- I'm just concerned  
6 that, you know, some of the symptoms he sees are going to be  
7 overlapping, so I don't know if you --

8 THE COURT: I mean, I -- I mean, here's the thing.  
9 If Ms. Weckerly doesn't intend to get into that they were  
10 infected at the clinic, but he mentions I'm treating other  
11 patients who have been infected with hepatitis and they're  
12 exhibiting signs of dementia and they happen to have been also  
13 infected patients at the clinic, then as long as he doesn't  
14 get into the method of infection, he's fine to talk about  
15 other patients because that's part of his basis of knowledge.

16 So maybe just -- I'm not going to limit him if he  
17 mentions other patients because that's how he knows. You  
18 know, he --

19 MS. WECKERLY: Yeah.

20 THE COURT: -- I mean, he's going to have to say,  
21 look, her symptomology is not, you know, totally isolated,  
22 it's not completely unique, blah, blah, blah. So if you just  
23 mention to him not to do the linking of the other patients to  
24 the clinic but that they're, you know, if it's recent onset or  
25 something like that or, you know --

1 MS. WECKERLY: Okay.

2 MR. SANTACROCE: I'm not talking about the patients  
3 in this case, he can talk about those.

4 THE COURT: No, we get it. Other patients that  
5 are --

6 MR. SANTACROCE: Yeah.

7 THE COURT: -- that were infected at the clinic but  
8 weren't genetically linked or aren't Lakota Quannah or --  
9 right?

10 MR. SANTACROCE: Correct. The other guy.

11 MS. WECKERLY: I'll just tell him to kind of --

12 MR. WRIGHT: Tell him he can talk about other  
13 patients, but just don't say where they're from.

14 MS. WECKERLY: Right.

15 THE COURT: Yeah, just don't say, oh, they're linked  
16 to the clinic --

17 MS. WECKERLY: Right.

18 THE COURT: -- because that's beyond -- that hasn't  
19 been established yet and it's beyond his expertise.

20 MS. WECKERLY: Okay.

21 THE COURT: But he can certainly talk about other  
22 patients.

23 MS. WECKERLY: Okay.

24 MR. SANTACROCE: The other thing, Your Honor, and I  
25 hate to keep bugging you about this. Can you just give me a

1 quick ruling on the record about his bail because it's --

2 THE COURT: Yeah, I mean, I'll --

3 MR. SANTACROCE: -- the bail bondsman is driving me  
4 crazy.

5 THE COURT: -- I'll reduce it to 25,000 on this case.

6 MR. SANTACROCE: Okay. Can we put that on the record  
7 so I have something --

8 THE COURT: Yeah, Ms. Husted is doing it right now.  
9 She's putting it on the record.

10 MR. SANTACROCE: Awesome. Thank you.

11 THE CLERK: There's double.

12 THE COURT: And Ms. -- Ms. Olsen is recording.

13 THE CLERK: So it's reduced to 25,000?

14 THE COURT: Right.

15 THE CLERK: And it's -- so that's the third time it's  
16 been on the record at court.

17 MR. SANTACROCE: What is that?

18 THE CLERK: Nothing.

19 (Off-record colloquy.)

20 THE COURT: Is everybody ready? Would you tell Kenny  
21 to --

22 Oh, just while we're waiting for the jury, did you  
23 folks, Ms. Weckerly, have an opportunity to show this memo to  
24 Scott Mitchell yesterday?

25 MS. WECKERLY: Not yet.

1 THE COURT: Okay.

2 MS. WECKERLY: I think -- or weren't you just  
3 distributing it? So do we need to -- or you -- I thought you  
4 were going to disclose it, or you want to wait before --

5 THE COURT: No, I distributed it.

6 MS. WECKERLY: -- oh.

7 THE COURT: Then it's -- it's you guys. I mean,  
8 don't disclose it beyond the lawyers --

9 MS. WECKERLY: Yes.

10 THE COURT: -- unless, you know, you can obviously  
11 talk to Mr. Labus about it --

12 MS. WECKERLY: Sure.

13 THE COURT: -- you can talk to Metro about it because  
14 the issue is whether or not they got it. According to  
15 everything I have from the civil cases Labus got it.

16 MS. WECKERLY: Okay. We --

17 THE COURT: And possibly Metro. So possibly Metro  
18 based just on the tape, not on what was said in the civil  
19 cases, but Labus definitely got it. It's distributed to you  
20 guys. I mean, all I'm saying is don't further distribute it  
21 unless it's, you know, germane to the case or -- you know.

22 MS. WECKERLY: I --

23 MR. WRIGHT: I found something else I want. This is  
24 a clue to the other document --

25 THE COURT: Okay.

1 MR. WRIGHT: -- that is missing.  
2 THE COURT: Which one is that? Oh --  
3 MR. STAUDAHER: Your Honor, do we -- could -- we  
4 don't either have our copy or we can't find it --  
5 MR. WRIGHT: Okay.  
6 THE COURT: Well, I gave one copy to the State, and  
7 then I gave copies to Mr. Santacroce and Mr. Wright.  
8 MR. WRIGHT: It's in there. It's in there.  
9 THE COURT: So, Ms. Weckerly, you've got a copy,  
10 or...  
11 MS. WECKERLY: I -- I don't --  
12 MR. WRIGHT: Yeah, she --  
13 MS. WECKERLY: -- I mean, I'm not saying you didn't  
14 give it to me, I just don't know --  
15 THE COURT: No, I --  
16 MS. WECKERLY: -- where it is.  
17 THE COURT: -- distributed it yesterday.  
18 MS. WECKERLY: Okay.  
19 THE COURT: I had the bailiff distribute it.  
20 MR. WRIGHT: If you look at --  
21 THE COURT: So yeah, you guys have it. I mean --  
22 MS. WECKERLY: Okay.  
23 MR. WRIGHT: -- the bottom of page --  
24 MS. WECKERLY: Well, we may need to make --  
25 MR. WRIGHT: -- 2, do you have --

1 MS. WECKERLY: -- another copy.  
2 MR. WRIGHT: -- a copy of it?  
3 THE COURT: Yeah, I kept a copy for --  
4 MR. WRIGHT: Okay.  
5 THE COURT: -- a Court's Exhibit and myself.  
6 MR. WRIGHT: Bottom of page --  
7 THE COURT: Jury's coming.  
8 THE CLERK: No, it's just me.  
9 THE COURT: Oh, it's Denise.  
10 MR. WRIGHT: -- bottom of page 2. It says -- on the  
11 fourth page of the document titled, Office of District  
12 Attorney, Grand Jury lines 14, 15, 16 have a translation  
13 transcription error. When Labus quotes me mentioning, They  
14 would use the needle once they wouldn't reuse needles, that  
15 was my response. It's that portion that -- in his statement  
16 he talks about having read --  
17 THE COURT: A transcript.  
18 MR. WRIGHT: -- a transcript.  
19 MR. STAUDAHER: That looks like it's a grand jury  
20 transcript of Labus, if that's -- doesn't it sound -- that's  
21 what it would sound like --  
22 MR. WRIGHT: Yeah, but that -- but that's pre --  
23 MS. WECKERLY: What year?  
24 MR. WRIGHT: -- but that's pre-grand jury of Labus.  
25 I mean, is what --

1 MR. STAUDAHER: I don't know. We didn't have the  
2 Labus -- well --

3 MR. WRIGHT: I mean --

4 THE COURT: Yeah, maybe --

5 MR. STAUDAHER: -- I don't know.

6 THE COURT: -- Kenny put it on your desk or  
7 something, but we -- I had to make copies and we distributed  
8 it --

9 MR. STAUDAHER: That's fine. He's just going to make  
10 another copy.

11 THE COURT: -- yesterday.

12 MS. WECKERLY: He probably did and we just misplaced  
13 it.

14 THE MARSHAL: We -- Judge, we've got one in the --

15 THE COURT: Rest room?

16 THE MARSHAL: -- rest room, everybody else --

17 THE COURT: Okay. As soon as they're --

18 THE MARSHAL: -- is lined up so --

19 THE COURT: -- ready just bring them in and --

20 (Off-record colloquy.)

21 THE COURT: Is this an out of state witness the  
22 doctor?

23 THE MARSHAL: Is everybody ready, Judge?

24 THE COURT: Yes, bring them in.

25 THE MARSHAL: Ladies and gentlemen, please rise for



1 the jury.

2 (Jury entering at 9:45 a.m.)

3 THE MARSHAL: Thank you, everybody. You may be  
4 seated.

5 THE COURT: All right. Court is now back in session.  
6 The record should reflect the presence of the State through  
7 the deputy district attorneys, the presence of the defendants  
8 and their counsel, the officers of the court, and the ladies  
9 and gentlemen of the jury.

10 Ladies and gentlemen, we're going to have a witness  
11 now out of order because that witness is from out of state and  
12 to accommodate his schedule he's going to testify before we  
13 get into the cross-examination of the last witness. As I told  
14 you before the order in which the testimony comes in is  
15 irrelevant. That you, you know, have to consider all of the  
16 testimony regardless of when you hear it.

17 So, Ms. Weckerly, why don't you go ahead and call  
18 your next witness.

19 MS. WECKERLY: Thank you. Richard Perrillo.

20 THE MARSHAL: Can you step right up there for me,  
21 please. Remain standing, raise your right hand, and face that  
22 lady to your left.

23 RICHARD PERRILLO, STATE'S WITNESS, SWORN

24 THE CLERK: Thank you. Please be seated. And would  
25 you please state and spell your name?

1 THE WITNESS: My name is Richard John Perrillo,  
2 P-E-R-R-I-L-L-O.

3 MS. WECKERLY: May I proceed, Your Honor?

4 THE COURT: Yes.

5 DIRECT EXAMINATION

6 BY MS. WECKERLY:

7 Q Sir, how are you employed?

8 A I'm a forensic, clinical, and neuropsychologist  
9 in my own practice.

10 Q And can you explain your educational background  
11 first to the members of the jury.

12 A Sure. I have a PhD with distinction from the  
13 University of Utah in Salt Lake City. I've done my clinical  
14 internship at the VA Hospital in Salt Lake City. For a short  
15 time I was director of the diagnostic unit for the county  
16 attorney's office in Salt Lake City. Afterwards, let's see, I  
17 had F.B.I. clearance twice, once in 1980 and 1990 because I  
18 was consulting for some 20-years with the sort of industrial  
19 military companies.

20 I've tested literally thousands of people across the  
21 United States. I do quite a few military cases with our  
22 veterans every year. Let me see. I do the beta testing on  
23 neuropsychological instruments which are brain-function  
24 instruments and beta testing means that I -- it goes through  
25 10 of us to see if the instruments are okay for public, you

1 know, public use to my colleagues.

2 Q And I -- you testified as an expert before in  
3 the area of neuropsychology and that sort of testing that's  
4 associated with it?

5 A Yes.

6 Q In your practice and in -- over the years of --  
7 that you worked since your training have you had the occasion  
8 to examine, treat, or even test people who have contracted  
9 hepatitis C?

10 A Yes.

11 Q And from your overall practice of those --  
12 treatment of those patients and testing of those patients have  
13 you seen any associations between hepatitis C and loss of  
14 brain function?

15 A Yes.

16 Q Can you explain to the members of the jury how  
17 it is that hepatitis C would affect the brain?

18 A Well, it's sort of a complicated process, but  
19 hepatitis C is neuro-virulent. It's a virus that affects the  
20 nervous system much like AIDS or HIV. And the research  
21 clearly shows that you don't have to be in the later stages of  
22 liver disease to have brain damage and brain dysfunction. So  
23 there's been quite a few studies that show that people were  
24 complaining of cognitive impairment even prior to the onset of  
25 any liver disease. And those studies clearly showed that

1 these individuals had sustained some brain damage and brain  
2 dysfunction.

3 I had tested 19 people with hepatitis C in ages  
4 ranging from 23 to about 85.

5 Q And -- in the people that you tested in that  
6 group did you test them for -- for what you said, like the --  
7 sort of assessing brain function after contracting hepatitis  
8 C?

9 A Oh, yes. You know, neuropsychological tests are  
10 very sensitive to brain damage and brain dysfunction, and even  
11 more sensitive than the techno scans like MRIs and CT scans.

12 Q And then, is the reason why it affects the brain  
13 because of, like, impaired liver function and so it's -- the  
14 liver isn't functioning properly and then the -- then the  
15 brain gets affected?

16 A Well, there's that and also the brain has a  
17 group of cells that are your scavengers, you know, call them  
18 microglia cells. And they sort of fight off any foreign, you  
19 know, any foreign cells that try to enter it. So your brain  
20 is pretty protective actually, you know, it's up there on its  
21 own little plain, and -- but then the rest of your body has  
22 white bloods, you know, called microcytes. And the thinking  
23 is that they get infected, they migrate across the blood brain  
24 barrier and then the microglia cells can't fight them off.  
25 This is what the thinking is.

1           And then that creates a metabolic imbalance. And as  
2 the metabolic imbalance then that causes brain dysfunction.  
3 But you can't do autopsies on live people. And so this -- you  
4 know, so this is -- this is -- so this is what the thinking  
5 is. And anyway the best we have is neuropsychological test to  
6 reveal whether there are abnormalities in one's brain.

7           Q     Now, what about the treatment that some people  
8 that contract hepatitis C go through, the Interferon  
9 treatment, how does that affect the brain in terms of dementia  
10 or causing damage in your -- in your experience with the  
11 patients you've dealt with?

12           A     Well, Interferon treatment is like chemotherapy  
13 and it's highly toxic. So it's a doubly whammy, you know, and  
14 there are numerous, numerous side-effects to Interferon  
15 treatment, including memory impairments and all kinds of  
16 physiological, you know, stomach, diarrhea, vomiting, nausea,  
17 depression, you know, fatigue. I mean, there's just a whole  
18 list of side effects with the Interferon treatment.

19                     And so it sort of accelerates, you know, the brain  
20 dysfunction.

21           Q     Now, once you --

22                     MR. WRIGHT: I didn't hear that last part.

23                     THE WITNESS: Oh, it accelerates one's brain  
24 dysfunction.

25                     BY MS. WECKERLY:

1           Q     Once you've stopped the Interferon treatment, or  
2 once the patient stops that does their brain go back to normal  
3 function, or can they recover that cognitive ability?

4           A     Well, it doesn't -- that doesn't seem to be the  
5 case. Age seems to be a -- there are several moderator  
6 variables and age is one. It's like anything else, the  
7 younger you are, the better off you have, you know, a better  
8 chance of recovery. The older you are, you know, your chances  
9 of recovery aren't so good.

10           The other thing is if people have a co-morbid  
11 medical condition -- so let's say they have diabetes or they  
12 have something else that's going on with them, well, that's  
13 going to make it more difficult for them to recover.

14           Q     So people with more -- that are older or with  
15 more compromised health before the onset of the infection  
16 don't do as well in terms of recovery after the treatment?

17           A     Exactly. And then, you know, if you think of  
18 your liver as sort of your purifier, you know, if it's not  
19 able to purify your blood, then that adds to the, you know, to  
20 the issue.

21           Q     And is -- and in terms of your liver functioning  
22 as a purifier, obviously it would probably function better  
23 when you're younger, at least for the majority of the  
24 population?

25           A     Right. And so, you know, for example, just as

1 -- just an example, with normal people, normal people could  
2 drink, for example. They could have one or two drinks a day  
3 no problem. But if you have a liver dysfunction, it's very  
4 difficult for your liver to process that because it can't  
5 purify your system. So that's going to then complicate, you  
6 know, that also.

7 Q Nothing works as well as you age.

8 A Yes, nothing works as well as you age. That's  
9 right.

10 Q I'd like to direct your attention to a woman by  
11 the name of Carole Grueskin. Did you meet Ms. Grueskin and do  
12 an assessment of her?

13 A I did.

14 Q And was that in -- on January the 28th of 2011?

15 A Yes.

16 Q At the time you assessed Ms. Grueskin how old  
17 was she, approximately?

18 A 71.

19 Q And when you examined Ms. Grueskin, how did  
20 you -- how did you start your interaction with her?

21 A Well, a friend brought her to me because she was  
22 unable to come by herself, and, you know, just globally she  
23 had -- she was demented. She had no sense of progress and  
24 time, you know, she -- she was disoriented and confused. So I  
25 started off with something pretty simple, I asked her, you

1 know, what year it was and she didn't know or couldn't  
2 retrieve what year it was.

3           So then I wrote down the years for her and asked her  
4 to circle the one because there I was testing recognition. So  
5 she couldn't retrieve it which would be a frontal lobe,  
6 prefrontal function but recognition would be, you know,  
7 temporal. So she was able to recognize the year and -- and  
8 then circle it. But --

9           Q     So if -- just if I could ask, in that instance  
10 you wrote a couple of different year choices on a piece of  
11 paper and asked her to circle which one was correct?

12           A     Correct.

13           Q     And she got it right?

14           A     And she got it right. But it was downhill from  
15 there. Most of the tests had to be aborted. She could not do  
16 most of the tests. So I then resorted to what's called a  
17 simple cognitive status exam. And again, it's very simple,  
18 what's the date, what's the time, who am I, where are you, you  
19 know, this kind of thing, and -- and she couldn't even go  
20 through that.

21                 And so she had severe brain damage, frontal-temporal  
22 dementia and she's not likely to recover.

23           Q     And in your -- in your assessment of her were  
24 there some tests that you attempted to perform on her in order  
25 to make an assessment that -- that it just wasn't possible



1 because of her cognitive ability or disability, I guess?

2 A Well, yes. One of -- two of the tests are world  
3 renowned and they're called the Trails Making Test A and B.  
4 And the Trails Making Test A is a very simple test, a visual  
5 scanning and planning. And all you have to do is connect the  
6 numbers quickly, all right, on a piece of paper. And she was  
7 incredibly slow in doing that. So she was in less than the 1  
8 percentile.

9 Q And those numbers that you're supposed to be  
10 connecting on a piece of paper, are they really high numbers  
11 or how -- what are the numbers?

12 A No, they're very low. They go from like 1 to  
13 13, you know. So you're just connecting the numbers in order.  
14 And this is within the context of her having preserved motor  
15 ability, her fine motor ability and a grip strength was  
16 preserved. So there wasn't any orthopedic injury that could  
17 interfere with this. It was white matter, you know, loss,  
18 processing speed loss.

19 And so that was one of the tests. The second test  
20 was the Trails Making Test B where you have to shift between  
21 numbers and letters. And that's a stronger cognitive  
22 load-type activity because you're not just connecting the  
23 numbers, now you're shifting between number and a letter.

24 Q Like 1A, 2B?

25 A Right.

1 Q Okay.

2 A 1A, 2B, 3C. So that -- that is a frontal-lobe  
3 activity. Your -- you know, for flexibility. And she  
4 couldn't do it. We had to abort it after about 3, 4 minutes.  
5 The average person can do Trails Making A within 30 seconds,  
6 and the average person could do Trails Making B within 60  
7 seconds and she did Trails Making A in 105 seconds, which is 3  
8 times the average individual for her age, and B, we had to  
9 abort after 3 or 4 minutes. She just, you know, she --

10 Q She couldn't complete it?

11 A -- right.

12 Q Now, you said, I think, that her fine motor  
13 skills are intact and normal for a woman in -- who is 70?

14 A Yes.

15 Q And so there's nothing physically wrong with her  
16 in terms of, like, I guess a structural brain damage or a  
17 muscular problem or anything like that?

18 A No, let me rephrase that for you. There's  
19 the -- in terms of motor, okay, she's able to grip, she's able  
20 to do fine motor ability, but she has organic brain damage. I  
21 mean, there is something physically wrong with her and -- and  
22 she has organic brain damage, you know, she can't process her  
23 world quickly. She's incredibly slow. Both visual and  
24 auditory memory is severely impaired.

25 Q And when you say her memory is severely impaired

1 can you give us an example of what she had -- what she can or  
2 can't remember?

3 A Well, she didn't remember, for example, where  
4 she went to high school. Couldn't remember what degree she  
5 had. It turns out she has an AA degree, but couldn't  
6 remember, you know, where she went or -- I got that from the  
7 medical records. She would leave things on the stove, so much  
8 so that she was becoming a danger to herself and others.

9 The neighbors were reporting that she was wandering  
10 in the streets aimlessly, so they called her son. I think he  
11 came from San Diego, who I met for a few minutes, actually,  
12 and -- or I spoke to him on the phone, and he, you know,  
13 reported that she's pretty disoriented and very demented.

14 Q Now, did you review Ms. Grueskin's medical  
15 records for signs of dementia prior to September the 21st of  
16 2007?

17 A I did.

18 Q And in your assessment were there signs of  
19 dementia before that date?

20 A No. Her medical records were pretty clean, you  
21 know, prior to that date, and then, all of this dementia stuff  
22 started when she took the Interferon treatment and then there  
23 were numerous notations in the medical records from the  
24 Interferon treatment itself, and then afterwards reporting of  
25 various doctors that she was demented.

1           Q     And, I mean, how can you tell that the dementia  
2 is either accelerated or attributed to hepatitis C versus, you  
3 know, some -- I mean, some people just get dementia as they  
4 get older, correct?

5           A     Yes, but the epidemiological study showed the  
6 following. Only 1 percent of the population gets dementia  
7 between 65 and 70 and only 30 percent get dementia by the age  
8 of 85. So that means 99 percent of the population do not have  
9 dementia between 65 and 70 or 75 and a clear 70 percent don't,  
10 you know, by the time they're 85.

11                 And so the probability that this woman would have  
12 dementia, you know, at 68 -- that's when she took the  
13 treatment and, you know, the Interferon and all that, and then  
14 up until 71 it's highly, highly unlikely. In addition to that  
15 no one in her family has reported Alzheimer's disease. And in  
16 addition to that she had a fairly good educational background  
17 which seems to, you know, sometimes interfere with the  
18 acquisition of Alzheimer's.

19           Q     And I think you answered this already, but is  
20 she likely to improve at all?

21           A     No.

22           Q     Thank you.

23           THE COURT: All right.

24           MS. WECKERLY: I'll pass the witness, Your Honor.

25           THE COURT: Cross, Ms. Stanish?

1 MS. STANISH: Thank you, Your Honor.

2 CROSS-EXAMINATION

3 BY MS. STANISH:

4 Q Good morning, sir.

5 A Good morning.

6 Q My name is Margaret Stanish. I represent Dr.  
7 Desai. You are not a medical doctor, correct?

8 A Correct.

9 Q You're a neuropsychologist?

10 A Yes.

11 Q And I want to start with your reference to the  
12 scientific literature that you state supports your conclusion  
13 that hepatitis C caused the demented state in Ms. Grueskin,  
14 okay?

15 A Okay.

16 Q I have a copy of your report and I see that you  
17 cited two articles in that report. Are there more?

18 A Oh, yes, there's -- and I have them with me. I  
19 have about nine hard copy ones, and then I have on my  
20 computer, which is with me, about, oh, 20 or 25 further ones.

21 Q And you could provide -- did you provide copies  
22 of those to the district attorney?

23 A No, they didn't ask for it.

24 Q Okay. I'm asking.

25 A All right.

1 Q Okay. Thank you. And the --

2 A It's okay to email it to you? I'm happy to --

3 Q That's fine.

4 A -- email you the folder.

5 THE COURT: Doctor, there's a copy machine in the --

6 I'm kidding.

7 THE WITNESS: Oh.

8 BY MS. STANISH:

9 Q Get to work. The -- moving to -- as I  
10 understand your testimony you're saying that the dementia can  
11 be attributed to one of two issues. Either the hepatitis C  
12 itself or the drug treatment; is that correct?

13 A Or the combination.

14 Q Okay. And the -- as far as Ms. Grueskin's  
15 medical records, I understand that you said that she had no  
16 family history of Alzheimer's. Do you know if her parents --  
17 how her parents died?

18 A I don't. I can't recall right offhand. I'd  
19 have to look at my notes.

20 Q Isn't it the case that many people who have  
21 genes for Alzheimer's die before Alzheimer's even manifests  
22 itself?

23 A Well, that could be true, yeah. But the -- the  
24 gene doesn't necessarily play out that you would get  
25 Alzheimer's, it's only a -- you know, it's only a, sort of,

1 one of the factors involved.

2 Q And let's talk about some of the other factors.  
3 Ms. Grueskin did have some, what I believe you called  
4 co-morbid --

5 A Medical conditions.

6 Q -- medical conditions. Tell us about those  
7 conditions that she had.

8 A Well, she had diabetes type 2 and she had breast  
9 cancer -- I think she had the breast cancer in the '90s.

10 Q And did she have to undergo both chemotherapy  
11 and radiation?

12 A Yes, she did.

13 Q And do you know for how long she had to undergo  
14 that treatment?

15 A I can't recall actually. There were 900 pages  
16 of medical records here.

17 Q Okay. Do you recall how long the treatment  
18 extended?

19 A No. I -- what I do know though is that -- is  
20 that prior to the Interferon treatment she was assessed by a  
21 neuropsychologist, who -- you know, with no signs of dementia  
22 or cognitive impairment, and then from that time of treatment  
23 of the breast cancer up until, you know, the time of the  
24 treatment, there was no notations in any of the medical  
25 records that she had any sort of cognitive impairment.

1 Q Let's go -- can we go back and talk about the  
2 co-morbid medical condition?

3 A Sure.

4 Q So we have -- you've identified the diabetes,  
5 you've identified the cancer treatment with radiation,  
6 chemotherapy?

7 A I think so.

8 Q And then what's the third co-morbid problem that  
9 she has?

10 A I think that -- there was just an allergy. She  
11 had some allergy in the mid'90s and that was it.

12 Q Do you recall your report mentions that she's a  
13 heavy daily smoker for over 20 years, smoking --

14 A Oh --

15 Q -- one or two packs?

16 A -- sure.

17 Q Now, I understand from your testimony that you  
18 don't see in her medical records any evidence of dementia  
19 prior to that -- the treatment, but I want you to explain to  
20 us the -- those three co-morbid conditions in combination do  
21 they contribute to dementia?

22 A I haven't seen that in my practice. People with  
23 diabetes don't become demented.

24 Q I --

25 A People with --



1 Q --- in combination?

2 A In combination? There is nothing I've seen in  
3 the literature, and I can -- I'll send you, you know, you'll  
4 see the articles I have in my portfolio that says that if you  
5 have diabetes and you smoke you're going to get dementia.  
6 Chemotherapy could be, you know, problematic if it's -- if the  
7 cancer comes back and you have to redo it and it's over and  
8 over again.

9 But the real culprit here is this hepatitis C. I  
10 mean, from what I know and the 19 people that I've evaluated.

11 Q And have you evaluated Stacy Hutchinson?

12 A I did.

13 Q Gwendolyn Martin?

14 A I did.

15 Q And have you evaluated Rodolfo Meana?

16 A I did. Michael Washington and --

17 Q And let me ask you in a -- was there a  
18 particular plaintiff's attorney who referred you to the  
19 district attorney's office to testify here today?

20 A I don't know how that came about.

21 Q Okay.

22 A I really don't. I got a notice from Mr.  
23 Staudaher.

24 Q Yeah, I don't know the guy.

25 A I don't know how you say his name, but anyway, I

1 got a notice from him. And he was interested in the, you  
2 know, the work that I had done on those people.

3 Q Okay. I saw that at the one -- the -- one of  
4 the two articles that you cited it was a article from some  
5 European medical journal, recall that? It dealt with the  
6 treatment of -- the drug treatment, and the effects on the --  
7 the mental-health effects during drug treatment --

8 A Yes.

9 Q -- do you recall that --

10 A Sort of.

11 Q -- study? Pardon?

12 A I said sort of. There's quite a bit.

13 Q Well, here, I'll --

14 A Let me see if I --

15 Q -- just -- let me just show you --

16 A -- may have a hard copy.

17 Q -- your report. I got it right here.

18 MS. STANISH: If I may approach, Your Honor.

19 THE COURT: That's fine.

20 BY MS. STANISH:

21 Q Just to refresh your memory. It's -- that's  
22 your report, okay?

23 A Oh.

24 Q I just want it to go to the part where you cite  
25 the two tests.

1 A Do you mean the two articles?  
2 Q Yeah.  
3 A Oh, it must be in the beginning.  
4 Q Do you know where it is?  
5 A Yeah.  
6 Q All right.  
7 A Sure.  
8 Q There it is.  
9 A Yeah.  
10 Q That's the one from Europe, right?  
11 A Okay. What's it called again?  
12 Q It's a really long title, of course.  
13 A Cognitive impairment, okay. I probably have  
14 that on my computer. I don't have it right here as a hard  
15 copy, but --  
16 Q Do you -- do you recall that that study  
17 ultimately concluded that far more -- more studies are needed  
18 in this area before conclusions could be drawn?  
19 A Yes, but I think -- wasn't that -- what was the  
20 date of that study, you know, because there's been a -- quite  
21 a bit since --  
22 Q I don't --  
23 A -- since that time.  
24 Q -- see a date in your report, so I don't know.  
25 A Let's see. But I'll -- let me look this up and

1 can you ask your questions, I guess? Let's see here.

2 Q I've never had a witness whip out an iPad during  
3 testimony.

4 THE COURT: Well, it's a new world --

5 MS. STANISH: Yeah, it --

6 THE COURT: -- Ms. Stanish.

7 MS. STANISH: -- really is.

8 THE WITNESS: I used to come with boxes and boxes.

9 THE COURT: It's a brave new world.

10 MS. STANISH: So long as he's not playing Scrabble up  
11 there.

12 THE WITNESS: I used to come with boxes.

13 MS. STANISH: What Angry Bird.

14 MR. WRIGHT: Are we going to make a record of what  
15 he's looking at?

16 MS. STANISH: I'll join him up there.

17 THE COURT: Ms. Stanish, you can move freely about  
18 the courtroom.

19 MS. STANISH: Thank you.

20 THE WITNESS: Okay. And --

21 THE COURT: And, Doctor, if you'd just kind of tell  
22 us without telling us the content there on your iPad, would  
23 you just -- say just for the record so we all know, and --  
24 what it is you're looking at.

25 THE WITNESS: All right. I'm looking at the original

1 article called, Cognitive impairment in patients --

2 THE COURT: Okay.

3 THE WITNESS: -- with chronic hepatitis treated with  
4 Interferon, results from the --

5 THE COURT: And that was your -- I'm sorry, I didn't  
6 mean to -- that was referred to in your report?

7 THE WITNESS: Yes.

8 THE COURT: Okay. Now, don't tell us the content of  
9 the -- that article unless Ms. Stanish asks you something  
10 about it --

11 MS. STANISH: All right.

12 THE COURT: -- okay?

13 THE WITNESS: Okay.

14 BY MS. STANISH:

15 Q And so that -- the year was 2000 and what did  
16 you say?

17 A It was received in 2004, and it was accepted  
18 2004 and available online in 2005.

19 Q And are you aware of whether additional studies  
20 were done in the United States on that issue that is raised in  
21 that European medical journal?

22 A Oh, yeah, you'll see them here. Robin Hilsabeck  
23 and others -- and I think the name was Fortin [phonetic]  
24 they've done additional studies since then, 2009, and '10 and  
25 '11.

1           Q     Okay. Why -- can I ask you why aren't -- why  
2 didn't you cite any of these 11 or numerous studies in your  
3 report? Because you only cite this one that you have there on  
4 your iPad and -- from 2005 and then one additional one that  
5 looks like it's dated in 2009, but I don't know what the  
6 publication is?

7           A     I don't know. I -- you know, I've done 19  
8 reports plus a master grid and you just can't, you know, cite  
9 everything.

10          Q     Okay.

11          A     You know, I was trying to deal with the issue at  
12 hand. This study was important because it said that there  
13 were -- I'm not supposed to read from it -- it said that there  
14 were, you know, disturbances in the prefrontal cortex and the  
15 hippocampus.

16          Q     That -- I don't -- all I really asked was why  
17 you didn't cite it, and I understood your answer to be that  
18 you -- you did -- wrote a bunch of other reports and you  
19 didn't think it was necessary; something to that effect?

20          A     Well, not that it wasn't necessary. You just  
21 have a certain amount of time available, you know, and so --

22          Q     Correct. And you were doing these -- Ms.  
23 Grueskin was -- and a plaintiff's attorney hired you to  
24 represent her in a lawsuit; is that correct?

25          A     Yes.

1           Q     And can you tell us how much fees you earned in  
2 the representation -- or the assessment of Ms. Grueskin,  
3 Hutchinson, Martin, Washington, Meana, those five people; can  
4 you estimate?

5           A     Well, depending upon the level of testing, it  
6 was 10 to \$15,000 per person roughly, but each person, like,  
7 Ms. Grueskin had over 900 pages or 1000 pages of medical  
8 records, and all those medical records had to be gone through  
9 and --

10          Q     Okay. By the way, do you know from your review  
11 of her medical records what her liver function test, her most  
12 recent liver function test showed as far as the hepatitis C  
13 virus; do you know?

14          A     I may have known at the time, but I can't  
15 remember right now.

16          Q     Okay. I'm about done. Hold on. Okay. I have  
17 nothing further. Thank you, sir.

18          A     Thank you.

19          THE COURT: All right. Mr. Santacroce?

20                   CROSS-EXAMINATION

21          BY MR. SANTACROCE:

22          Q     Doctor, can you tell me a little bit about what  
23 your employment practice consists of right now?

24          A     Well, I -- let's see. I do quite a few military  
25 cases. I do a lot of forensic work.

1           Q     Okay. Now, let me stop you there. When you say  
2 you do a lot of cases, I'm a little confused. Are you talking  
3 about court cases or are you talking about diagnosis of  
4 certain ailments?

5           A     Well, everyone gets tested that comes to my  
6 office, and so the forum is just the forum. So there's the  
7 forensic forum, there's the military forum, I am doing  
8 research on neuro exercise and putting them in various  
9 communities. In fact, I put one here in Las Vegas. Once in a  
10 while I go to Berkeley and teach the pre and post doctoral  
11 students on updates of testing and I do the beta testing on  
12 neuropsychological instruments.

13          Q     And what do you --

14          A     I mean, that's roughly --

15          Q     -- mean when you say forensic? What is the  
16 forensic aspect of your work?

17          A     Well, forensic is sort of, you know, when  
18 there's a dispute and -- and then the forensic scientists  
19 would come in and try to resolve the dispute in some way.

20          Q     When you say dispute you're talking about court  
21 dispute?

22          A     I guess you would call it a court dispute or  
23 some sort of, you know, dispute over damage or dispute --

24          Q     Money damages?

25          A     Well, not --- not so much money damages, but, you



1 know, the actual damage to the person. Sometimes there's a  
2 dispute where a person may claim they're injured when they're  
3 not or they're severely injured and there has to be  
4 verification of it. And so I guess the neuropsychologist, in  
5 terms of brain functions, would be the verifier.

6 Q So when you talk about forensic does that have  
7 to do with court?

8 A Yes, it has to do with court, but there are  
9 different levels. I mean, there's, you know, in the military  
10 cases, I guess you can call that forensic too but it's not a  
11 courtroom like this if there's a military tribunal consisting  
12 of doctors and surgeons that I report to and I send my reports  
13 to and that kind of stuff.

14 Q But it's still a judicial process whether it's  
15 under the UCMJ or if it's under civil law?

16 A Sort of, yeah.

17 Q Okay. And how many times have you testified in  
18 court regarding your expertise?

19 A Actually at trial? About -- I want to say over  
20 30.

21 Q And you've testified mostly for plaintiff's in  
22 those cases?

23 A Mostly.

24 Q Or prosecution?

25 A Well, I only did one other criminal case in

1 Bethel, Alaska --

2 Q Okay.

3 A -- but I didn't --

4 Q But when you worked for the county attorney's  
5 office in Salt Lake City, what did you do?

6 A Oh, there we were designing an  
7 alternative-treatment program to incarceration. So the idea  
8 was, you know, if we could test these people -- I tested them,  
9 and -- and if there were some other factors involved and they  
10 were candidates for rehabilitation maybe that was a viable  
11 alternative to then imprisoning them and that's what I did.

12 Q Okay. So you didn't work for the prosecution  
13 and the county attorney's office in Salt Lake City?

14 A It was -- yeah, it was the -- it was the county  
15 attorney's office of Salt Lake City. And then the county  
16 attorney's office of Santa Clara hired me once as a consultant  
17 for a case.

18 Q In this particular outbreak in Clark County  
19 Nevada, you were retained on Carole Grueskin, Patty Aspinwall;  
20 is that fair?

21 A No, Patty who?

22 Q Okay. Well, then you have Stacy Hutchinson?

23 A Yes.

24 Q Rodolfo Meana?

25 A Yes.

1 Q Gwendolyn Martin?

2 A Yes.

3 Q And those other individuals that you were  
4 retained for -- and we're not talking about Carole Grueskin  
5 now, but the ones I just mentioned, okay?

6 A Yes.

7 Q Did any of those have any cognizant deficiencies  
8 that you noted?

9 A Oh, yes, they all did.

10 Q Okay. And isn't it a fact that most hepatitis C  
11 patients have some cognitive problems?

12 A Well, it appears that way and the literature  
13 appears to say that -- that you don't have to have a  
14 full-blown liver disease to have the cognitive issues. That's  
15 why they think it's neuro-virulent.

16 Q I see.

17 A That it affects your brain even before the  
18 evidence comes forward that -- that your liver has been  
19 damaged.

20 Q Well, there was no dementia for Stacy  
21 Hutchinson, Gwendolyn Martin, was there?

22 A No, but Stacy Hutchinson was pretty impaired  
23 actually. Gwendolyn was better -- she did better. But Carole  
24 Grueskin is -- was the fully demented one. They -- the other  
25 two or those other people that they mentioned could complete

1 their exams, but she was so impaired that she couldn't even  
2 complete it.

3 Q And don't some of the studies indicate that  
4 they're not quite fully understanding how it's related to the  
5 hep C? That it may be related to the fatigue from the hep C?

6 A No, just the opposite is true. When I send your  
7 colleague my file on hep C literature, you'll see that the  
8 cognitive impairment is independent of depression, independent  
9 of fatigue, independent of all of these sort of psychiatric  
10 problems that happened. There's been several studies with  
11 regard to that issue.

12 Q Are you familiar with the July 2012 study that  
13 was reported in the HCV Advocate newsletter? Are you familiar  
14 with that study?

15 A What's the title?

16 Q That's the title. It's by Alan Franciscus.

17 A I can't say I recall it.

18 Q Okay. In that study he indicates that a  
19 possibility is due to the constant state of fatigue that these  
20 hep C patients have as a symptom of their disease; do you  
21 disagree with that?

22 A Well, it seems to be contradicted by the studies  
23 that show that prior to getting, you know -- you know,  
24 outright liver disease, so in other words, the subclinical  
25 people, they also have cognitive impairment. And so no

1 question that, you know, Interferon creates fatigue and a host  
2 of other things. You know, it is a complicated process, but  
3 there seems to be some -- some research that indicates before  
4 your liver even progresses to the point where, you know, it's  
5 noticeable these individuals are suffering from brain  
6 dysfunction.

7 Q Well, is it the disease or the treatment of the  
8 disease that causes the problem?

9 A Well, it's both. It's the disease and the  
10 treatment of the disease that causes the problem.

11 Q Okay. What's brain fog?

12 A Some people describe brain fog as, you know,  
13 they're not thinking clearly and they can't, you know,  
14 literally see clearly -- not vision-wise, but they just can't  
15 put things together clearly, and it sounds, you know -- it  
16 feels to them as if their brain is in a, you know, sort of  
17 like in a fog state.

18 Q So a possible loss of concentration?

19 A Loss of concentration, loss of attention, you  
20 know, loss of the ability to process your world quickly.

21 Q Okay. And don't the studies indicate that  
22 that's what most -- or that's what the people experience as  
23 this brain fog and not dementia due to the hep C virus?

24 A Well, brain fog is not dementia, you know.  
25 People that report brain fog are able to, you know, where they

1 went to high school. They're able to know the year. They're  
2 able to know -- it was 4:00 in the afternoon and I asked her  
3 to draw a clock and she wasn't able to do it and she put, you  
4 know, 10 minutes to 10.

5           People that have brain fog don't wander around the  
6 neighborhood, you know, confused and disoriented. And in  
7 addition to that, you know from my report that after this  
8 treatment, including the report of the treatment that the  
9 medical records reported dementia. There were several entries  
10 in her medical records where it said, dementia, dementia,  
11 dementia, dementia. It wasn't just me, you know. Before she  
12 even saw me all the practitioners reported that she was  
13 demented.

14           Q     Are you familiar with the University of Alberta  
15 Canada's study of 2000 -- October 7, 2010?

16           A     I'm sure that --

17           Q     I mean, there's a lot of studies --

18           A     -- I'm sure there's hundreds of --

19           Q     -- I'm not -- I'm not trying --

20           A     -- studies.

21           Q     -- to put you on the spot, I'm just trying to  
22 understand this, you know.

23           A     Does it have a title?

24           Q     The lady might have dementia. I'm just trying  
25 to understand it, I don't know, so in my research of this

1 subject which is very limited, I don't have the expertise that  
2 you do and I don't pretend to have that, okay?

3 A All right.

4 Q So I'm just trying to get some information from  
5 you.

6 A Does it have a title, maybe I have it?

7 Q That's all I have is the site, the University of  
8 Alberta, October 7, 2010, study.

9 A You don't have a title or a --

10 Q No, I don't. Are you familiar with any Canadian  
11 studies?

12 A Not off the top of my head because I don't look  
13 at where the --

14 Q Okay.

15 A -- studies are published.

16 Q Well, you understand -- I mean, you don't  
17 confine your study and resource just to studies out of the  
18 United States, do you?

19 A No.

20 Q And you look at things from all over the  
21 world --

22 A Well, sure.

23 Q -- to get a big picture?

24 A Sure.

25 Q And in Canada it's reported that, at least in

1 this study there was -- there's 300,000 people with hep C  
2 walking around, and they tested, at least according to this  
3 study and found that only 13 percent of those people had any  
4 kind of brain impairment.

5 And I guess what I'm trying to understand, is that  
6 13 percent some sort of secondary problem, or is it -- can you  
7 attribute it directly and are you medically certain that it  
8 comes from the hep C and doesn't come from the Interferon or  
9 the ribavirin or something else?

10 A Well, first of all, you don't have a title of  
11 the study, so I can't even look at the study right now and  
12 tell you -- and answer your question. Secondly, the 13  
13 percent that they report is inconsistent with what the  
14 Americans report and Robin Hilsabeck at UCLA because it's more  
15 like 39 or 40 percent.

16 Thirdly, in the 19 people that I've seen it's about  
17 50 percent that have some sort of a cognitive impairment.  
18 Fourthly, I would have to see the way the research was  
19 conducted. What neuropsychological test they gave. I would  
20 have to see the battery of tests. I would have to see whether  
21 they actually did a thorough and comprehensive job. Whether  
22 they tested all the issues at hand, including white matter and  
23 the processing speed loss and verbal and visual memory as well  
24 as frontal and prefrontal, you know, kinds of issues.

25 But without giving me the evidence to look at, it's



1 very hard to answer --

2 Q Okay. I'm just --

3 A -- your question.

4 Q -- I'm just asking you to comment on what they  
5 found.

6 A Well, how do I know what they found when you  
7 don't --

8 Q Okay. Well, I'm --

9 A -- have it?

10 Q -- telling you if that's what the study says.  
11 If you don't trust me on that that's fine. You know, that's  
12 fine. You want to --

13 A Well, you can't pluck a statement from a study  
14 that seems to be comprehensive and I'm supposed to rely on the  
15 way you represent it, you know, that's not proper and that's  
16 not science, you know. And so any questions that you have  
17 related to that my answers would be nonsensical. You know,  
18 the general question is does the hep C cause brain damage?  
19 The answer is yes.

20 Does the Interferon combination with hep C cause  
21 brain damage? The answer is yes. And so, you know, Carole  
22 Grueskin is an unfortunate. She's demented.

23 Q How many people in the United States have  
24 hepatitis C to your knowledge?

25 A I don't know. I'm not sure.

1 Q Four percent of the population?

2 A And?

3 Q I'm asking you, as a person that studies this,  
4 can you tell me how many people in the United States are  
5 walking around with hepatitis C?

6 A I don't know.

7 Q You told me you studied 19 people, and from 19  
8 people you're telling me that's a scientific study or  
9 sampling?

10 A Well, it's not a -- it's not a random sampling.  
11 It's a sampling of people from this community, you know. It's  
12 not a -- it's not a -- I didn't go out and sample, you know,  
13 the American population who have hep C, you know. It was a  
14 random -- it was a sample from this community of 19  
15 individuals that I happened to test. And there was a  
16 remarkable consistency amongst these genetic strangers in  
17 terms of their brain dysfunction.

18 Q So I'm supposed to accept that as scientific  
19 data that you studied 19 people, and the jury is supposed to  
20 accept that as scientific data that you studied 19 people?

21 A Well, you don't have to accept anything. I'm  
22 not asking you to accept anything. The point of the matter is  
23 is that Carole Grueskin is demented, okay? And out of this  
24 context, if I told you that she was demented, you wouldn't  
25 challenge it. She's demented. And all the medical people

1 that have seen her has labeled her as demented. Percipient  
2 witnesses, her neighbors, her son have labeled her as  
3 demented.

4 And her neuro-cognitive, you know, impressions shows  
5 that she's demented, okay? You weren't there with her all  
6 day, I was.

7 Q I'm not denying she's demented, Doctor. You're  
8 drawing the conclusion that she's demented because of the hep  
9 C virus. That's what I'm challenging with you, and I'm  
10 challenging it based on the 19 people you studied and the  
11 conclusions you drew from those 19 people when there's  
12 hundreds of thousands of people in the United States walking  
13 around with hepatitis C that you didn't study.

14 A But those hundreds of thousands of people around  
15 the United States aren't relevant for the individual, okay?  
16 You know, scientific psychology studies individual differences  
17 not group differences. It doesn't matter to me, you know,  
18 whether there's 10 people that aren't demented but she's the  
19 one that is, okay?

20 The pattern of results and the literature seems to  
21 indicate that individuals with hep C and combination  
22 Interferon treatment makes it worse and they become -- they  
23 have cognitive impairments. In her case, she's an  
24 unfortunate, you know. She has more cognitive impairment than  
25 some others and she's fully demented.

1 Q Well, it may not matter to you, sir, but it  
2 matters to me and it matters to my client.

3 MR. SANTACROCE: I have nothing further.

4 THE COURT: All right. Redirect?

5 MS. WECKERLY: Just briefly.

6 REDIRECT EXAMINATION

7 BY MS. WECKERLY:

8 Q Dr. Perrillo, you actually tested the 19 people  
9 that you're talking about, correct?

10 A Yes.

11 Q So you performed all those tests on them and  
12 concluded that there was some impairment that you actually  
13 personally saw from your testing results?

14 A Yes.

15 Q But you're also aware of wider studies or the  
16 scientific literature that show the association between  
17 hepatitis C and cognitive impairment?

18 A Yes. I must have -- I must have, I don't know,  
19 30 or 40 studies here just on hepatitis C alone.

20 Q Okay. And specifically, in terms of Carole  
21 Grueskin, her level of cognitive disability and dementia  
22 occurred after she contracted hepatitis C and did the  
23 Interferon treatment?

24 A Yes.

25 Q Thank you.

1 THE COURT: Ms. Stanish?

2 MS. STANISH: Just a few.

3 RECROSS-EXAMINATION

4 BY MS. STANISH:

5 Q Based on the testing that was referred to, did  
6 you -- you test -- did you say you tested Ms. Martin?

7 A Yes.

8 Q And what was your conclusion with respect to Ms.  
9 Martin? Did she have brain fog or dementia?

10 A I'd have to --

11 Q Okay.

12 A Just give me a moment.

13 Q Okay. I'll get up there -- I want to look at  
14 the iPad.

15 A Let's see. Those are her medical records. Hold  
16 on. Here we are. She didn't have brain fog, I'll tell you  
17 that.

18 Q What did she have?

19 A Well, she had brain damage, you know. Ms.  
20 Martin was -- these are her predictive results. These are her  
21 actuals. And you can see what the base rates are and the  
22 differences.

23 Q When did you evaluate her?

24 A Let's see. August 26, 27, 2009.

25 Q So you're saying Ms. Martin has some kind of

1 permanent dementia?

2 A No, I didn't say she had dementia. I just --

3 Q Oh, okay.

4 A -- I didn't say dementia. Let's see what the  
5 diagnosis -- what I wrote in the diagnosis here. She had  
6 moderate brain dysfunction. Well, she had frontal, temporal,  
7 and occipital dementia also, but not to the same degree as Ms.  
8 Grueskin.

9 Q And does that mean --

10 A And she had post traumatic stress disorder.

11 Q Your eyes are better than mine.

12 A Here, I can make it bigger --

13 Q Yeah, do that.

14 A -- for you.

15 Q Yeah, that's good. And --

16 A I don't know if I can --

17 Q -- oh, no, that's okay. I got it. That -- this  
18 frontal, temporal occipital --

19 A Occipital.

20 Q Yeah, that's what I said. Dementia?

21 A Yes.

22 Q Is that permanent?

23 A It's permanent. Well, she was permanently  
24 disabled at the time that I saw her. Is it permanent? Let's  
25 see. You know, the brain has plasticity. It can improve over

1 time if you do neuro exercise when you're younger.

2 MR. WRIGHT: I can't hear you when you're talking to  
3 her.

4 THE WITNESS: Oh. The brain has what's called  
5 plasticity. It can improve over time, especially if you're  
6 younger and you do neuro exercise, but I don't -- I can't  
7 remember how old she was. I think she was fairly old  
8 actually. Let's see. She was 62.

9 Q And what about Stacy Hutchinson? What was your  
10 diagnosis of her?

11 A Well, Stacy Hutchinson was younger. She was  
12 like 35 or 38, and she had a host of cognitive, emotional, and  
13 psychological issues, including not being able to consummate  
14 her marriage because people get spooked and so she was spooked  
15 and her husband got spooked and they just -- at the time that  
16 I saw them they --

17 Q Yeah.

18 MR. WRIGHT: They got what?

19 MS. STANISH: Spooked.

20 MR. WRIGHT: Spooked?

21 THE WITNESS: Spooked?

22 MS. STANISH: It's a medical term, spooked.

23 THE WITNESS: Well, it's not a medical term, but it's  
24 a --

25 MR. WRIGHT: Spooked?

1 BY MS. STANISH:

2 Q A psychological term.

3 A No. It's not a psychological term, but it's  
4 meant to convey the idea that if you have an infection, you  
5 know, people get concerned and they get scared. And so they  
6 think that it's highly contagious and can be contagious, you  
7 know, in ways that aren't contagious.

8 Q Okay.

9 A And so I say in quotes, they get, "spooked".

10 Q Okay. We get it. Can we get back to talking  
11 about dementia and brain damage?

12 A Sure.

13 Q And I guess what I'm interested in knowing, sir,  
14 is to the extent that you've made diagnoses of these people,  
15 who has permanent dementia amongst them with respect to -- I  
16 see on your iPad here that you also evaluated Lakota Quannah.  
17 Did he have dementia?

18 A No.

19 Q Okay. And I -- let's see who else you got  
20 there.

21 A Well, Rodolfo Meana didn't have dementia but his  
22 cognitive impairment was so -- it was so impaired that his  
23 prognosis was, you know, extremely poor and subsequently he  
24 died, as you know.

25 Q And can I ask you something else? How about



1 Sonia Rivera? Is that a Oriental?

2 A Yes. No, she didn't have dementia either. She  
3 was continuing to work, but having some difficulties. I  
4 forgot what she did. I think she was like an accountant type,  
5 or something within the hotels here.

6 Q Okay. Okay. Thank you.

7 MS. STANISH: I have nothing further.

8 THE COURT: All right. Mr. Santacroce, anything  
9 else?

10 MR. SANTACROCE: Nothing further.

11 THE COURT: Mr. -- I'm sorry, Ms. Weckerly?

12 MS. WECKERLY: No, Your Honor. Thank you.

13 THE COURT: All right. We have a couple juror  
14 questions up here.

15 THE WITNESS: Oh.

16 THE COURT: A juror would like to know: How can you  
17 differentiate between regular dementia due to age and dementia  
18 caused by liver function due to the treatment of hepatitis C?

19 THE WITNESS: Well, I think, you know, one way to  
20 determine it is the onset and its temporal or time, you know,  
21 contiguousness. In other words, with the genetic type of  
22 dementia it's usually a slow, progressing, you know, process  
23 so the person make -- we call them mild cognitive impairment.  
24 And they may complain of just some mild issues, and then it  
25 slowly progresses over time.

1           In Ms. Grueskin's case it seemed to be almost at the  
2 time that she took the treatment -- the Interferon treatment,  
3 that's what the medical records say, it was at the time that  
4 she took the treatment. In fact, she had to stop the  
5 treatment because it was noted as one of its side effects, you  
6 know, in the medical records that she became demented as a  
7 result of that treatment.

8           There is a bit of overlap. Individuals, for  
9 example, with traumatic brain injury will have -- they could  
10 become demented too in quote, like the NFL players could have  
11 early dementia. But the pattern of results, brain function  
12 results are different. The genetic variety affects all  
13 functions, including reading ability, vocabulary and  
14 comprehension. You know, your language stuff, left hemisphere  
15 stuff.

16           Some of the other types of dementia will only, you  
17 know, pick and choose so to speak, but not affect all  
18 functions.

19           THE COURT: Okay. And a juror wants to know: Does  
20 the type of dementia you're talking about affect just the  
21 frontal lobe or the whole brain function?

22           THE WITNESS: Well, in -- you mean specifically Ms.  
23 Grueskin or --

24           THE COURT: Well, talk about Ms. Grueskin and then  
25 also hepatitis C related dementia, the -- what part of the

1 brain -- if that's isolated to a particular part of the brain  
2 or it could be --

3 THE WITNESS: A very, very good question. The -- the  
4 literature and my understanding of Ms. Grueskin and the other  
5 people that I evaluated, the brain dysfunction affects the  
6 white matter tracks. So that's -- that's your corpus callosum  
7 superhighway between the hemisphere. Think of your brain as  
8 wires, okay, and it affects the speed at which you could  
9 process your world and information, so white matter.

10 It affects the frontal area of your brain. That's  
11 your executive functions, your ability to plan and anticipate  
12 and integrate information. And it appears to affect the, you  
13 know, sometimes the temporal and then the occipital area --  
14 your visual memory tracks. But it doesn't appear to affect  
15 motor and the cerebellum

16 And so in Ms. Grueskin's case, for example, she had,  
17 you know, within expected results on all of her motor ability.  
18 She was able to do fine motor and grip strength and things  
19 like that.

20 So it seems to affect the higher cortical functions,  
21 not necessarily the cerebellum and below.

22 THE COURT: Okay. That --

23 THE WITNESS: With other types of dementia though,  
24 everything gets affected, you know, the whole thing pretty  
25 much shuts down.

1 THE COURT: All right. And that's a great segue into  
2 the next juror question, which is, does this kind of dementia  
3 cause you to, you know, forget to breathe or to not -- you  
4 lose your ability to talk or walk?

5 THE WITNESS: Usually not, you know, but -- but, you  
6 know, it could affect balance. You know, there could be  
7 balance issues and, you know, dizziness and things like that.  
8 But usually the involuntary motor functions are preserved.  
9 Breathing, you know, those things are preserved.

10 But what gets most affected is -- is, you know,  
11 memory aspects, you know, like visual and verbal memory and  
12 attention concentration. Some of the frontal areas get  
13 affected, primarily attention concentration, and your -- your  
14 ability to process your world quickly.

15 THE COURT: Now --

16 THE WITNESS: So --

17 THE COURT: -- I'm sorry. I didn't mean to --

18 THE WITNESS: -- so by the time you're attending to  
19 one item you lose the rest. And -- and so then you don't  
20 remember the rest. And, you know, in her case -- in Ms.  
21 Grueskin's case it obviously is more complicated in that her  
22 whole brain seems to be, you know, seems to be shutting down.

23 But Mr. Meana is a good contrast case in point  
24 because he didn't have the typical type of -- of demented  
25 behavior as you would think demented, you know, wandering

1 around aimlessly. But he was severely impaired. And his  
2 prognosis was extremely poor, and subsequently he passed away,  
3 you know.

4 And I -- unfortunately, I don't think Ms. Grueskin  
5 is going to last much longer either.

6 MR. SANTACROCE: Your Honor, I'm going to move to  
7 strike that.

8 THE COURT: Yeah, I would ask the jury to disregard  
9 that. I think that's beyond the scope of what this expert is  
10 here to talk about.

11 Now, regular dementia, meaning age-related dementia  
12 or Alzheimer's type dementia, does that cause people to forget  
13 to breathe or does that cause them to lose the ability to do  
14 things like talking, walking?

15 THE WITNESS: Well, I don't -- it doesn't -- no. I  
16 mean, Alzheimer's doesn't affect, you know, people's -- they  
17 don't forget to breathe because breathing is, you know,  
18 involuntary. And in the early stages of Alzheimer's an  
19 individual could still drive. And individual could still  
20 retain what's overlearned. And driving is over, you know, is  
21 overlearned.

22 But eventually in the severe later stages of  
23 Alzheimer's your whole -- your whole brain shuts down, and  
24 then you don't breathe anymore and you can't walk and talk and  
25 you -- or you just speak nonsensical things, and so...

1 THE COURT: All right. Thank you. Does the State --  
2 Ms. Weckerly, do you have any follow-up to anything?  
3 MS. WECKERLY: No.  
4 THE COURT: The last juror questions or where Ms.  
5 Stanish left off?  
6 MS. WECKERLY: No, thank you.  
7 THE COURT: All right. Ms. Stanish, do you have any  
8 follow-up to those last juror questions?  
9 MS. STANISH: No, Your Honor. Thank you.  
10 THE COURT: Mr. Santacroce.  
11 MR. SANTACROCE: No.  
12 THE COURT: Any additional juror questions before we  
13 excuse the witness? All right. I see no further juror  
14 questions. Thank you for your testimony. You are excused at  
15 this time.  
16 THE WITNESS: Thank you.  
17 THE COURT: And the State may call it's next witness.  
18 Everybody okay? Or does anybody need a break? No?  
19 MS. WECKERLY: Your Honor, it's Ms. Syler, and I --  
20 she's on cross, but I'll get her.  
21 THE COURT: Okay.  
22 MS. WECKERLY: Just -- just so --  
23 THE COURT: All right.  
24 MS. WECKERLY: -- where we're at.  
25 THE COURT: And, ladies and gentlemen, we're now

1 going to resume with the witness that we left off with  
2 yesterday. As you'll recall, the State had concluded its  
3 direct examination, and we took our evening recess.

4 Ma'am, come on back up here by me, please. Have a  
5 seat, and you are still under oath; do you understand that?

6 THE WITNESS: Yes, ma'am.

7 THE COURT: All right. Thank you.

8 Ms. Stanish?

9 MS. STANISH: Thank you, Your Honor.

10 CROSS-EXAMINATION

11 JOAEN SYLER, STATE'S WITNESS

12 BY MS. STANISH:

13 Q Good morning, ma'am.

14 A Good morning.

15 Q My name is Margaret Stanish; I represent Dr.  
16 Desai. I hope that you can start off by educating us a bit  
17 about the world -- the wonderful world of medical building --  
18 billing. As I understand your testimony, the CMS -- Center  
19 for Medicare -- and what's the S?

20 A And Medicaid Services.

21 Q Services. Why isn't it CMMS?

22 A I've wondered --

23 Q That's my first --

24 A -- that myself.

25 Q -- question. CMS is -- sets -- provides some

1 standards that insurance companies can either elect to adopt  
2 or not; is that correct?

3 A Yes, to a certain extent. If it's a Medicare  
4 patient, then -- and the private insurer is the secondary  
5 insurance, then they have to follow Medicare rules and  
6 secondary insurance doesn't pay until Medicare or Medicaid is  
7 paid.

8 Q And so my -- just to clarify, whenever there's a  
9 patient that gets some kind of government reimbursement for  
10 medical services, there's going to have to be reliance on the  
11 CMS standards?

12 A Yes.

13 Q And is that the case with the Veterans  
14 Administration; if you know?

15 A Yes, usually with the VA if they're the primary  
16 insurer, then the VA pays. Sometimes the private insurance  
17 will then pick up the rest. Sometimes the provider will  
18 accept what VA pays, and then there is no further payment at  
19 all. So it just depends on different circumstances.

20 Q Is it safe to say that medical billing  
21 reimbursement is quite complicated?

22 A It can be. It can be.

23 Q And when it comes to the CPT codes -- and what  
24 does CPT stand for?

25 A CPT is current procedural terminology. It's a



1 physician-based coding book that AMA and CMS with some input  
2 from private -- large private insurers contribute to have this  
3 book of codes for services and procedures.

4 Q And these CPT codes, do they often get revised?

5 A There are revisions -- the book is published  
6 annually, then there may be a few revisions once during that  
7 year. But when the book is published annually, the vast  
8 majority of the codes remain the same.

9 Q And is there -- is -- in your experience as a,  
10 what sounds like a long experience in dealing with the world  
11 of medical billing, I understand that you have done audits for  
12 Blue Cross and Blue Shield?

13 A Yes, I have. Many.

14 Q And have you been part of that process that  
15 deals with trying to recoup overpayments from providers?

16 A Yes, many times.

17 Q And have -- do you find -- have you done that in  
18 the context of anesthesia billing?

19 A Yes, I have.

20 Q Okay. And in preparation, by the way, for your  
21 testimony here today, did you review the anesthesia billing  
22 requirements of CMS?

23 A The review I did was a medical-record review of  
24 approximately 140 records. I did not see any claims or any of  
25 the actual billings.

1           Q     Okay. I was wondering about that. So thanks  
2 for answering that without me asking. But the -- what I --  
3 what I was trying to get at was whether you reviewed the  
4 CMS -- the CPT codes that relate to anesthesia?

5           A     I -- for my personal review I did, but I did not  
6 review any codes associated with those records that I  
7 reviewed.

8           Q     I guess what I'm trying to understand -- I want  
9 to -- you discussed yesterday how anesthesia billing works,  
10 and I'm going to discuss that with you in a moment. I just  
11 want to understand what your foundation was for that  
12 testimony, what you studied in order to testify about the base  
13 units, the timing, et cetera.

14          A     Basically, it's my experience and a quick review  
15 on research, just to ensure that my knowledge base was still  
16 as it should be.

17          Q     Fresh?

18          A     Fresh.

19          Q     And did you specifically look at the CMS  
20 requirements, the CPT codes that were in place in the year  
21 2007?

22          A     I attempted to -- to locate those codes because  
23 I no longer have my book from 2007. So I researched trying to  
24 find 2007 anesthesia codes. I could easily locate the 2007  
25 codes for the actual GI procedure, such as the endoscopy or

1 the colonoscopy, I could easily find those, but I could not  
2 find the anesthesia codes for 2007.

3 Q Right. That -- the CMS has a website where some  
4 of their codes are available or the current codes, correct,  
5 but to do historical --

6 A It's difficult.

7 Q -- code research you can't do that prior to, I  
8 think, 2009; is that correct?

9 A Yes.

10 Q And the -- I guess this question you've already  
11 answered it, you don't know what the requirements were for --  
12 or the standards were, I should say, for CMS and the CPT codes  
13 back in the calendar year of 2000?

14 A No, I could not say for sure.

15 Q Is it possible that from the year 2000 to 2007  
16 the -- there has been changes in the standards for calculating  
17 the value of anesthesia services?

18 A From 2000 to 2007?

19 Q Yes, ma'am.

20 A There's a good chance that there could have been  
21 revisions, but I do not know that for a fact.

22 Q Based on your experience with billing for over  
23 the years, is it common that there would indeed be revisions?

24 A Most of the revisions that occur in CPT come  
25 about because of physician input. And frequently the

1 revisions involve further explanatory remarks to describe the  
2 code, or a sentence or two added to the guidelines affecting  
3 those codes to try to help physicians as well as coders to  
4 determine the correct code. So frequently the revisions are  
5 only explanatory remarks rather than a complete change in the  
6 code.

7           And the other more common thing that occurs with CPT  
8 annually is they add codes. For example, I began working with  
9 coding in the mid-'80s, and the book at that time was probably  
10 a quarter of an inch to a half an inch thick, and now the book  
11 is approximately an inch and a half thick. And that's because  
12 of codes continually being added, again because physicians  
13 have input, and, you know, new procedures and new technology  
14 have come along.

15           Q     Right. And it's interesting what you said about  
16 how the explanations have to be further elaborated on in order  
17 to assist providers and billers. And I -- I want to stem from  
18 that concept there.

19           As part of the evolution of the standards of  
20 billings, does it -- does the evolution of the healthcare come  
21 into play? So -- and I know this is -- I'm getting wordy  
22 here, but to get to the question does the evolution from  
23 hospital-based procedures to ambulatory surgical centers, does  
24 that relate to further clarifications or the need for  
25 revisions of the code?

1           A     Through the years as ASC, Ambulatory Surgery  
2 Centers, have come along, there has been some revisions to  
3 specifically speak to whether something is hospital-based or  
4 ASC-based.

5           Q     All right. And by the way, too, do you know  
6 from your research if you were able to see whether there were  
7 changes in the standards for anesthesia building -- billing --  
8 from the year 2007 to 2013?

9           A     I can't say for sure from my research that I can  
10 actually put my finger on specific changes. Since I could not  
11 locate 2007, I could not say whether there had been a lot of  
12 changes from '7 to '13.

13          Q     And going back more now to what you touched --  
14 we touched on earlier, and that is how insurance companies  
15 interplay with CMS and the CPT. I guess I understand  
16 everybody uses the CPT codes to identify the procedure,  
17 whether it's a colonoscopy plus the anesthesia service. But  
18 the -- the CMS, as I understand it, is kind of the decoding  
19 book, how you're actually going to put a price tag on that  
20 service that's rendered. Is that -- oh, like a real simple  
21 explanation for it?

22          A     Well, Medicare does have a fee schedule.

23          Q     Right. And I -- and that's what I want to get  
24 at next, is the -- the fee determination by private insurance  
25 companies.

1           A     They use the Medicare fee schedule as a  
2 guideline. Sometimes the fee will be the same, sometimes it's  
3 different, but they do utilize the Medicare fee schedule as a  
4 guide.

5           Q     All right. And as I understand it the -- you  
6 had mentioned yesterday that part of this equation is contract  
7 negotiations, correct?

8           A     Yes.

9           Q     And so to the extent that you have a provider  
10 who might be a -- a large, private group there's going to be  
11 negotiations between the medical group and the insurance  
12 company to define how the procedure should be reimbursed?

13          A     They have contract negotiations, but as to what  
14 all that entail,s, I've never actually been involved in  
15 contract negotiations so I couldn't say what it entails but  
16 there are contract negotiations. Usually they're done  
17 annually.

18          Q     And is that -- when they are negotiating, does  
19 that necessarily -- it can affect the rate of reimbursement?

20          A     It's possible. You know, like I said --

21          Q     You're not sure --

22          A     -- I've never been involved --

23          Q     -- okay.

24          A     -- in contract negotiations, so...

25          Q     All right. So pleasant to have a witness from

1 the South, it's -- instead of L.A.

2 A I sound perfectly normal to myself.

3 Q You do. That is so --

4 THE COURT: And to everyone else from the South.

5 THE WITNESS: It's you guys that have the accent.

6 BY MS. STANISH:

7 Q You got that right.

8 A Let me just point that out.

9 Q All right. I -- I want you to help us through  
10 the -- I want to go through the formula that the CMS -- that  
11 you discussed yesterday with the CMS, okay? And you are  
12 familiar with Form 1500s, I assume?

13 A Oh, yes.

14 Q Okay. And so real basic, we're trying to  
15 determine the value of anesthesia service, and so we have to  
16 resort to the CMS standards, the formula that you discussed  
17 yesterday with base units, correct?

18 A Yes.

19 Q Now -- but I'm making an assumption when I do  
20 this. I'm assuming that the private insurance company has  
21 actually adopted in whole the CMS formula, all right?

22 A The major insurers that I'm familiar with, yes,  
23 they have.

24 Q All right. And you -- we've -- so I'm just  
25 going to jot value of [inaudible]. You mentioned first that

1 we start with the base unit, and I -- as I understand your --  
2 well, explain that to me again so I make sure I have it  
3 correct.

4 A The formula basically is the base unit plus time  
5 units plus modifying units.

6 Q Modify -- modifier units?

7 A Modifying units, it's usually called.

8 Q Okay. And in anesthesia do you know what the  
9 base unit is for colonoscopies?

10 A No, I do not.

11 Q All right. Let's just assume for this  
12 hypothetical that it's 5. Do you know how the time units are  
13 calculated according to the CMS standards?

14 A 15-minute increments, I guess is the simplest  
15 answer.

16 Q And so I'm just going to try to fit that here.  
17 0 to what, 14 or 15?

18 A 15.

19 Q And then the next increment would be 16 to 30?

20 A Yes, to my knowledge that's the way it would  
21 work.

22 Q And then 31 to 45; is that right?

23 A I would assume that's correct. So I'll say yes  
24 because, you know, I think in terms of -- I don't think of it  
25 that way. I think of it in terms of, you know, is 18